Unnamed: 0,title,date,stock,sentiment
126987.0,Johnson & Johnson To Start Coronavirus Vaccine Human Trials Ahead Of Schedule In July,2020-06-11 00:16:00-04:00,AZN,neutral
126988.0,"NIH Official Says U.S. Plans 3 Large Studies of Experimental Coronavirus Vaccines  From Moderna, AstraZeneca Johnson & Johnson Starting in July, August, September",2020-06-10 05:34:00-04:00,AZN,neutral
126989.0,Potential Covid-19 Vaccine From China BBIBP-CorV Shows Promise in Animal Tests,2020-06-10 05:22:00-04:00,AZN,positive
126990.0,Barda Says It Awards $23.7M To Support Development Of Astrazeneca  SARS-CoV-2 Monoclonal Antibody Combination,2020-06-09 10:03:00-04:00,AZN,positive
126991.0,4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize,2020-06-08 18:26:00-04:00,AZN,neutral
126992.0,Astrazeneca CEO Soriot Said To Have Called Gilead CEO On May 9; Proposed Exploring Merger On A Call,2020-06-08 17:08:00-04:00,AZN,neutral
126993.0,PreMarket Prep Stock Of The Day: Gilead Sciences,2020-06-08 12:20:00-04:00,AZN,neutral
126994.0,"Navarro: China Is 'Trying To Steal Our Vaccines, As We Speak'",2020-06-08 10:28:00-04:00,AZN,negative
126995.0,3 Gilead-Heavy ETFs To Watch Amid The AstraZeneca-Gilead Rumor,2020-06-08 10:10:00-04:00,AZN,neutral
126996.0,"'Gilead, AstraZeneca not in merger talks' CNBC's Faber Reports",2020-06-08 09:19:00-04:00,AZN,neutral
126997.0,A Peek Into The Markets: US Stock Futures Up; OPEC+ Agrees To Extend Output Cuts,2020-06-08 06:01:00-04:00,AZN,positive
126998.0,AstraZeneca Approached Gilead With A Deal That Could Be The Biggest On Record: Report,2020-06-08 03:56:00-04:00,AZN,neutral
126999.0,AstraZeneca Approaches Gilead Regarding Potential Record Health-Care Merger,2020-06-07 08:47:00-04:00,AZN,neutral
127000.0,'AstraZeneca blood cancer drug shows signs of helping COVID-19 patients' -Reuters,2020-06-05 14:01:00-04:00,AZN,negative
127001.0,AstraZeneca Presents New Data Across Continuum of Care from its Broad Renal Portfolio at ERA-EDTA 2020 Virtual Congress,2020-06-05 05:19:00-04:00,AZN,positive
127002.0,"AstraZeneca CEO Says We Have 300M Doses In Spare Capacity As Part Of Total 2B Doses Planned, Additional Parties Could Be Intereted",2020-06-04 12:27:00-04:00,AZN,positive
127003.0,"AstraZenica CEO Says We Expect To Know By August Whether The Vaccine Works, But We Are Dependent On The Infection Rates In The Vaccinated Groups And In The Control Groups In The Trials",2020-06-04 12:25:00-04:00,AZN,neutral
127004.0,'AstraZeneca takes next steps towards broad and equitable access to Oxford University's COVID-19 vaccine' -Company Release,2020-06-04 11:15:00-04:00,AZN,neutral
127005.0,AstraZeneca Secured Manufacturing Capacity For 2B Doses Of Vaccine,2020-06-04 11:13:00-04:00,AZN,positive
127006.0,"AstraZeneca Reports $750M Deal With CEPI, Gavi, Serum Institute Of India To Bring Vaccine To Low-, Middle-Income Countries",2020-06-04 11:03:00-04:00,AZN,neutral
127007.0,Ex-FDA Chief On White House's Coronavirus Vaccine Shortlist: 'They Chose Very Novel Platforms',2020-06-04 11:02:00-04:00,AZN,positive
127008.0,"The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic",2020-06-04 08:13:00-04:00,AZN,positive
127009.0,AstraZeneca to Discover and Develop Novel Therapies Targeting RNA-modifying Proteins in Oncology Collaboration With Accent Therapeutics,2020-06-04 05:30:00-04:00,AZN,positive
127010.0,Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics,2020-06-03 17:53:00-04:00,AZN,neutral
127011.0,"UPDATE: Five Companies Chosen For 'Vaccine Finalist' Are Moderna, Johnson & Johnson, Merck, Pfizer And AstraZeneca",2020-06-03 13:09:00-04:00,AZN,neutral
127012.0,"U.S. Army Planning To Test Vaccines From Moderna, Astrazeneca, Johnson & Johnson And Sanofi; Army Will Test Its Own Vaccine Candidate In Human Trials Later This Summer",2020-06-02 12:03:00-04:00,AZN,neutral
127013.0,Merck and AstraZeneca's LYNPARZA Receives a Positive Opinion from the European Medicines Agency,2020-06-01 06:46:00-04:00,AZN,positive
127014.0,AstraZeneca Announces Brilinta Obtains Additional FDA Approval,2020-06-01 05:33:00-04:00,AZN,positive
127015.0,AstraZeneca Announces Lynparza Recommended for Approval in EU by CHMP for BRCA-mutated Metastatic Pancreatic Cancer,2020-06-01 05:31:00-04:00,AZN,negative
127016.0,"The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight",2020-05-30 09:25:00-04:00,AZN,neutral
127017.0,AstraZeneca shares are trading higher after the company announced is ENHERTU significantly improved tumor response rate. The Overall survival in HER2 positive metastatic gastric cancer in Phase 2 DESTINY-Gastric01 Trial.,2020-05-29 08:44:00-04:00,AZN,positive
127018.0,10 Biggest Price Target Changes For Friday,2020-05-29 08:23:00-04:00,AZN,neutral
127019.0,"AstraZeneca Reports ENHERTU Significantly Improved Tumor Response Rate, Overall Survival In HER2-Positive Metastatic Gastric Cancer In Phase 2 DESTINY-Gastric01 Trial",2020-05-29 08:19:00-04:00,AZN,negative
127020.0,AstraZeneca's Announces IMFINZI (durvalumab) Showed 'Sustained Overall Survival Benefit' In 1st-Line Extensive-Stage Small Cell Lung Cancer In Phase III CASPIAN Trial,2020-05-29 08:14:00-04:00,AZN,negative
127021.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,AZN,positive
127022.0,AVEO Oncology Reports Phase 1b/2 DEDUCTIVE Study Of FOTIVDA In Combo With IMFINZI in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2,2020-05-29 07:11:00-04:00,AZN,neutral
127023.0,"SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $65",2020-05-29 06:21:00-04:00,AZN,neutral
127024.0,AstraZeneca Announces Tagrisso Unprecedented Adjuvant Lung Cancer Data,2020-05-29 05:29:00-04:00,AZN,negative
127025.0,Genestack Signs Multi-Year Agreement With AstraZeneca to Implement Genestack's Omics Data Manager -,2020-05-29 05:23:00-04:00,AZN,positive
127026.0,AstraZeneca Says TAGRISSO 'Demonstrated Unprecedented Patient Benefit in the Adjuvant Treatment of EGFR-Mutated Lung Cancer',2020-05-28 17:02:00-04:00,AZN,negative
127027.0,"'I'll have story at 5 pm ET on $AZN Tagrisso in early-stage lung cancer patients. This is the ADAURA adjuvant study stopped in April for ""overwhelming benefit.""' -Adam Feuerstein Tweet",2020-05-28 13:32:00-04:00,AZN,negative
127028.0,Why AstraZeneca's Stock Is Trading Higher Today,2020-05-28 11:00:00-04:00,AZN,neutral
127029.0,AstraZeneca shares are trading higher after the company announced a commercial supply deal with Oxford Biomedica for manufacturing of its AZD1222 coronavirus vaccine candidate.,2020-05-28 10:25:00-04:00,AZN,positive
127030.0,"Oxford Biomedica Reports 1-Year Clinical, Commercial Supply Deal With AstraZeneca For Manufacture Of Adenovirus Vector-Based Coronavirus Vaccine Candidate, AZD1222",2020-05-28 07:26:00-04:00,AZN,neutral
127031.0,AstraZeneca Collaborates with ArcherDX to Use Personalized Cancer Assays to Detect Minimal Residual Disease in Lung Cancer Trials,2020-05-26 05:28:00-04:00,AZN,negative
127032.0,Project Leader Adrian Hill Says Oxford University Covid-19 Vaccine Trial Has Only 50% Chance of Success,2020-05-23 17:24:00-04:00,AZN,positive
127033.0,China Plans to Start Using Coronavirus Vaccine by End of Year Even if Trials Have Not Been Completed,2020-05-23 13:24:00-04:00,AZN,neutral
127034.0,"The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray",2020-05-22 07:10:00-04:00,AZN,neutral
127035.0,Enhertu Granted FDA Orphan Drug Designation for Gastric Cancer,2020-05-22 06:58:00-04:00,AZN,negative
127036.0,Oxford COVID-19 Vaccine to Begin Phase II/III Human Trials,2020-05-22 06:55:00-04:00,AZN,neutral
127037.0,"Trump Says He Believes AstraZeneca Vaccine Holds Tremendous Promise, As Do Those From Other Companies",2020-05-21 16:25:00-04:00,AZN,positive
127038.0,AstraZeneca Shares Quiet As Trump Welcomes Announcement By Co. On Oxford Vaccine,2020-05-21 12:38:00-04:00,AZN,positive
127039.0,A Peek Into AstraZeneca's P/E Ratio,2020-05-21 11:27:00-04:00,AZN,neutral
127040.0,Stocks That Hit 52-Week Highs On Thursday,2020-05-21 10:25:00-04:00,AZN,neutral
127041.0,AstraZeneca CEO Says Oxford Vaccine Phase 3 Trial To Start In Jun.,2020-05-21 09:51:00-04:00,AZN,neutral
127042.0,AstraZeneca Receives Over $1B In BARDA Funding For Coronavirus Vaccine,2020-05-21 09:48:00-04:00,AZN,neutral
127043.0,AstraZeneca shares are trading higher after the company announced receipt of commitment of 400 million doses for Oxford's potential coronavirus vaccine.,2020-05-21 08:47:00-04:00,AZN,positive
127044.0,"AstraZeneca CEO Recently Interviewing On CNBC, Highlights Earlier News Co. Received Commitment For 400M Doses Of Oxford's Potential Coronavirus Vaccine",2020-05-21 07:30:00-04:00,AZN,positive
127045.0,AstraZeneca Receives Commitment of 400M Doses for Oxford's Potential Covid-19 Vaccine,2020-05-21 05:18:00-04:00,AZN,positive
127046.0,Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market,2020-05-20 08:33:00-04:00,AZN,negative
127047.0,"The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test",2020-05-20 08:12:00-04:00,AZN,neutral
127048.0,AstraZeneca And Merck Announce LYNPARZA Approved By FDA For Treatment Of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment With Enzalutamide Or Abiraterone,2020-05-20 06:56:00-04:00,AZN,negative
127049.0,AstraZeneca Says Lynparza Approved in the U.S. for Prostate Cancer,2020-05-20 05:22:00-04:00,AZN,negative
127050.0,"These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley",2020-05-18 12:07:00-04:00,AZN,positive
127051.0,AstraZeneca's ENHERTU Granted Breakthrough Therapy Designation in the US for HER2-Mutant Metastatic Non-Small Cell Lung Cancer,2020-05-18 07:18:00-04:00,AZN,negative
127052.0,AstraZeneca and Daiichi Sankyo Announce Enhertu Ggranted Breakthrough Therapy Designation in the US for HER2-mutant Metastatic NSCLC,2020-05-18 05:13:00-04:00,AZN,neutral
127053.0,AstraZeneca Says Bevespi Aerosphere Approved in China for Patients with COPD,2020-05-18 05:11:00-04:00,AZN,positive
127054.0,Shares of several healthcare companies are trading lower amid market weakness following US unemployment data and recent cautious comments from the WHO. Sentiment is also negative following cautious comments from Fed Chair Powell and bearish outlook from some major US investors on Wednesday. Negative investor sentiment has affected stocks across sectors for the session.,2020-05-14 11:18:00-04:00,AZN,negative
127055.0,"Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand",2020-05-14 10:55:00-04:00,AZN,neutral
127056.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,AZN,positive
127057.0,Innate Pharma to Present New Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ASCO Virtual Scientific Program,2020-05-14 05:41:00-04:00,AZN,negative
127058.0,"AstraZeneca Highlights Data For TAGRISSO, ENHERTU To Be Presented At ASCO",2020-05-13 17:26:00-04:00,AZN,neutral
127059.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-13 10:35:00-04:00,AZN,neutral
127060.0,"Inovio Q1 Results Miss Estimates, Coronavirus Vaccine Program On Track",2020-05-11 17:07:00-04:00,AZN,negative
127061.0,AstraZeneca And Merck Announce LYNPARZA Approved In US As 1st-line Maintenance Treatment With bevacizumab For HRD-Positive Advanced Ovarian Cancer,2020-05-11 07:26:00-04:00,AZN,negative
127062.0,AstraZeneca And Daiichi Sankyo ENHERTU Granted Breakthrough Therapy Designation In US For HER2-Positive Metastatic Gastric Cancer,2020-05-11 07:11:00-04:00,AZN,negative
127063.0,Myriad Receives FDA Approval Of myChoice CDx As Companion Diagnostic For Lynparza In Patients With Advanced Ovarian Cancer,2020-05-11 07:06:00-04:00,AZN,negative
127064.0,A Peek Into The Markets: US Stock Futures Edge Lower; Crude Oil Down Over 3%,2020-05-11 05:57:00-04:00,AZN,negative
127065.0,"AstraZeneca Announces Lynparza Approved in the U.S, as 1st-line Maintenance Treatment With Bevacizumab for HED-positive Advanced Ovarian Cancer",2020-05-11 05:22:00-04:00,AZN,negative
127066.0,AstraZeneca Announces Recovery of Global Rights to Brazikumab from Allergan Completed,2020-05-11 05:20:00-04:00,AZN,neutral
127067.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,AZN,neutral
127068.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,AZN,negative
127069.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-06 10:43:00-04:00,AZN,neutral
127070.0,AstraZeneca Option Alert: Oct 16 $65 Calls at the Ask: 349 @ $0.7 vs 469 OI; Ref=$54.22,2020-05-06 09:38:00-04:00,AZN,positive
127071.0,"Argus Research Maintains Buy on AstraZeneca, Raises Price Target to $60",2020-05-06 09:22:00-04:00,AZN,neutral
127072.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,AZN,positive
127073.0,AstraZeneca Reports FARXIGA Approved In US For Treatment Of Heart Failure In Patients With Heart Failure With Reduced Ejection Fraction,2020-05-06 07:25:00-04:00,AZN,negative
127074.0,AstraZeneca Announces Farxiga Approved by FDA for the Treatment of Heart Failure n Patients With Heart Failure With Reduced Ejection Fraction,2020-05-06 05:15:00-04:00,AZN,negative
127075.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,2020-05-03 09:25:00-04:00,AZN,neutral
127076.0,RedHill's CEO On Biopharma's 'Two Shots On Goal' For Coronavirus Drug,2020-05-01 11:39:00-04:00,AZN,neutral
127077.0,"The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO",2020-05-01 07:54:00-04:00,AZN,neutral
127078.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-30 10:31:00-04:00,AZN,neutral
127079.0,AstraZeneca PLC shares are trading higher after the company announced it entered into an agreement with Oxford University for a coronavirus vaccine.,2020-04-30 08:23:00-04:00,AZN,positive
127080.0,Astrazeneca Executive Baselga Says To Start Vaccine Clinical Trials With Oxford University With Healthy Volunteers 'Very Very Soon',2020-04-30 08:11:00-04:00,AZN,positive
127081.0,AstraZeneca and Oxford University Announce Landmark Agreement for COVID-19 Vaccine; AstraZeneca CEO Says We Should Have a Pretty Good Idea in June or July Whether Its Vaccine Works,2020-04-30 05:21:00-04:00,AZN,positive
127082.0,Morning Market Stats in 5 Minutes,2020-04-29 11:09:00-04:00,AZN,neutral
127083.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,AZN,positive
127084.0,"Earnings Scheduled For April 29, 2020",2020-04-29 04:50:00-04:00,AZN,neutral
127085.0,Stocks That Hit 52-Week Highs On Tuesday,2020-04-28 10:18:00-04:00,AZN,neutral
127086.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,AZN,neutral
127087.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,AZN,neutral
127088.0,AstraZeneca' Reports LOKELMA US Label Updated to Include Dosing Guidance for the Treatment of Hyperkalemia in Patients With End-Stage Renal Disease on Hemodialysis,2020-04-27 07:06:00-04:00,AZN,neutral
127089.0,Lynparza Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-mutated Metastatic Castration-resistant Prostate Cancer,2020-04-27 05:41:00-04:00,AZN,negative
127090.0,"AstraZeneca, Merck Announce Lynparza Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-mutated Metastatic Castration-resistant Prostate Cancer",2020-04-24 05:24:00-04:00,AZN,negative
127091.0,AstraZeneca and Saint Luke's Mid America Heart Institute initiate Phase III DARE-19 Trial with Farxiga in COVID-19 Patient,2020-04-23 05:21:00-04:00,AZN,neutral
127092.0,AstraZeneca Shares Unaffected Amid Report Co. Will Be Apart Of The UK's Coronavirus Vaccine Taskforce,2020-04-17 12:19:00-04:00,AZN,positive
127093.0,AstraZeneca Says Tagrisso Adjuvant Trial Overwhelmingly Positive,2020-04-14 05:20:00-04:00,AZN,positive
127094.0,AstraZeneca Initiates CALAVI Vlinical Trial with Calquence against COVID-19,2020-04-14 05:18:00-04:00,AZN,neutral
127095.0,Why AstraZeneca's Stock Is Trading Higher Today,2020-04-13 12:08:00-04:00,AZN,neutral
127096.0,"AstraZeneca shares are trading higher after the company and Merck received approval for KOSELUGO for pediatric patients two years and older with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.",2020-04-13 09:47:00-04:00,AZN,positive
127097.0,"AstraZeneca and Merck Announce Approval of KOSELUGO for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas",2020-04-13 06:57:00-04:00,AZN,positive
127098.0,Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca,2020-04-09 10:04:00-04:00,AZN,neutral
127099.0,"Collaboration with AstraZeneca, GSK and University of Cambridge to support UK national effort to increase COVID-19 testing",2020-04-08 05:23:00-04:00,AZN,positive
127100.0,10 Biotech Winners And Losers In Q1,2020-04-01 16:35:00-04:00,AZN,negative
127101.0,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,2020-04-01 09:20:00-04:00,AZN,negative
127102.0,AstraZeneca Announces Lokelma Recommended for Approval in EU for Patients with Hyperkalaemia on Stable Haemodialysis,2020-03-31 05:19:00-04:00,AZN,positive
127103.0,AstraZeneca shares are trading higher amid strength in the healthcare sector. The company also earlier announced US approval for IMFINZI in extensive-stage small cell lung cancer.,2020-03-30 13:19:00-04:00,AZN,positive
127104.0,"FDA Reports Approved AstraZeneca's Durvalumab In Combo With Etoposide, Either Carboplatin Or Cisplatin",2020-03-30 09:55:00-04:00,AZN,positive
127105.0,AstraZeneca Reports Brilinta Reduced Bleeding vs Dual Therapy In High-Risk Coronary Patients In Sub Analyses From Phase 4 TWILIGHT Trial,2020-03-30 09:08:00-04:00,AZN,neutral
127106.0,AztraZeneca to Conclude its Phase III DAPA-CKD Trial Early Following Ealy Positive Trial Results,2020-03-30 07:21:00-04:00,AZN,positive
127107.0,AstraZeneca Announces that its IMFINZI Has Been Approved in the US for Extensive-Stage Small Cell Lung Cancer,2020-03-30 07:09:00-04:00,AZN,negative
127108.0,AstraZeneca Announces Imfinzi Approved in U.S. for Small Cell Lung Cancer,2020-03-30 05:22:00-04:00,AZN,negative
127109.0,AstraZeneca Says Farxiga Phase III DAPA-CKD Trial to be Stopped Early Following Overwhelming Efficacy in Patients with Chronic Kidney Disease,2020-03-30 05:20:00-04:00,AZN,negative
127110.0,"The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty",2020-03-29 12:10:00-04:00,AZN,negative
127111.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,AZN,positive
127112.0,"A Peek Into The Markets: US Stock Futures Down, Jobless Claims Data In Focus",2020-03-26 05:53:00-04:00,AZN,neutral
127113.0,"Silence Therapeutics Announces Collaboration with AstraZeneca to Discover, Develop and Commercialize Small Interfering RNA Therapeutics for the Treatment of Cardiovascular, Renal, Metabolic and Respiratory Diseases",2020-03-25 05:24:00-04:00,AZN,neutral
127114.0,Schrödinger Announces Expanded Collaboration with AstraZeneca to Extend Computational Modeling Solutions to Biologics,2020-03-23 07:01:00-04:00,AZN,positive
127115.0,Shares of several healthcare companies are trading higher as the market rebounds from coronavirus-related selloffs.,2020-03-20 09:43:00-04:00,AZN,positive
127116.0,A Peek Into The Markets: US Stock Futures Down; WTI Crude Oil Rises Over 10%,2020-03-19 06:38:00-04:00,AZN,negative
127117.0,AstraZeneca Announces Lynparza Granted Orphan Drug Designation in Japan,2020-03-19 05:38:00-04:00,AZN,positive
127118.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,AZN,positive
127119.0,"Shares of several healthcare companies are trading higher, rebounding from Monday's crash. Stocks may also potentially be getting a boost from expectations of further stimulus proposals.",2020-03-17 09:10:00-04:00,AZN,positive
127120.0,AstraZeneca shares are trading higher after the company announced that Imfinzi confirmed the overall survival in the final analysis of its phase 3 CASPIAN trial.,2020-03-17 08:13:00-04:00,AZN,positive
127121.0,AstraZeneca Announces Imfinzi Confirmed Overall Survival in CASPIAN,2020-03-17 05:32:00-04:00,AZN,neutral
127122.0,Insmed Announces AstraZeneca Has Exercised Option To Develop INS1007 In Chronic Obstructive Pulmonary Disease Or Asthma,2020-03-16 16:03:00-04:00,AZN,neutral
127123.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,AZN,negative
127124.0,"The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review",2020-03-15 09:55:00-04:00,AZN,neutral
127125.0,Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.,2020-03-12 09:26:00-04:00,AZN,negative
127126.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,AZN,negative
127127.0,AstraZeneca and Merck Announce Phase 3 GY004 for Cediranib and LYNPARZA in Platinum-Sensitive Relapsed Ovarian Cancer Did Not Meet the Primary Endpoint of Progression-Free Survival vs. Platinum-Based Chemotherapy,2020-03-12 05:16:00-04:00,AZN,negative
127128.0,Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.,2020-03-11 07:15:00-04:00,AZN,neutral
127129.0,"The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study",2020-03-06 08:49:00-05:00,AZN,negative
127130.0,"AstraZeneca  Phase III DANUBE Trial for Imfinzi and Tremelimumab in Unresectable, Stage IV Bladder Cancer Did Not Meet Primary Endpoints",2020-03-06 05:55:00-05:00,AZN,negative
127131.0,36 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-03-04 08:00:00-05:00,AZN,neutral
127132.0,Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,2020-03-04 07:48:00-05:00,AZN,positive
127133.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2020-03-02 16:46:00-05:00,AZN,neutral
127134.0,Shares of several healthcare companies are trading higher in sympathy with the overall market as it rebounds from a selloff caused by coronavirus fears.,2020-03-02 11:18:00-05:00,AZN,positive
127135.0,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,2020-02-28 09:06:00-05:00,AZN,negative
127136.0,Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.,2020-02-27 09:28:00-05:00,AZN,negative
127137.0,18 Medical Stocks To Watch Amid The Coronavirus Outbreak,2020-02-25 15:25:00-05:00,AZN,neutral
127138.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,AZN,negative
127139.0,RedHill Biopharma Acquires Rights to Movantik from AstraZeneca for $52.5M Upfront Plus $15M 18 Months after Closing,2020-02-25 05:16:00-05:00,AZN,neutral
127140.0,Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.,2020-02-24 08:37:00-05:00,AZN,negative
127141.0,AstraZeneca shares are trading higher. Not seeing any news to justify the price action.,2020-02-21 09:49:00-05:00,AZN,positive
127142.0,AstraZeneca shares are trading higher. Not seeing any news to justify the price action.,2020-02-18 09:07:00-05:00,AZN,positive
127143.0,AstraZeneca shares are trading lower following Q4 results. The company's Tagrisso and Lynparza sales came in below projections while revenue growth forecasts were below analyst expectations.,2020-02-14 09:51:00-05:00,AZN,positive
127144.0,"AstraZeneca Earlier Reported Q4 EPS $0.89, Sales $6.664B Miss $6.75B Estimate",2020-02-14 09:45:00-05:00,AZN,negative
127145.0,"8 Stocks To Watch For February 14, 2020",2020-02-14 05:04:00-05:00,AZN,neutral
127146.0,"Earnings Scheduled For February 14, 2020",2020-02-14 04:14:00-05:00,AZN,neutral
127147.0,Myriad Submits sPMA For myChoice CDx With Lynparza In First-Line Maintenance Therapy In Advanced Ovarian Cancer,2020-02-11 07:14:00-05:00,AZN,negative
127148.0,Coronavirus-Related Stocks On Watch Ahead Of WHO Discussion On Whether Coronavirus Is Public Health Emergency,2020-01-30 14:36:00-05:00,AZN,negative
127149.0,AstraZeneca's Phase 3 THALES Trial in Stroke Met its Primary Endpoint,2020-01-27 07:11:00-05:00,AZN,neutral
127150.0,"AstraZeneca Sells Global Commercial Rights to Hypertension Medicines to Atnahs Pharma for $350M, Contingency Payments Up to $40M",2020-01-27 05:30:00-05:00,AZN,neutral
127151.0,AstraZeneca Says Enhertu Phase II Trial Met Primary Endpoint of Improvement in ORR,2020-01-27 05:22:00-05:00,AZN,positive
127152.0,AstraZeneca Says Brilinta Met Primary Endpoint in Stroke Trial,2020-01-27 05:19:00-05:00,AZN,neutral
127153.0,AstraZeneca to Recover the Global Rights to Brazikumab from Allergan,2020-01-27 05:13:00-05:00,AZN,neutral
127154.0,Biocartis Enters into Master Collaboration Agreement with AstraZeneca and Initiates EGFR Liquid Biopsy Study,2020-01-22 05:22:00-05:00,AZN,positive
127155.0,Penny Stock Rips 260% Higher On Fast Track Designation For Experimental Lung Cancer Gene Therapy,2020-01-21 11:40:00-05:00,AZN,negative
127156.0,20 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-01-21 07:57:00-05:00,AZN,neutral
127157.0,Myriad Submits sPMA For BRACAnalysis CDx As A Companion Diagnostic For Lynparza In Metastatic Castration-resistant Prostate Cancer,2020-01-21 07:05:00-05:00,AZN,negative
127158.0,FDA Accepts Regulatory Submission Of Supplemental New Drug Application For Merck's LYNPARZA In HRR-Mutated Metastatic Castration-Resistant Prostate Cancer And Grants Priority Review,2020-01-21 06:56:00-05:00,AZN,negative
127159.0,7 Blockbuster Drugs Expected To Be Launched In 2020,2020-01-20 14:18:00-05:00,AZN,positive
127160.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,AZN,neutral
127161.0,"Acasti Shares Slump On Failed Late-Stage Trial, Amarin Moves In Sympathy",2020-01-13 12:18:00-05:00,AZN,positive
127162.0,AstraZeneca and Merck's Supplemental New Drug Application for LYNPARZA Granted Priority Review by the FDA,2020-01-13 07:46:00-05:00,AZN,positive
127163.0,PhaseBio Rallies On Funding Agreement For Early Stage Anticoagulant Reversal Agent,2020-01-10 11:52:00-05:00,AZN,positive
127164.0,Veracyte Announces Biopharmaceutical Collaboration With Acerta Pharma,2020-01-08 08:22:00-05:00,AZN,neutral
127165.0,AstraZeneca's FARXIGA Granted Priority Review by the FDA and a Supplemental New Drug Application is Accepted,2020-01-06 07:02:00-05:00,AZN,positive
127166.0,AstraZeneca Announces Lokelma Approved in China for Hyperkalaemia,2020-01-06 05:14:00-05:00,AZN,positive
127167.0,AstraZeneca Announces Farxiga Granted FDA Heart Failure Priority Review,2020-01-06 05:12:00-05:00,AZN,negative
127168.0,34 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-01-03 07:45:00-05:00,AZN,neutral
127169.0,Innate Pharma Rallies On Acceptance Of European Regulatory Application For Leukemia Drug,2020-01-02 10:09:00-05:00,AZN,positive
127170.0,Merck-AstraZeneca's Lynparza Snags FDA Nod For Pancreatic Cancer,2019-12-30 11:41:00-05:00,AZN,negative
127171.0,A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Economic Data,2019-12-30 07:19:00-05:00,AZN,neutral
127172.0,Merck's LYNPARZA Approved By FDA As First-Line Maintenance Treatment Of Germline BRCA-Mutated Metastatic Pancreatic Cancer,2019-12-30 06:55:00-05:00,AZN,negative
127173.0,AstraZeneca Says FDA Approved Lynparza for Pancreatic Cancer,2019-12-30 05:27:00-05:00,AZN,negative
127174.0,Starpharma Announces AstraZeneca's Commencement of Phase 1 Trial for AZD0466 Utilising DEP Delivery Technology,2019-12-29 19:36:00-05:00,AZN,neutral
127175.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,AZN,neutral
127176.0,31 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-12-27 08:13:00-05:00,AZN,neutral
127177.0,A Perspective On Biopharma's Record M&A Run In 2019,2019-12-23 14:57:00-05:00,AZN,neutral
127178.0,Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca And Cincinnati Children's Hospital Medical Center To Develop Novel Treatment For Select CNS Disorders,2019-12-23 08:33:00-05:00,AZN,positive
127179.0,AstraZeneca Announces Enhertu Approved in the US for HER2-positive Unresectable or Metastatic Breast Cancer Following Two or More Prior anti-HER2 Based Regimens,2019-12-23 04:58:00-05:00,AZN,negative
127180.0,AstraZeneca's Triple-combination Therapy Approved in China for Patients with COPD,2019-12-23 04:56:00-05:00,AZN,positive
127181.0,Stocks That Hit 52-Week Highs On Friday,2019-12-20 11:59:00-05:00,AZN,neutral
127182.0,28 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-12-20 08:19:00-05:00,AZN,neutral
127183.0,"The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering",2019-12-20 08:12:00-05:00,AZN,positive
127184.0,AstraZeneca Sells rights to Arimidex and Casodex in Europe and Certain Additional Countries to Juvisé Pharmaceuticals for  Upfront Payment of $181M,2019-12-20 05:29:00-05:00,AZN,positive
127185.0,"FDA Panel Backs AstraZeneca's LYNPARZA For Pancreatic Cancer, Voted LYNPARZA Demonstrated Clinically Meaningful Favorable Risk-Benefit Profile",2019-12-17 13:09:00-05:00,AZN,negative
127186.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,AZN,positive
127187.0,Stocks That Hit 52-Week Highs On Monday,2019-12-16 10:16:00-05:00,AZN,neutral
127188.0,AstraZeneca shares are trading higher after the company announced it reached an agreement with Cheplapharm for the rights to its Seroquel and Seroquel XR in Europe and Russia.,2019-12-16 08:14:00-05:00,AZN,positive
127189.0,AstraZeneca Announces Agreement with Cheplapharm for Rights to Seroquel and Seroquel XR in Europe and Russia Completed,2019-12-16 05:33:00-05:00,AZN,positive
127190.0,8 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-12-13 06:52:00-05:00,AZN,neutral
127191.0,AstraZeneca Option Alert: Dec 20 $48 Calls Sweep (2) above Ask!: 1130 @ $0.526 vs 1349 OI; Ref=$47.91,2019-12-12 12:50:00-05:00,AZN,positive
127192.0,"AstraZeneca Announces Imfinzi Approved in China for the Treatment of Unresectable, Stage III NSCLC Based on Phase III PACIFIC Trial",2019-12-12 05:20:00-05:00,AZN,positive
127193.0,AstraZeneca Highlights PResentation Of Data Showing Trastuzumab Deruxtecan Achieved Tumor Response Of 60.9% In Pivotal Phase II HER2-Positive Metastatic Breast Cancer Trial,2019-12-11 08:21:00-05:00,AZN,negative
127194.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,AZN,negative
127195.0,41 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-10 08:10:00-05:00,AZN,neutral
127196.0,DeepMatter Group PLC Announces Collaboration with AstraZeneca to Improve Productivity and Reproducibility of Compound Synthesis,2019-12-09 05:21:00-05:00,AZN,positive
127197.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,AZN,positive
127198.0,AstraZeneca Reports Calquence Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukaemia at ASH 2019,2019-12-07 08:12:00-05:00,AZN,negative
127199.0,"AstraZeneca, Merck Announce Lynparza Approved in China as a 1st-line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer",2019-12-05 05:24:00-05:00,AZN,negative
127200.0,19 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-03 07:46:00-05:00,AZN,neutral
127201.0,"Cowen & Co. Maintains Outperform on AstraZeneca, Raises Price Target to $55",2019-12-02 09:17:00-05:00,AZN,neutral
127202.0,A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street,2019-11-29 07:08:00-05:00,AZN,negative
127203.0,AstraZeneca Announces Imfinzi Granted FDA Priority Review for SCLC,2019-11-29 05:28:00-05:00,AZN,positive
127204.0,AstraZeneca And PCI Biotech Expand Collaboration Agreement,2019-11-26 12:14:00-05:00,AZN,positive
127205.0,Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca,2019-11-26 03:43:00-05:00,AZN,neutral
127206.0,AstraZeneca CEO: Closing In On A Cancer Cure,2019-11-22 15:39:00-05:00,AZN,negative
127207.0,SVB Leerink Initiates Coverage On AstraZeneca with Outperform Rating,2019-11-22 08:59:00-05:00,AZN,neutral
127208.0,19 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-11-22 07:47:00-05:00,AZN,neutral
127209.0,AstraZeneca Reports Calquence Approved For Patients With Chronic Lymphocytic Leukemia In US,2019-11-21 13:19:00-05:00,AZN,positive
127210.0,"Health Canada Says For Past Several Weeks, Apotex, Astrazeneca Canada And Teva Canada Have Reported Tamoxifen Shortages On Drug Shortages Canada Website; Reasons Included Unexpected Manufacturing Disruptions & Increased Demand",2019-11-20 14:07:00-05:00,AZN,negative
127211.0,AstraZeneca Announced Consistent Effects of FARXIGA in Heart Failure Patients With Reduced Ejection Fraction Shown in New Analyses From Landmark Phase III DAPA-HF Trial,2019-11-17 19:58:00-05:00,AZN,negative
127212.0,Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevation Acute Coronary Syndrome Who Underwent PCI Showed BRILINTA Monotherapy Reduced the Risk of Clinically Relevant Bleeding Compared With Dual Antiplatelet Therapy,2019-11-17 19:55:00-05:00,AZN,negative
127213.0,"AstraZeneca, Merck Report FDA Acceptance Of Regulatory Submission For New Drug Application For Selumetinib In Neurofibromatosis Type 1, Priority Review Granted",2019-11-14 06:55:00-05:00,AZN,positive
127214.0,AstraZeneca Defends Analysis Of Roxadustat After A Report Said Key Data Was Excluded,2019-11-13 09:00:00-05:00,AZN,negative
127215.0,"Aravive, AstraZeneca Report Initiation Of Randomized Phase 1/2 Study Of AVB-500 In Combo With Durvalumab In Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer",2019-11-12 09:08:00-05:00,AZN,negative
127216.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,AZN,neutral
127217.0,AstraZeneca Announces Anifrolumab Demonstrated Superiority in TULIP 2,2019-11-12 04:28:00-05:00,AZN,positive
127218.0,"UPDATE: On Primary Endpoint, Anifrolumab Achieved Statistically Significant & Clinically Meaningful Reduction In Disease Activity At Week 52; 47.8% Of Patients Receiving Anifrolumab Responded Compared With 31.5% Of Patients On Placebo",2019-11-11 11:06:00-05:00,AZN,positive
127219.0,Astrazeneca Says Anifrolumab Showed Superiority Across Multiple Efficacy Endpoints In Patients With Systemic Lupus Erythematosus In Phase III Tulip 2 Trial,2019-11-11 11:06:00-05:00,AZN,positive
127220.0,These Are The Winners Of The Inaugural WeTrader Paper Trading Competition,2019-11-11 10:53:00-05:00,AZN,positive
127221.0,"Bulls And Bears Of The Week: Roku, Tesla, Twitter, Uber And More",2019-11-09 16:43:00-05:00,AZN,neutral
127222.0,AstraZeneca Says Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy And No Increased Cardiovascular Risk In Patients With Anemia From Chronic Kidney Disease Versus Comparators,2019-11-08 14:04:00-05:00,AZN,positive
127223.0,"AstraZeneca Files For Potential Debt Shelf Offering, Size Not Disclosed",2019-11-08 08:59:00-05:00,AZN,negative
127224.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,AZN,neutral
127225.0,AstraZeneca Says Roxadustat Significantly Increased Haemoglobin,2019-11-08 04:44:00-05:00,AZN,positive
127226.0,"Former Google, Pharma Execs Start Ritual-Based Cannabis Company",2019-11-07 17:15:00-05:00,AZN,neutral
127227.0,Biotech Stock On The Radar: Alkermes At A Crossroads,2019-11-07 11:53:00-05:00,AZN,neutral
127228.0,"AstraZeneca Highlights Will Present First Data From Phase 3 ELEVATE-TN Trial Assessing CALQUENCE In Patients with Previously-Untreated Chronic Lymphocytic Leukemia At ASH Dec. 7-10, 2019",2019-11-06 15:18:00-05:00,AZN,neutral
127229.0,AstraZeneca Named The Most Innovative Global Pharma Company,2019-11-06 11:20:00-05:00,AZN,positive
127230.0,Sun Pharma and AstraZeneca enter into License Agreement for Novel Oncology products in China,2019-11-06 04:14:00-05:00,AZN,positive
127231.0,AstraZeneca Announces Three Large-scale Initiatives in China to Advance Global Medicine Research and Development,2019-11-06 04:09:00-05:00,AZN,neutral
127232.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,AZN,neutral
127233.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,AZN,positive
127234.0,AstraZeneca shares are trading higher after the company announced it will sell its commercial rights to Seroquel and Seroquel XR in Europe and Russia to Cheplapharm for $178 million plus up to $61 million in future sales-contingent payments.,2019-10-30 12:42:00-04:00,AZN,positive
127235.0,13 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-30 07:32:00-04:00,AZN,neutral
127236.0,AstraZeneca Divests Rights to Seroquel and Seroquel XR in Europe and Russia to Cheplapharm for $178M Plus Up to $61M in Future Sales-Contingent Payments,2019-10-30 03:48:00-04:00,AZN,neutral
127237.0,"The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study",2019-10-29 07:32:00-04:00,AZN,positive
127238.0,"AstraZeneca Issues Press Release Confirmed IMFINZI, IMFINZI Plus Tremelimumab Delayed Disease Progression In Phase 3 POSEIDON Trial",2019-10-28 15:16:00-04:00,AZN,negative
127239.0,AstraZeneca's Triple Combo Lung Cancer Therapy Aces Late-Stage Trial,2019-10-28 15:13:00-04:00,AZN,negative
127240.0,"AstraZeneca Shares Resume Trade, Up 1.3% For Session",2019-10-28 12:03:00-04:00,AZN,positive
127241.0,"CORRECTION On Aggregated Headline From 2 Other Publications: AstraZeneca Reported Imfinzi, Imfinzi Plus Tremelimumab Delayed Disease Progression In Phase 3 POSEIDON Trial",2019-10-28 11:44:00-04:00,AZN,negative
127242.0,UPDATE: AstraZeneca Says Triple Combo Did Not Result In Increased Discontinuation Of Threapy,2019-10-28 11:40:00-04:00,AZN,negative
127243.0,UPDATE: AstraZeneca Says Phase 3 Poseidon Trial Met Primary Endpoint,2019-10-28 11:39:00-04:00,AZN,neutral
127244.0,"Merck Shares Fall 2% Following Report AstraZeneca Trial Of Imfinzi, Imfinzi Plus Tremelimumab Delayed Disease Progression In Phase 3 Trial",2019-10-28 11:38:00-04:00,AZN,positive
127245.0,UPDATE: AstraZeneca Says Poseidon Trial Will Continue To Assess Added Primary Endpoint Of Overall Survival,2019-10-28 11:33:00-04:00,AZN,neutral
127246.0,"AstraZeneca Says Imfinzi, Imfinzi Plus Tremelimumab Delayed Disease Progression In Phase 3 POSEIDON Trial",2019-10-28 11:32:00-04:00,AZN,negative
127247.0,AstraZeneca Shares Halted News Pending,2019-10-28 11:22:00-04:00,AZN,positive
127248.0,NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with AstraZeneca's Durvalumab in Solid Tumors,2019-10-28 04:11:00-04:00,AZN,positive
127249.0,WeTrader Competition: Round Three Wrap-up,2019-10-25 16:03:00-04:00,AZN,neutral
127250.0,"The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug",2019-10-25 07:12:00-04:00,AZN,positive
127251.0,AstraZeneca shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.,2019-10-24 07:29:00-04:00,AZN,positive
127252.0,AstraZeneca Q3 EPS $0.99 vs $0.95 Est; Revenue $6.41B vs $6.11B Est,2019-10-24 04:19:00-04:00,AZN,neutral
127253.0,"Earnings Scheduled For October 24, 2019",2019-10-24 04:05:00-04:00,AZN,neutral
127254.0,Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption,2019-10-23 16:27:00-04:00,AZN,neutral
127255.0,"3 Stocks Moving On FDA Verdicts: Alexion, AstraZeneca, Foamix",2019-10-21 12:42:00-04:00,AZN,positive
127256.0,Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition,2019-10-21 11:16:00-04:00,AZN,neutral
127257.0,AstraZeneca's FARXIGA Approved in the US to Reduce the Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes,2019-10-21 07:16:00-04:00,AZN,negative
127258.0,AstraZeneca Announces Farxiga Approved in the US to Reduce the Risk of Hospitalization for Heart Failure in Patients With Type-2 Diabetes,2019-10-21 04:03:00-04:00,AZN,negative
127259.0,"Benzinga's Bulls And Bears Of The Week: Beyond Meat, Netflix, Johnson & Johnson And More",2019-10-19 12:40:00-04:00,AZN,neutral
127260.0,AstraZeneca Shares Trade Higher After FDA Grants Breast Cancer Drug Priority Review,2019-10-17 10:51:00-04:00,AZN,negative
127261.0,AstraZeneca And Daiichi Sankyo's Trastuzumab Deruxtecan Granted FDA Priority Review For Treatment Of Patients With HER2-Positive Metastatic Breast Cancer,2019-10-17 07:10:00-04:00,AZN,negative
127262.0,AstraZeneca Says Trastuzumab Deruxtecan Granted FDA Priority Review,2019-10-17 04:11:00-04:00,AZN,positive
127263.0,Innate Pharma IPO: What You Need To Know,2019-10-15 13:26:00-04:00,AZN,neutral
127264.0,IPO Outlook For The Week: Cancer Therapies And Protein Powders,2019-10-14 08:21:00-04:00,AZN,negative
127265.0,"ImaginAb Signs Multi-party Collaboration Agreement With Pfizer, AstraZeneca, Takeda to Help Further Develop Company's Cd8 Immunopet Technology",2019-10-14 04:25:00-04:00,AZN,positive
127266.0,"Notable Insider Buys In The Past Week: Assured Guaranty, Red Rock Resorts, TerraForm Power",2019-10-12 17:30:00-04:00,AZN,positive
127267.0,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,2019-10-11 11:19:00-04:00,AZN,positive
127268.0,13 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-09 07:54:00-04:00,AZN,neutral
127269.0,"Fitch Affirms Astrazeneca At 'BBB+', Stable Outlook",2019-10-08 12:50:00-04:00,AZN,positive
127270.0,"Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks",2019-10-08 11:08:00-04:00,AZN,positive
127271.0,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,2019-10-08 10:36:00-04:00,AZN,positive
127272.0,Hearing Wellington Mgmt. Co. Filing On AstraZeneca Shows 5.88% Stake; BZ NOTE: Wellington Mgmt. Group Had Shown ~66M Share Stake As Of End Of Last Qtr.,2019-10-04 10:07:00-04:00,AZN,positive
127273.0,AstarZeneca Reports FASENRA Approved In US For Self Administration Via FASENRA Pen,2019-10-04 07:00:00-04:00,AZN,positive
127274.0,"Fasenra Approved in the US for Self-administration in a New Pre-filled Auto-injector, the Fasenra Pen",2019-10-04 05:08:00-04:00,AZN,positive
127275.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.,2019-10-02 10:33:00-04:00,AZN,negative
127276.0,"AstraZeneca Divests Rights for Losec to Cheplapharm; Cheplapharm to Pay AstraZeneca ~$243M on Completion of the Agreement, Plus Sales-contingent Milestones of up to $33M in 2021, 2022",2019-10-01 04:52:00-04:00,AZN,positive
127277.0,"Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More",2019-09-30 13:13:00-04:00,AZN,positive
127278.0,TAGRISSO Is the Only 1st-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer to Deliver a Median Overall Survival of More Than Three Years,2019-09-30 10:34:00-04:00,AZN,negative
127279.0,"Merck, AstraZeneca Highlight Data LYNPARZA More Than Doubled Median Radiographic Progression-Free Survival In BRCA1/2, ATM Metastatic Castration-Resistant Prostate Cancer",2019-09-30 10:31:00-04:00,AZN,negative
127280.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,AZN,positive
127281.0,"AstraZeneca , Merck Announced LYNPARZA Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer at ESMO 2019",2019-09-28 18:31:00-04:00,AZN,negative
127282.0,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave",2019-09-27 07:56:00-04:00,AZN,positive
127283.0,AstraZeneca Reports BRILINTA  Monotherapy In High-bleeding Risk Patients Who Underwent Pci Had Reduced Risk Of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy In The Twilight Trial; Says Achieved Secondary Endpoint Of Non-Inferiority,2019-09-26 14:55:00-04:00,AZN,negative
127284.0,Innate Pharma Announces  AstraZeneca to Advance Monalizumab to Phase III in Head and Neck Cancer,2019-09-26 03:51:00-04:00,AZN,negative
127285.0,"The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug",2019-09-25 07:13:00-04:00,AZN,positive
127286.0,14 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-24 08:07:00-04:00,AZN,neutral
127287.0,Astrazeneca Says Qtrilmet Recommended for Approval in EU by CHMP-,2019-09-23 03:56:00-04:00,AZN,positive
127288.0,The Week Ahead In Biotech: Spotlight On ESMO Conference,2019-09-22 16:22:00-04:00,AZN,neutral
127289.0,15 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-20 08:24:00-04:00,AZN,neutral
127290.0,CHMP Recommends Granting Marketing Authorisation for Astrazeneca's Qtrilmet for Treatment of Type 2 Diabetes Mellitus,2019-09-20 06:29:00-04:00,AZN,positive
127291.0,"CHMP Recommends Granting Marketing Authorization For Astrazeneca's Qtrilmet, Rhokiinsa And Xospata",2019-09-20 06:29:00-04:00,AZN,positive
127292.0,AstraZeneca PLC shares are trading higher on seemingly no company-specific news.,2019-09-19 09:09:00-04:00,AZN,neutral
127293.0,18 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-09-19 08:19:00-04:00,AZN,neutral
127294.0,"The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts",2019-09-18 07:39:00-04:00,AZN,neutral
127295.0,"Ironwood Pharmaceuticals, AstraZeneca Amend LINZESS Collaboration in China",2019-09-18 04:18:00-04:00,AZN,neutral
127296.0,Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline,2019-09-17 16:35:00-04:00,AZN,neutral
127297.0,9 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-17 08:13:00-04:00,AZN,neutral
127298.0,AstraZeneca Reports FDA Granted Fast Track Designation For FARXIGA In Heart Failure,2019-09-16 07:36:00-04:00,AZN,negative
127299.0,A Peek Into The Markets: US Stock Futures Down; Crude Oil Jumps Following Saudi Attack,2019-09-16 06:38:00-04:00,AZN,negative
127300.0,AstraZeneca Announces FDA Grants Fast Track Designation for Farxiga in Heart Failure,2019-09-16 04:13:00-04:00,AZN,negative
127301.0,Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.,2019-09-10 10:30:00-04:00,AZN,positive
127302.0,22 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-10 09:02:00-04:00,AZN,neutral
127303.0,AstraZeneca shares trading lower on continued momentum despite yesterday's news that the company's Imfinzi improved durable responses in extensive-stage small cell lung cancer.,2019-09-10 08:15:00-04:00,AZN,negative
127304.0,AstraZeneca shares trading lower despite earlier news the company's Imfinzi improved durable responses in extensive-stage small cell lung cancer.,2019-09-09 13:26:00-04:00,AZN,negative
127305.0,"AstraZeneca's Imfinzi Shows Both Significant Survival Benefit and Improved, Durable Responses in Extensive-stage Small Cell Lung Cancer",2019-09-09 03:45:00-04:00,AZN,positive
127306.0,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",2019-09-08 11:01:00-04:00,AZN,neutral
127307.0,Theragnostics Signs IP Agreement with AstraZeneca,2019-09-05 05:29:00-04:00,AZN,positive
127308.0,Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day,2019-09-04 16:42:00-04:00,AZN,neutral
127309.0,"The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight",2019-09-02 15:13:00-04:00,AZN,neutral
127310.0,AstraZeneca Announces BRILINTA Reduced the Risk of Cardiovascular Events in Patients With Coronary Artery Disease and Type 2 Diabetes in Phase III THEMIS Trial,2019-09-01 10:58:00-04:00,AZN,negative
127311.0,AstraZeneca Announces Detailed Results from Phase III DAPA-HF Trial Showed FARXIGA Significantly Reduced Both the Incidence of Cardiovascular Death and the Worsening of Heart Failure,2019-09-01 10:56:00-04:00,AZN,negative
127312.0,AstraZeneca Spin-Off Viela Bio Files For IPO,2019-08-30 13:50:00-04:00,AZN,neutral
127313.0,AstraZeneca Announces Phase III ETHOS Trial Met Its Primary Endpoint In Chronic Obstructive Pulmonary Disease,2019-08-28 07:00:00-04:00,AZN,neutral
127314.0,Grants Fast Track Designation To AstraZeneca For FARXIGA In Chronic Kidney Disease,2019-08-27 07:02:00-04:00,AZN,positive
127315.0,"Bulls And Bears Of The Week: Chevron, Disney, Target And More",2019-08-24 15:04:00-04:00,AZN,neutral
127316.0,10 Biopharmaceutical Companies Trying To Cure Cancer,2019-08-24 13:46:00-04:00,AZN,negative
127317.0,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study",2019-08-22 07:18:00-04:00,AZN,positive
127318.0,AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi for $95M in Cash,2019-08-22 04:18:00-04:00,AZN,positive
127319.0,AstraZeneca Announces Roxadustat Approved in China for the Treatment of Anaemia in Non-dialysis-dependent Patients With Chronic Kidney Disease,2019-08-22 04:17:00-04:00,AZN,positive
127320.0,AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study,2019-08-21 09:04:00-04:00,AZN,negative
127321.0,AstraZeneca Announces FARXIGA Met Primary Endpoint In Landmark Phase III DAPA-HF Trial For The Treatment Of Patients With Heart Failure,2019-08-20 07:01:00-04:00,AZN,negative
127322.0,AstraZeneca Says Farxiga Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients With Heart Failure,2019-08-20 04:02:00-04:00,AZN,negative
127323.0,AstraZeneca 's CALQUENCE Granted US Breakthrough Therapy Designation For Chronic Lymphocytic Leukemia,2019-08-14 08:07:00-04:00,AZN,positive
127324.0,"The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering",2019-08-14 07:50:00-04:00,AZN,negative
127325.0,AstraZeneca And Merck Announce LYNPARZA) Phase 3 PAOLA-1 Trial Met Primary Endpoint In Ovarian Cancer Patients,2019-08-14 06:56:00-04:00,AZN,negative
127326.0,AstraZeneca Says Calquence Granted US Breakthrough Therapy Designation from FDA for Chronic Lymphocytic Leukaemia,2019-08-14 04:42:00-04:00,AZN,positive
127327.0,Lynparza Phase Iii Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer,2019-08-14 04:40:00-04:00,AZN,negative
127328.0,"AstraZeneca, Merck Announce Lynparza Phase III PAOLA-1 Trial Met Primary Endpoint",2019-08-14 04:37:00-04:00,AZN,neutral
127329.0,﻿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,AZN,positive
127330.0,AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis,2019-08-13 10:58:00-04:00,AZN,positive
127331.0,No-deal Brexit Could Worsen Europe's Medicine Shortage,2019-08-12 04:35:00-04:00,AZN,negative
127332.0,AstraZeneca PLC shares are trading higher after the company announced its Phase 3 FLAURA trial of Tagrisso significantly improved overall survival in patients with NSCLC.,2019-08-09 09:15:00-04:00,AZN,positive
127333.0,31 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-09 09:00:00-04:00,AZN,neutral
127334.0,AstraZeneca Reports TAGRISSO Significantly Improved Overall Survival In Phase III FLAURA Trial For 1st-Line EGFR-Mutated Non-Small Lung Cancer,2019-08-09 07:06:00-04:00,AZN,negative
127335.0,AstraZeneca Announces Tagrisso Significantly Improves Overall Survival in NSCLC,2019-08-09 04:06:00-04:00,AZN,positive
127336.0,Aevi Genomic Medicine Enters Into License Agreement With AstraZeneca For Anti-IL-18 Antibody,2019-08-07 09:10:00-04:00,AZN,positive
127337.0,"AstraZeneca, Merck Announce Lynparza Phase III PROfound Trial in HRR Mutation-selected Metastatic Castration-resistant Prostate Cancer Met Primary Endpoint",2019-08-07 04:33:00-04:00,AZN,negative
127338.0,"Inovalon Reports Will Implement Comprehensive Value Platform Initiative For AstraZeneca, No Terms Disclosed",2019-08-06 08:25:00-04:00,AZN,positive
127339.0,AstraZeneca Announces Forxiga Label Updated in the EU in Type-2 Diabetes,2019-08-05 05:10:00-04:00,AZN,neutral
127340.0,New Equities that Broke Through 52-Week Highs Monday Morning,2019-07-29 10:13:00-04:00,AZN,negative
127341.0,Companies That Achieved 52-Week Highs Friday,2019-07-26 15:37:00-04:00,AZN,neutral
127342.0,64 Biggest Movers From Yesterday,2019-07-26 04:36:00-04:00,AZN,neutral
127343.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-07-25 13:22:00-04:00,AZN,neutral
127344.0,AstraZeneca shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also extended its 2017 development agreement with BioCardia.,2019-07-25 08:24:00-04:00,AZN,positive
127345.0,25 Stocks Moving In Thursday's Pre-Market Session,2019-07-25 07:28:00-04:00,AZN,neutral
127346.0,"AstraZeneca Q2 EPS $0.73 Beats $0.29 Estimate, Sales $5.823B Beat $5.51B Estimate",2019-07-25 07:25:00-04:00,AZN,neutral
127347.0,BioCardia and AstraZeneca Extend Their 2017 Development Agreement,2019-07-25 06:29:00-04:00,AZN,positive
127348.0,"AstraZeneca Shares Rise 6% in London on Strong Sales, Demand for Cancer Drugs",2019-07-25 04:11:00-04:00,AZN,negative
127349.0,FDA Approves Inclusion Of Overall Survival Data On Phase III PACIFIC Trial Of AstraZeneca's IMFINZI,2019-07-22 08:01:00-04:00,AZN,positive
127350.0,AstraZeneca Announces FDA Issues CRL for Farxiga,2019-07-15 03:25:00-04:00,AZN,neutral
127351.0,"Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug",2019-07-12 10:19:00-04:00,AZN,neutral
127352.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,AZN,negative
127353.0,"The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight",2019-07-05 08:55:00-04:00,AZN,negative
127354.0,AstraZeneca Announces Forxiga Receives Positive EU CHMP Opinion for DECLARE-TIMI 58 Cardiovascular Outcomes Data,2019-07-01 04:29:00-04:00,AZN,positive
127355.0,AstraZeneca Announces Imfinzi Improves Overall Survival at Interim Analysis in Phase III CASPIAN Trial in 1st-line Extensive-stage Small Cell Lung Cancer,2019-06-27 04:25:00-04:00,AZN,negative
127356.0,"AstraZeneca,Merck Announce Lynparza Approved in Japan for 1st-line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer",2019-06-19 04:58:00-04:00,AZN,negative
127357.0,AstraZeneca Annonces Breztri Aerosphere Approved in Japan for Patients with COPD,2019-06-19 04:55:00-04:00,AZN,positive
127358.0,AstraZeneca shares trading higher following news of Lynparza approval in the European Union.,2019-06-18 13:39:00-04:00,AZN,positive
127359.0,"The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale",2019-06-18 07:31:00-04:00,AZN,neutral
127360.0,"AstraZeneca, Merck Report LYNPARZA Approved In EU For Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer",2019-06-18 06:31:00-04:00,AZN,negative
127361.0,"AstraZeneca, Merck Announce Lynparza Approved in the EU for 1st-line Maintenance Treatment Of BRCA-mutated Advanced Ovarian Cancer",2019-06-18 04:27:00-04:00,AZN,negative
127362.0,AstraZeneca  Announces Calquence Significantly Prolonged Time Patients Lived Without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia,2019-06-17 04:33:00-04:00,AZN,neutral
127363.0,Astrazeneca Says Lokelma Showed Efficacy Treating Hyperkalaemia Patients,2019-06-14 06:33:00-04:00,AZN,neutral
127364.0,"AstraZeneca Reports FARXIGA Study Showed Reduced Progression Of Kidney Disease, Renal Death In Patients with Type-2 Diabetes: 'showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death'",2019-06-10 08:04:00-04:00,AZN,negative
127365.0,Sanofi's Leadership Transition: What You Need To Know,2019-06-07 12:25:00-04:00,AZN,neutral
127366.0,AstraZeneca Announces Calquence Phase III ELEVATE-TN Trial Met Primary Endpoint,2019-06-06 04:32:00-04:00,AZN,neutral
127367.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,AZN,positive
127368.0,"The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer",2019-06-04 07:45:00-04:00,AZN,negative
127369.0,"AstraZeneca Board Is At Early Stages Of Planning To Seek Eventual Replacement For Leif Johansson, Who Has Chaired Co For 7 Years",2019-06-03 14:06:00-04:00,AZN,neutral
127370.0,Myriad Genetics Announces BRACAnalysis CDx Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza at #ASCO19,2019-06-02 10:14:00-04:00,AZN,negative
127371.0,"AstraZeneca IMFINZI Demonstrates Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer at #ASCO19",2019-06-02 10:12:00-04:00,AZN,negative
127372.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,AZN,neutral
127373.0,"The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation",2019-05-29 07:38:00-04:00,AZN,neutral
127374.0,Inovio Pharmaceuticals Receives Notification From AstraZeneca Subsidiary MedImmune That AstraZeneca Intends To Discontinue Activities With Respect To Most Research Collaboration Programs,2019-05-28 16:10:00-04:00,AZN,positive
127375.0,AstraZeneca to Invest $220M in Vietnam from 2020-2024,2019-05-28 04:04:00-04:00,AZN,neutral
127376.0,AstraZeneca Highlights Phase III Data For FASENRA Showed Patients With Severe Eosinophilic Asthma Treated For Up To 2 Years ' reduced their use of oral corticosteroids',2019-05-20 08:04:00-04:00,AZN,negative
127377.0,AstraZeneca Announces New Data Show Symbicort Reduces Attacks in Mild Asthma When Used as Anti-inflammatory Reliever,2019-05-20 03:52:00-04:00,AZN,negative
127378.0,"Shares of many Healthcare companies are trading higher as markets rebound from the recent volatility caused by uncertainty regarding US-China trade talks. Also, lawmakers were not able to pass a bill that would end 'surprise medical bills'.",2019-05-16 15:09:00-04:00,AZN,positive
127379.0,AstraZeneca Reports New Data on Symbicort as Potential Anti-inflammatory Reliever in Mild Asthma to be Presented at ATS 2019,2019-05-16 04:05:00-04:00,AZN,positive
127380.0,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.",2019-05-14 13:32:00-04:00,AZN,positive
127381.0,Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%,2019-05-10 13:09:00-04:00,AZN,positive
127382.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,AZN,negative
127383.0,AstraZeneca  Announces Pooled Analyses of the Roxadustat Global Phase III Programme Confirmed Cardiovascular Safety,2019-05-10 04:30:00-04:00,AZN,positive
127384.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,AZN,negative
127385.0,AstraZeneca Announces Trastuzumab Deruxtecan Demonstrated Clinically-meaningful Response in Patients With Refractory Her2-positive Metastatic Breast Cancer,2019-05-08 04:03:00-04:00,AZN,negative
127386.0,AstraZeneca Reports Calquence Phase III ASCEND Trial Met Primary Endpoint At Interim Analysis in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Will Stop Early,2019-05-07 04:02:00-04:00,AZN,negative
127387.0,AstraZeneca Says Safety And Tolerability Of Calquence Was Consistent With Known Profile; Says Study Results Showed Statistically-Significant & Clinically-Meaningful Improvement In Progression-Free Survival With Calquence Monotherapy,2019-05-06 14:02:00-04:00,AZN,positive
127388.0,AstraZeneca Announces Qternmet XR Approved in US for Type-2 Diabetes,2019-05-03 04:27:00-04:00,AZN,positive
127389.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,AZN,positive
127390.0,"Transgene, Astrazeneca Enter Collaboration, Exclusive License Option Agreement for Innovative Invir.iotm Based Armed Oncolytic Immunotherapies",2019-05-02 03:59:00-04:00,AZN,positive
127391.0,Shares of several pharmaceutical companies are trading higher in sympathy with Pfizer and Merck after the companies reported strong Q1 earnings.,2019-04-30 09:34:00-04:00,AZN,positive
127392.0,Astrazeneca Starts Artificial Intelligence Collaboration with BenevolentAI to Accelerate Drug Discovery,2019-04-30 03:24:00-04:00,AZN,positive
127393.0,"AstraZeneca, Merck Announce Lynparza Receives Positive EU CHMP Opinion for 1st-line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer",2019-04-29 04:10:00-04:00,AZN,positive
127394.0,AstraZeneca shares trading lower despite better-than-expected Q1 earnings and sales and reaffirmed FY19 guidance.,2019-04-26 10:17:00-04:00,AZN,neutral
127395.0,AstraZeneca PLC Q1 EPS $0.47 Beats $0.42 Est.; Revenue $5.49B Beats $5.42B Est,2019-04-26 03:36:00-04:00,AZN,neutral
127396.0,AstraZeneca Option Alert: May 17 $40 Calls Sweep (23) near the Ask: 500 @ $0.549 vs 3443 OI; Earnings 5/17 Before Open [est] Ref=$38.8,2019-04-24 14:06:00-04:00,AZN,positive
127397.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-18 10:51:00-04:00,AZN,negative
127398.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-17 10:31:00-04:00,AZN,negative
127399.0,FDA Approves AstraZeneca's Duaklir Pressair For Patients With Chronic Obstructive Pulmonary Disease (COPD),2019-04-17 06:56:00-04:00,AZN,positive
127400.0,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.,2019-04-16 15:34:00-04:00,AZN,negative
127401.0,"AstraZeneca, Merck Announce Lynparza Approved in EU for the treatment of Germline BRCA-mutated HER2-negative Advanced Breast Cancer",2019-04-10 03:56:00-04:00,AZN,negative
127402.0,Mid-Afternoon Market Update: Dow Down Over 200 Points; Precipio Shares Spike Higher,2019-04-09 14:52:00-04:00,AZN,positive
127403.0,Mid-Day Market Update: Command Center Surges Following Merger Deal With Hire Quest; Hollysys Automation Shares Slide,2019-04-09 12:25:00-04:00,AZN,positive
127404.0,Mid-Morning Market Update: Markets Open Lower; PhaseBio Gets Breakthrough Therapy Designation For PB2452,2019-04-09 10:10:00-04:00,AZN,negative
127405.0,"The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing",2019-04-09 08:10:00-04:00,AZN,neutral
127406.0,Inovio Pharma Reports Achieved Third Indication Milestone From AstraZeneca Related To Dosing Of Patient In Phase 2 Combo Trial Evaluating MEDI0457,2019-04-08 09:06:00-04:00,AZN,neutral
127407.0,"Myriad Genetics, AstraZeneca, Merck Report Expansion Of Companion Diagnostic Partnership",2019-04-04 07:18:00-04:00,AZN,neutral
127408.0,"Benzinga's Top Upgrades, Downgrades For April 2, 2019",2019-04-02 09:13:00-04:00,AZN,positive
127409.0,UBS Downgrades AstraZeneca to Sell,2019-04-02 07:57:00-04:00,AZN,neutral
127410.0,AstraZeneca's Rare Pediatric Genetic Disorder Drug Granted Breakthrough Therapy Designation,2019-04-01 11:19:00-04:00,AZN,negative
127411.0,10 Biggest Price Target Changes For Monday,2019-04-01 09:36:00-04:00,AZN,neutral
127412.0,"Benzinga's Top Upgrades, Downgrades For April 1, 2019",2019-04-01 09:02:00-04:00,AZN,positive
127413.0,24 Stocks Moving In Monday's Pre-Market Session,2019-04-01 08:14:00-04:00,AZN,neutral
127414.0,AstraZeneca shares are trading higher after the FDA granted Breakthrough Therapy Designation for the company's Zelumetinib and the stock was upgraded from Market Perform to Outperform by Cowen.,2019-04-01 06:54:00-04:00,AZN,positive
127415.0,Merck and AstraZeneca's Selumetinib is Granted Breakthrough Therapy Designation in Neurofibromatosis Type 1,2019-04-01 06:33:00-04:00,AZN,positive
127416.0,"Cowen & Co. Upgrades AstraZeneca to Outperform, Raises Price Target to $48",2019-04-01 06:19:00-04:00,AZN,neutral
127417.0,62 Biggest Movers From Friday,2019-04-01 04:46:00-04:00,AZN,neutral
127418.0,"AstraZeneca, Merck Announce Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1",2019-04-01 04:22:00-04:00,AZN,positive
127419.0,44 Stocks Moving In Friday's Mid-Day Session,2019-03-29 12:38:00-04:00,AZN,neutral
127420.0,Japan's Daiichi Strikes Cancer Therapy Deal With AstraZeneca Worth Up To $6.9B,2019-03-29 11:30:00-04:00,AZN,negative
127421.0,FDA Approves Astrazeneca's Duaklir Pressair For Maintenance Treatment Of Patients With Chronic Obstructive Pulmonary Disease,2019-03-29 10:48:00-04:00,AZN,positive
127422.0,AstraZeneca PLC shares are trading lower after the company announced it would need to make a public offering for $3.5 billion to fund a $6.9 billion cancer drug deal with the Japanese company Daiichi Sankyo.,2019-03-29 08:58:00-04:00,AZN,negative
127423.0,AstraZeneca Announced A $3.5B Equity Placement To Fund Deal With Daiichi Sankyo For Collaboration On Novel HER2-Targeting Antibody-Drug Conjugate,2019-03-29 08:58:00-04:00,AZN,positive
127424.0,31 Stocks Moving In Friday's Pre-Market Session,2019-03-29 08:05:00-04:00,AZN,neutral
127425.0,"The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead",2019-03-29 07:42:00-04:00,AZN,positive
127426.0,"Daiichi Sankyo, AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo's HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201); Total Payments by AstraZeneca to Daiichi Could Reach $6.9B",2019-03-29 05:16:00-04:00,AZN,neutral
127427.0,UK's NHS to Pay for AstraZeneca's Cancer Drug Imfinzi,2019-03-28 03:57:00-04:00,AZN,negative
127428.0,"UPDATE: Seeking Alpha Post On AstraZeneca For Aveo Shows Price In $800M-$1.2B Range; BZ NOTE: Author Of Post Has 5 Followers, Has Posted On SA Only 2 Times Previously, Disclosed Is Long Aveo",2019-03-27 09:05:00-04:00,AZN,positive
127429.0,"'According to representatives from several large investment banks, it is their firm belief that Astrazeneca will acquire Aveo Oncology...' -Seeking Alpha Blog Post From TheBlueLion",2019-03-27 09:04:00-04:00,AZN,neutral
127430.0,Astrazeneca Announces Forxiga Approved In Japan For Type-1 Diabetes,2019-03-27 04:18:00-04:00,AZN,positive
127431.0,"Ichor Medical Reports Entered Collab, Research License Deal With AstraZeneca For Development, Clinical Assessment Of Plasmid DNA Constructs",2019-03-26 07:18:00-04:00,AZN,neutral
127432.0,AstraZeneca Announces Forxiga Approved in Europe for Type-1 Diabetes,2019-03-25 03:50:00-04:00,AZN,positive
127433.0,"The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering",2019-03-21 07:51:00-04:00,AZN,negative
127434.0,"The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company",2019-03-20 07:46:00-04:00,AZN,negative
127435.0,"The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed",2019-03-19 07:40:00-04:00,AZN,neutral
127436.0,AstraZeneca Says First Sub-Analyses From The DECLARE-TIMI 58 Trial Further Support The Cardiovascular Effects Of FARXIGA In Type 2 Diabetes,2019-03-18 09:02:00-04:00,AZN,positive
127437.0,AstraZeneca is Mounting a Big Push into Digital Technologies,2019-03-18 03:46:00-04:00,AZN,neutral
127438.0,AstraZeneca Announces FDA Grants Saracatinib Orphan Drug Designation for Idiopathic Pulmonary Fibrosis,2019-03-18 03:39:00-04:00,AZN,positive
127439.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2019-03-16 08:35:00-04:00,AZN,neutral
127440.0,"UPDATE: Seres Will Receive $20M, Financial Support For Research Activities",2019-03-11 09:31:00-04:00,AZN,positive
127441.0,Seres Therapeutics Reports Microbiome Immuno-Oncology Focused Collaboration With AstraZeneca,2019-03-11 09:31:00-04:00,AZN,positive
127442.0,AstraZeneca To Present New Cardiovascular Data On FARXIGA In Type 2 Diabetes At ACC 2019,2019-03-11 08:04:00-04:00,AZN,neutral
127443.0,"The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split",2019-03-06 07:39:00-05:00,AZN,negative
127444.0,Merck Reports Positive CHMP Opinion For Use In Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer,2019-03-01 08:45:00-05:00,AZN,positive
127445.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,AZN,positive
127446.0,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings",2019-02-27 08:13:00-05:00,AZN,neutral
127447.0,AstraZeneca Announces FDA Approval Of Expanded FARXIGA And XIGDUO XR Labels For Use In Patients With Type 2 Diabetes And Moderate Renal Impairment,2019-02-27 08:01:00-05:00,AZN,positive
127448.0,"UPDATE: Merck, AstraZeneca Report Phase III POLO Trial Met Primary Endpoint",2019-02-26 06:57:00-05:00,AZN,neutral
127449.0,"Merck, AstraZeneca Report LYNPARZA Reduced the Risk of Disease Progression or Death as 1st-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer",2019-02-26 06:56:00-05:00,AZN,negative
127450.0,"AstraZeneca, Merck Announce Phase III POLO Trial Met its Primary Endpoint of Progression-free Survival",2019-02-26 04:01:00-05:00,AZN,neutral
127451.0,AstraZeneca's Brilinta Found To Alleviate Cardiovascular Risk In Late-Stage Study,2019-02-25 10:51:00-05:00,AZN,negative
127452.0,AstrazZeneca's Brilinta's Phase 3 Trial Met its Primary Endpoint in Patients with Established Coronary Artery Disease and Type-2 Diabetes,2019-02-25 07:04:00-05:00,AZN,neutral
127453.0,AstraZeneca Announces Brilinta's PhIII THEMIS Trial Met Primary Endpoint,2019-02-25 04:47:00-05:00,AZN,neutral
127454.0,71 Biggest Movers From Yesterday,2019-02-15 04:59:00-05:00,AZN,neutral
127455.0,52 Stocks Moving In Thursday's Mid-Day Session,2019-02-14 12:27:00-05:00,AZN,neutral
127456.0,AstraZeneca shares are trading higher after the company reported Q4 revenue of $6.42B versus the $6.27B estimate and announced better than expected 2019 guidance.,2019-02-14 08:17:00-05:00,AZN,positive
127457.0,30 Stocks Moving In Thursday's Pre-Market Session,2019-02-14 08:07:00-05:00,AZN,neutral
127458.0,"Earnings Scheduled For February 14, 2019",2019-02-14 04:21:00-05:00,AZN,neutral
127459.0,AstraZeneca Q4 Adj EPS $1.58; Revenue $6.42B vs $6.27B Est,2019-02-14 04:02:00-05:00,AZN,neutral
127460.0,AstraZeneca FDA Breakthrough Therapy Designation for Potential Next-generation RSV Medicine MEDI8897,2019-02-05 04:07:00-05:00,AZN,neutral
127461.0,AstraZeneca Announces EMA Grants PRIME Eligibility for MEDI8897,2019-02-05 04:05:00-05:00,AZN,positive
127462.0,Astrazeneca's FORXIGA Receives Positive EU Opinion,2019-02-01 08:21:00-05:00,AZN,positive
127463.0,"The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study",2019-01-23 07:22:00-05:00,AZN,positive
127464.0,Astellas Pharma Announces Sale And Distribution Of Symbicort Turbuhaler Conducted By Astellas In Japan To Be Transferred To Astrazeneca,2019-01-17 04:05:00-05:00,AZN,neutral
127465.0,Luye Pharma Grants AstraZeneca China Exclusive Rights To Promote Co's Xuezhikang Capsules In Mainland China,2019-01-16 06:42:00-05:00,AZN,positive
127466.0,Sosei Heptares to Receive $15M Milestone Payment in Q1 From AstraZeneca,2019-01-07 03:55:00-05:00,AZN,neutral
127467.0,Ironwood Pharmaceuticals Picks AztraZeneca Executive To Be Next CEO,2019-01-04 11:15:00-05:00,AZN,neutral
127468.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,AZN,neutral
127469.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,AZN,neutral
127470.0,When Larger Firms Walk Away From Partnerships With Smaller Ones: How Bad Is The Damage?,2018-12-21 13:38:00-05:00,AZN,negative
127471.0,AstraZeneca's Bevespi Aerosphere Approved In EU For COPD,2018-12-20 08:51:00-05:00,AZN,positive
127472.0,AstraZeneca shares are trading higher after announcing Phase III Olympus And Rockies Trials For Roxadustat Met Primary Endpoints In Chronic Kidney Disease Patients With Anaemia.,2018-12-20 08:40:00-05:00,AZN,positive
127473.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,AZN,positive
127474.0,"AstraZeneca Reports Phase III OLYMPUS, ROCKIES Trials For Roxadustat Each Met Primary Endpoint",2018-12-20 07:14:00-05:00,AZN,neutral
127475.0,"AstraZeneca, Merck Report LYNPARZA Met Primary Endpoint In Phase 3 SOLO-3 Trial For Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer",2018-12-20 06:36:00-05:00,AZN,negative
127476.0,AstraZeneca Reports Phase III Olympus And Rockies Trials For Roxadustat Met Primary Endpoints In Chronic Kidney Disease Patients With Anaemia,2018-12-20 03:58:00-05:00,AZN,neutral
127477.0,"AstraZeneca, Merck Report FDA Approval For LYNPARZA For First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer",2018-12-19 16:01:00-05:00,AZN,negative
127478.0,Myriad Genetics Announces FDA Approval Of BRACAnalysis CDxAs A Companion Diagnostic For AstraZeneca's Lynparza For Ovarian Cancer,2018-12-19 13:11:00-05:00,AZN,negative
127479.0,"Benzinga's Top Upgrades, Downgrades For December 14, 2018",2018-12-14 09:08:00-05:00,AZN,positive
127480.0,"SunTrust Robinson Humphrey Initiates Coverage On AstraZeneca with Buy Rating, Announces $48 Price Target",2018-12-14 08:53:00-05:00,AZN,neutral
127481.0,"Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate",2018-12-11 12:42:00-05:00,AZN,positive
127482.0,"Jefferies Assumes AstraZeneca at Hold, Announces Price Target $42",2018-12-11 10:03:00-05:00,AZN,neutral
127483.0,Circassia Pharmaceuticals Issued Notice Of Option Exercise To AstraZeneca To Axquire Full US Commercial Rights To Tudorza,2018-12-11 07:17:00-05:00,AZN,neutral
127484.0,"AstraZeneca, Cancer Research UK Launch Functional Genomics Centre To Accelerate The Discovery Of New Medicines",2018-12-10 04:05:00-05:00,AZN,negative
127485.0,AstraZeneca's Head and Neck Cancer Treatment Fails to Meet Primary Endpoint,2018-12-07 04:21:00-05:00,AZN,negative
127486.0,"AstraZeneca Says Divestment of Rights to Alvesco, Omnaris and Zetonna to Covis for $350M has been Completed",2018-12-06 04:19:00-05:00,AZN,neutral
127487.0,"AstraZeneca Announces Grünenthal Agreement for Nexium, Vimovo Completed; AstraZeneca has Received Upfront Payments Totaling $815M",2018-12-03 04:33:00-05:00,AZN,positive
127488.0,Dynavax Technologies Informed By Collaborator AstraZeneca That Initial High-Level Results From Phase 2a Study Indicate AZD1419 Did Not Meet Primary Endpoint; AstraZeneca To Review Will Data Before Deciding Next Steps,2018-11-29 17:08:00-05:00,AZN,neutral
127489.0,Merck Is Up 40% In 2018: What's Driving The Rally?,2018-11-29 16:11:00-05:00,AZN,neutral
127490.0,"Biocartis, AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results",2018-11-29 04:23:00-05:00,AZN,negative
127491.0,AstraZeneca Announces FDA grants Fasenra Orphan Drug Designation for Eosinophilic Granulomatosis with Polyangiiti,2018-11-26 04:08:00-05:00,AZN,positive
127492.0,"Benzinga's Top Upgrades, Downgrades For November 19, 2018",2018-11-19 09:14:00-05:00,AZN,positive
127493.0,Investec Downgrades AstraZeneca to Hold,2018-11-19 07:54:00-05:00,AZN,neutral
127494.0,AstraZeneca shares are trading down 2.5% after the company's Imfinzi failed to meet primary endpoints in study of lung cancer.,2018-11-16 10:49:00-05:00,AZN,negative
127495.0,28 Stocks Moving In Friday's Pre-Market Session,2018-11-16 08:06:00-05:00,AZN,neutral
127496.0,AstraZeneca Reports Combination Of Imfinzi Plus Tremelimumab Did Not Meet The Primary Endpoints Of Improving OS Compared To Soc Chemotherapy in Stage IV NSCLC,2018-11-16 03:59:00-05:00,AZN,positive
127497.0,"The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut",2018-11-14 08:17:00-05:00,AZN,neutral
127498.0,"Sobi to Acquire Synagis US Rights from AstraZeneca for $1.5B in Cash, Sobi Stock",2018-11-13 03:20:00-05:00,AZN,neutral
127499.0,"AstraZeneca, Merck Announce FDA Accepts Regulatory Submission for Lynparza Maintenance Therapy in Newly-diagnosed, BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review",2018-11-12 04:09:00-05:00,AZN,negative
127500.0,AstraZeneca Reports FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial,2018-11-10 16:51:00-05:00,AZN,negative
127501.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,AZN,neutral
127502.0,AstraZeneca Shares are up 4.3% after the company beat Q3 EPS estimates but missed on sales.,2018-11-08 10:45:00-05:00,AZN,negative
127503.0,"Astrazeneca PLC Earlier Reported Q3 EPS $0.71 Beat $0.40 Estimate, Sales $5.34B Missed $5.49B Estimate",2018-11-08 10:42:00-05:00,AZN,negative
127504.0,"Earnings Scheduled For November 8, 2018",2018-11-08 04:00:00-05:00,AZN,neutral
127505.0,Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer,2018-11-07 16:11:00-05:00,AZN,negative
127506.0,Astrazeneca Q3 Earnings Preview,2018-11-07 13:29:00-05:00,AZN,neutral
127507.0,"AstraZeneca Announces Agreement to Sell Rights to Alvesco, Omnaris and Zetonna to Covis Pharma for $350M at Closing, Plus up yo $21M in Sales Milestones",2018-11-06 04:13:00-05:00,AZN,positive
127508.0,UPDATE: AstraZeneca to Receive $815M Upfront; Up to $107M in Milestones,2018-10-30 04:09:00-04:00,AZN,neutral
127509.0,"AstraZeneca Announces Agreement to Sell Rights to Grünenthal for Nexium in Europe, Vimovo Worldwide",2018-10-30 04:07:00-04:00,AZN,positive
127510.0,UPDATE: AztraZeneca Stake In PhaseBio Pharmaceuticals Was Acquired Before PhaseBio IPO,2018-10-29 13:12:00-04:00,AZN,neutral
127511.0,PhaseBio Pharmaceuticals 13D Shows AstraZeneca Holds 12.6% Stake In Co.,2018-10-29 13:09:00-04:00,AZN,neutral
127512.0,"Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week",2018-10-26 16:22:00-04:00,AZN,positive
127513.0,'A New Way To Treat The Brain': Stanford University Scientists Launch Cannabis Pharma Company,2018-10-26 13:14:00-04:00,AZN,positive
127514.0,AstraZeneca Says Phase III Harmonize Global Trial Of LOKELMA Confirms Efficacy In Maintaining Normal Potassium Levels In Patients With Hyperkalemia,2018-10-25 13:07:00-04:00,AZN,positive
127515.0,Innate Pharma Expands its Oncology Development Collaboration with AstraZeneca; AstraZeneca to Purchase Newly-issued 9.8% Equity Stake in Innate Pharma,2018-10-23 04:25:00-04:00,AZN,positive
127516.0,11 Stocks That Moved From ESMO 2018,2018-10-22 13:39:00-04:00,AZN,neutral
127517.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,AZN,neutral
127518.0,"AstraZeneca, Merck Announce Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer at ESMO",2018-10-21 15:40:00-04:00,AZN,negative
127519.0,PhaseBio's IPO: What You Need To Know,2018-10-17 13:19:00-04:00,AZN,neutral
127520.0,AstraZeneca shares are up 3.8% after the company and Merck received Orphan Drug Designation for Lymparza in pancreatic cancer.,2018-10-16 14:08:00-04:00,AZN,negative
127521.0,U.S. FDA Grants Merck And AstraZeneca's LYNPARZA Orphan Drug Designation For Pancreatic Cancer,2018-10-16 06:35:00-04:00,AZN,negative
127522.0,"AstraZeneca, Merck Receive FDA Orphan Drug for Lynparza in Pancreatic Cancer",2018-10-16 04:51:00-04:00,AZN,negative
127523.0,GMB Issues Jobs Warning As AstraZeneca Halts UK Investment Over Brexit Uncertainty,2018-10-15 13:52:00-04:00,AZN,negative
127524.0,AstraZeneca Has Suspended Investments In UK Due To Lack Of Clarity Over Brexit,2018-10-15 09:44:00-04:00,AZN,negative
127525.0,"Stocks Which Set New 52-Week High Yesterday, October 3rd",2018-10-04 11:18:00-04:00,AZN,neutral
127526.0,"The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut",2018-10-04 07:59:00-04:00,AZN,neutral
127527.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,AZN,neutral
127528.0,"The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares",2018-10-02 09:10:00-04:00,AZN,positive
127529.0,AstraZeneca Announces Completion of Agreement with Cheplapharm for Rights to Atacand in 28 European Countries for $200M,2018-10-01 04:54:00-04:00,AZN,positive
127530.0,AstraZeneca And MedImmune Announce Publication Of Data From Phase III Trial Of IMFINZI (durvalumab) Showing REduced Risk Of Death By Nearly One-Third,2018-09-25 08:25:00-04:00,AZN,negative
127531.0,AstraZeneca Announces Bydureon Receives Positive EU CHMP Opinion for EXSCEL Cardiovascular Outcomes Data,2018-09-25 04:30:00-04:00,AZN,positive
127532.0,AstraZeneca Gets EU Marking Authorization for Imfinzi,2018-09-24 11:12:00-04:00,AZN,neutral
127533.0,A Peek Into The Markets: US Stock Futures Edge Lower; Crude Oil Surges,2018-09-24 07:25:00-04:00,AZN,negative
127534.0,"AstraZeneca Announces its Phase III DECLARE-TIMI 58 Trial Met its Primary Safety Endpoint, Met 1 Efficacy Endpoint and Missed 1 Efficacy Endpoint",2018-09-24 07:17:00-04:00,AZN,positive
127535.0,"AstraZeneca Reports Farxiga Gets Positive Result in DECLARE-TIMI 58, a Large Cardiovascular Outcomes Trial in 17K Patients with Type-2 Diabetes",2018-09-24 04:03:00-04:00,AZN,positive
127536.0,"The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers",2018-09-22 16:15:00-04:00,AZN,positive
127537.0,AstraZeneca's FASENRA Showed 'Consistent' Safety And Sustained Efficacy In Long Term Phase III BORA Trial In Severe Eosinophilic Asthma,2018-09-18 07:08:00-04:00,AZN,positive
127538.0,AstraZeneca Announces The Lancet Respiratory Medicine Published First Phase III Trial for PT010 Triple Combination Therapy in Moderate to Very Severe COPD,2018-09-16 12:02:00-04:00,AZN,negative
127539.0,PR Confirms FDA Approves AstraZeneca's LUXOMITI In Hairy Cell Leukemia,2018-09-13 16:15:00-04:00,AZN,positive
127540.0,FDA Says Granted Approval Of Lumoxiti To AstraZeneca,2018-09-13 14:17:00-04:00,AZN,positive
127541.0,AstraZeneca to present Fasenra Long-term Safety and Efficacy data at European Respiratory Society International Congress 2018,2018-09-13 04:54:00-04:00,AZN,positive
127542.0,"The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering",2018-09-07 07:55:00-04:00,AZN,neutral
127543.0,"Amgen, AstraZeneca Announce Tezepelumab Granted Breakthrough Therapy Designation By FDA for Treatment of Patients With Severe Asthma Without an Eosinophilic Phenotype",2018-09-07 03:53:00-04:00,AZN,negative
127544.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,AZN,positive
127545.0,Biohaven Licenses Novel Myeloperoxidase Inhibitor from AstraZeneca; Financial Terms Not Disclosed,2018-09-05 03:34:00-04:00,AZN,positive
127546.0,AstraZeneca Reports TULIP 1 Phase III Trial for Anifrolumab in SLE Did Not Meet Primary Endpoint,2018-08-31 04:38:00-04:00,AZN,neutral
127547.0,"AstraZeneca, Voluntis Extend In Digital Therapeutics for Oncology With A New Phase Of Clinical Evaluation Of Digital Therapeutic Designed To Support Platinum Resistant Ovarian Cancer Patients",2018-08-30 12:02:00-04:00,AZN,negative
127548.0,AstraZeneca Announces EC Approves Bydureon BCise Device for T2 Diabetes,2018-08-30 04:23:00-04:00,AZN,positive
127549.0,AbbVie's Rare Blood Cancer Drug Combo Snags FDA Approval,2018-08-27 09:38:00-04:00,AZN,negative
127550.0,AstraZeneca Says Lynparza Becomes The First PARP Inhibitor To Win Approval In China,2018-08-23 08:26:00-04:00,AZN,positive
127551.0,AstraZeneca Says Data from AERISTO Phase IIIb trial for Bevespi Aerosphere in Chronic Obstructive Pulmonary Disease is Inconsistent with Previous Data,2018-08-23 04:30:00-04:00,AZN,neutral
127552.0,"Jefferies Downgrades AstraZeneca, Sees Limited Additional Upside",2018-08-16 11:05:00-04:00,AZN,negative
127553.0,"Benzinga's Top Upgrades, Downgrades For August 16, 2018",2018-08-16 08:54:00-04:00,AZN,positive
127554.0,A Peek Into The Markets: US Stock Futures Surge Ahead Of Earnings,2018-08-16 06:41:00-04:00,AZN,neutral
127555.0,Jefferies Downgrades AstraZeneca to Hold,2018-08-16 06:22:00-04:00,AZN,neutral
127556.0,Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech,2018-08-13 14:52:00-04:00,AZN,neutral
127557.0,"Stocks Which Set New 52-Week High Yesterday, August 9th",2018-08-10 10:03:00-04:00,AZN,neutral
127558.0,"The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss",2018-08-10 07:38:00-04:00,AZN,negative
127559.0,"Stocks Which Set New 52-Week High Yesterday, August 8th",2018-08-09 11:03:00-04:00,AZN,neutral
127560.0,"Stocks Trading Ex Dividend For Thurs., Aug. 9, 2018",2018-08-09 08:42:00-04:00,AZN,neutral
127561.0,"The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings",2018-08-09 08:39:00-04:00,AZN,positive
127562.0,"Stocks Which Will Trade Ex Dividend On Thurs., Aug. 9, 2018",2018-08-08 11:48:00-04:00,AZN,neutral
127563.0,"Stocks Which Set New 52-Week High Yesterday, August 7th",2018-08-08 11:01:00-04:00,AZN,neutral
127564.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,AZN,positive
127565.0,Earlier Ironwood Pharma Announced Termination of Its Licensing Agreement With AstraZeneca for U.S. Lesinurad Franchise,2018-08-06 08:55:00-04:00,AZN,positive
127566.0,"Merck Reports Co., AstraZeneca's Selumetinib Granted Orphan Designation In Europe For Neruofibromatosis Type 1",2018-08-03 06:30:00-04:00,AZN,positive
127567.0,"Stocks Which Set New 52-Week High Yesterday, July 31",2018-08-01 12:04:00-04:00,AZN,neutral
127568.0,"Price Action In Several Major Healthcare Names Mixed, Stocks Appear Largely Unaffected Following Late-Tues. NY Times Article 'Justice Dept. Investigating Claims That Drug Companies Funded Terrorism in Iraq'",2018-08-01 10:59:00-04:00,AZN,negative
127569.0,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",2018-08-01 09:01:00-04:00,AZN,negative
127570.0,"Stocks Which Set New 52-Week High Yesterday, July 26th:",2018-07-27 10:42:00-04:00,AZN,neutral
127571.0,"Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter",2018-07-27 08:44:00-04:00,AZN,neutral
127572.0,"Earnings Scheduled For July 26, 2018",2018-07-26 04:20:00-04:00,AZN,neutral
127573.0,A Preview Of AstraZeneca's Q2 Earnings,2018-07-25 14:45:00-04:00,AZN,neutral
127574.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,AZN,neutral
127575.0,Dr. Reddy's Labs Confirms AstraZeneca Filed Suit Against Co. Related To Infringement Of 3 Patents On Generic Version Of Brilinta,2018-07-25 10:27:00-04:00,AZN,negative
127576.0,"Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile",2018-07-25 08:41:00-04:00,AZN,positive
127577.0,"AstraZeneca Agrees to Sell Commercial Rights to Atacand to Cheplapharm in Europe for $200M, $10M in Milestones",2018-07-24 04:49:00-04:00,AZN,positive
127578.0,Immunomedics Reports Clinical Partnership With AstraZeneca in First-Line Triple-Negative Breast and Urothelial Cancers,2018-07-23 08:08:00-04:00,AZN,neutral
127579.0,Immunomedics to Collaborate with AstraZeneca to Evaluate the Combination of Imfinzi and Sacituzumab Govitecan,2018-07-23 08:07:00-04:00,AZN,neutral
127580.0,"Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut",2018-07-19 09:14:00-04:00,AZN,neutral
127581.0,AstraZeneca Option Alert: Aug 17 $37.5 Calls Sweep (33) near the Ask: 3000 @ $0.551 vs 1274 OI; Earnings 7/26 Before Open Ref=$36.35,2018-07-12 09:37:00-04:00,AZN,positive
127582.0,Health Canada Has Approved AstraZeneca's Tagrisso As First-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer,2018-07-12 08:11:00-04:00,AZN,negative
127583.0,Revon Systems Digital Therapeutics Enters Partnership With AstraZeneca In Respiratory Medicine,2018-07-10 09:41:00-04:00,AZN,neutral
127584.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,AZN,neutral
127585.0,"AstraZeneca, Merck Announce LYNPARZA Approved in Japan for BRCA-Mutated Metastatic Breast Cancer",2018-07-02 03:56:00-04:00,AZN,negative
127586.0,AstraZeneca Reports LYNPARZA Phase III Trial First-Line SOLO-1 Trial For Ovarian Cancer Met Primary Endpoint,2018-06-27 07:02:00-04:00,AZN,negative
127587.0,"AstraZeneca, Merck Announce LYNPARZA S Met Primary Endpoint of Progression-Free Survival in Women with BRCA-Mutated Advanced Ovarian Cancer and Showed a Safety Profile Consistent with Previous Trials",2018-06-27 04:01:00-04:00,AZN,negative
127588.0,AstraZeneca Says FARXIGA in Combination with ONGLYZA Has Similar Glycemic Control with Additional Benefits as Insulin for Type 2 Diabetes Patients,2018-06-25 08:02:00-04:00,AZN,positive
127589.0,Dapagliflozin as Adjunct Therapy to Insulin for People with Type 1 Diabetes May Improve Glycemic Control,2018-06-24 21:23:00-04:00,AZN,positive
127590.0,"AstraZeneca Will Report Latest Data From Cardiovascular, Renal, Metabolism Therapy Area At American Diabetes Association Sessions Jun. 22-26",2018-06-19 07:02:00-04:00,AZN,neutral
127591.0,AstraZeneca Option Alert: Jul 20 $37.5 Calls Sweep (3) near the Ask: 2444 @ $0.367 vs 4868 OI; Earnings 7/26 Before Open [est] Ref=$36.33,2018-06-15 13:34:00-04:00,AZN,positive
127592.0,"Eli Lilly, AstraZeneca Discontinuing Global Phase 3 Clinical Trials of Lanabecestat",2018-06-12 03:44:00-04:00,AZN,neutral
127593.0,EU Has Approved AstraZeneca's Tagrisso For First-Line Treatment Of EGFR-Mutated Non-Small Cell Lunch Cancer,2018-06-08 12:49:00-04:00,AZN,negative
127594.0,"Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index",2018-06-05 08:05:00-04:00,AZN,positive
127595.0,Merck and Astrazeneca Pres Relase Announces LYNPARZA In Combo With Abiraterone Delayed Metastatic Prostate Cancer Disease Progression,2018-06-04 17:01:00-04:00,AZN,negative
127596.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,AZN,negative
127597.0,"UPDATE: AstraZeneca, MedImmune Report IMFINZI Phase III Trial Met Second Primary Endpoint Of Overall Survival",2018-05-25 07:01:00-04:00,AZN,neutral
127598.0,"AstraZeneca, MedImmune Report IMFINZI Significantly Improved Overall Survival In Phase III Pacific Trial For Unresectable Stage III N-Small Cell Lung Cancer",2018-05-25 07:00:00-04:00,AZN,negative
127599.0,"Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing",2018-05-23 08:15:00-04:00,AZN,neutral
127600.0,"Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict",2018-05-22 08:05:00-04:00,AZN,positive
127601.0,Hearing AstraZeneca NDA for Lokelma Gets FDA Approvla,2018-05-18 16:06:00-04:00,AZN,neutral
127602.0,"Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved",2018-05-18 08:00:00-04:00,AZN,positive
127603.0,"7 Stocks To Watch For May 18, 2018",2018-05-18 04:35:00-04:00,AZN,neutral
127604.0,AstraZeneca Q1 Core EPS $0.48 vs $0.60 Est; Revenue $5.178B vs $5.283B Est,2018-05-18 04:21:00-04:00,AZN,neutral
127605.0,"Earnings Scheduled For May 18, 2018",2018-05-18 04:01:00-04:00,AZN,neutral
127606.0,AstraZeneca's Asthma Drug Fasenra Fails In COPD Study,2018-05-15 11:15:00-04:00,AZN,negative
127607.0,"The Week Ahead: Coindesk Conference, Walmart And Retailers Close Out Earnings Season",2018-05-14 12:46:00-04:00,AZN,neutral
127608.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-13 10:06:00-04:00,AZN,neutral
127609.0,AstraZeneca and Merck Announce LYNPARZA Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer,2018-05-08 06:47:00-04:00,AZN,negative
127610.0,Bactiguard's Licensing Partner Smartwise Enters Collaboration with AstraZeneca,2018-05-07 03:36:00-04:00,AZN,neutral
127611.0,"AstraZeneca Shares Make Near-Term Parabolic Move, Spike To High Over $36; Traders Circulating Takeover Chatter",2018-05-01 10:08:00-04:00,AZN,positive
127612.0,AstraZeneca Reports Tagrisso Received Positive CHMP Opinion For First-Line Treatment Of EGFR-Mutated NSCLC,2018-04-27 07:34:00-04:00,AZN,positive
127613.0,AstraZeneca to Raise Stake in Circassia to up to 19.9%,2018-04-24 04:13:00-04:00,AZN,neutral
127614.0,AstraZeneca Shares Are Looking Very Weak Right Now,2018-04-20 14:37:00-04:00,AZN,negative
127615.0,AstraZeneca Says Approves Tagrisso as 1st-line Treatment for EGFR-mutated Non-small Cell Lung Cancer,2018-04-18 18:43:00-04:00,AZN,negative
127616.0,"UPDATE: AstraZeneca at AACR: Phase Ib Study Showed Clinical Activity In PD-L1 Greater Than Or Equal To 25%, Greater Than 25% Groups In Second Line NSCLC",2018-04-16 17:07:00-04:00,AZN,positive
127617.0,AstraZeneca Presents Imfinzi Plus tremelimumab Combination Data at AACR Annual Meeting,2018-04-16 17:06:00-04:00,AZN,neutral
127618.0,Merck Sunday Announced Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at #AACR18,2018-04-16 04:03:00-04:00,AZN,negative
127619.0,BMO's Bearish Stance On Eli Lilly Comes To An End,2018-04-13 11:00:00-04:00,AZN,neutral
127620.0,Ionis Licenses IONIS-AZ6-2.5-LRx to AstraZeneca for $30M,2018-04-09 07:05:00-04:00,AZN,neutral
127621.0,Astrazeneca Reports The FDA Approves BYDUREON for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control,2018-04-03 08:03:00-04:00,AZN,neutral
127622.0,AstraZeneca And MedImmune Report US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia,2018-04-03 07:01:00-04:00,AZN,positive
127623.0,"AstraZeneca, Merck Announces EMA Accepts Regulatory Submission for LYNPARZA in BRCA-Mutated HER2-Negative Metastatic Breast Cancer",2018-04-03 06:06:00-04:00,AZN,negative
127624.0,AstraZeneca Reports Lokelma Approved For Treatment Of Adults With Hyperkalaemia In EU,2018-03-22 12:50:00-04:00,AZN,positive
127625.0,"AstraZeneca Announced Results Of DERIVE, Says Study Met Its Primary And Secondary Efficacy Endpoints",2018-03-19 12:15:00-04:00,AZN,neutral
127626.0,"Benzinga's Top Upgrades, Downgrades For March 19, 2018",2018-03-19 09:11:00-04:00,AZN,positive
127627.0,Jefferies Upgrades Astrazeneca PLC Common Stock to Buy,2018-03-19 06:56:00-04:00,AZN,neutral
127628.0,Height Casts 65% Odds That Congress Rolls Back Pharma Discounts,2018-03-07 11:31:00-05:00,AZN,neutral
127629.0,AstraZeneca's Forxiga Label Expansion Filing Accepted In EU,2018-03-07 10:51:00-05:00,AZN,positive
127630.0,"Pharma Stock Roundup: AstraZeneca, Merck, AbbVie And More",2018-02-23 11:26:00-05:00,AZN,neutral
127631.0,"Merck, AstraZeneca Reports LYNPARZA Received Positive EU CHMP Opinion In Platinum-Sensitive Relapsed Ovarian Cancer",2018-02-23 07:30:00-05:00,AZN,negative
127632.0,"AstraZeneca Reports Renewed Recommendation, Availability Of FLUMIST QUADRIVALENT Vaccine In US",2018-02-21 15:10:00-05:00,AZN,neutral
127633.0,"Ionis Licences New Antisense Drug for Kidney Disease to AstraZeneca, Earns $30M License Fee And May Receive Up To $300M In Additional Milestone Payments",2018-02-20 07:07:00-05:00,AZN,neutral
127634.0,FDA Approves Imfinz for Unresectable Stage III Non-Small Cell Lung Cancer,2018-02-17 08:58:00-05:00,AZN,negative
127635.0,"Merck Reports Co., AstraZeneca Won Orphan Drug Designation By FDA For Selumetinib For Treatment Of NF1",2018-02-15 06:38:00-05:00,AZN,positive
127636.0,AstraZeneca Says Selumetinib Granted Orphan Drug Designation by FDA for Neurofibromatosis Type 1,2018-02-15 03:59:00-05:00,AZN,positive
127637.0,"AHNS, ASTRO, ASCO Issue Press Release Highlighting Phase II Trial Of AstraZeneca's Durvalumab Showed Activity In Patients With Recurrent, Metastatic Head And Neck Cancer",2018-02-13 13:04:00-05:00,AZN,negative
127638.0,"CDC Still Recommends Sanofi, GlaxoSmithKline Vaccines As Flu-Related Deaths Rise",2018-02-12 16:26:00-05:00,AZN,positive
127639.0,The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease,2018-02-08 09:41:00-05:00,AZN,negative
127640.0,"Earnings Scheduled For February 2, 2018",2018-02-02 04:10:00-05:00,AZN,neutral
127641.0,Syndax Pharma Reports Immuno-Oncology Trial Collab With AstraZeneca,2018-02-01 07:12:00-05:00,AZN,neutral
127642.0,Here's Why Nektar Stock Skyrocketed Almost 500% In A Year,2018-01-19 12:46:00-05:00,AZN,neutral
127643.0,"Pieris' Artificial Protein Platform Is Undervalued By The Street, Analyst Says",2018-01-17 15:03:00-05:00,AZN,neutral
127644.0,Watching Shares Of AstraZeneca and Merck As White House Doctor Says Pres. Trump Takes Crestor For Cholesterol and Propecia For Hair Loss,2018-01-16 15:44:00-05:00,AZN,neutral
127645.0,"FDA Approves AstraZeneca and Merck's Lynparza, For Breast Cancer With A Certain Inherited Genetic Mutation",2018-01-12 09:42:00-05:00,AZN,negative
127646.0,AstraZeneca Reports Fasenra Approved In EU,2018-01-10 10:11:00-05:00,AZN,positive
127647.0,"Horizon Pharma Earlier Announced Licensing Global Rights To MEDI4945 From AstraZeneca, Will Provide Upfront Cash Payment And Future Milestone Payments",2018-01-08 11:01:00-05:00,AZN,neutral
127648.0,Myriad Genetics Announces AstraZeneca to Use the Company's myChoice HRD Plus in an Exploratory Cancer Analysis,2018-01-03 07:06:00-05:00,AZN,negative
127649.0,AstraZeneca Option Alert: Jan 19 $36 Calls Sweep (24) at the Ask: 1750 @ $0.3 vs 8 OI; Ref=$35.18,2018-01-02 14:44:00-05:00,AZN,positive
127650.0,"The Market In 5 Minutes: Apple Issues Apology, Softbank & Uber, The Year In Cryptos",2017-12-29 09:53:00-05:00,AZN,positive
127651.0,UPDATE: ANI Pharma Says 4 Products Purchased From AstraZeneca Generated ~$19M In US Market Sales During Trailing 12 Mos. Through Oct.,2017-12-29 09:24:00-05:00,AZN,neutral
127652.0,"UPDATE: ANI Pharma Will Buy NDAs, US Rights To Market ATACAND, ATACAND HCT, ARIMIDEX, CASODEX",2017-12-29 09:23:00-05:00,AZN,neutral
127653.0,ANI Pharma Reports Purchase Of 4 NDAs From AstraZeneca For $46.5M,2017-12-29 09:22:00-05:00,AZN,neutral
127654.0,"Benzinga's Top Upgrades, Downgrades For December 29, 2017",2017-12-29 08:55:00-05:00,AZN,positive
127655.0,A Peek Into The Markets: U.S. Stock Futures Surge On Last Trading Day Of 2017,2017-12-29 07:49:00-05:00,AZN,neutral
127656.0,JP Morgan Upgrades AstraZeneca to Overweight,2017-12-29 06:38:00-05:00,AZN,neutral
127657.0,"AstraZeneca Announces FDA Updates SYMBICOURT Label With LABA Safety Revisions, Removes Boxed Warning For Serious Asthma-Related Outcomes",2017-12-21 11:16:00-05:00,AZN,neutral
127658.0,UPDATE: Pieris Says First Dosing Triggers $12.5M Milestone Payment From AstraZeneca,2017-12-20 07:54:00-05:00,AZN,neutral
127659.0,"Chembio Diagnostics, AstraZeneca Report Collaboration To Develop Point-Of-Care Diagnostic Test; Chembio Will Receive Up To $2.9M In Funding",2017-12-19 08:53:00-05:00,AZN,neutral
127660.0,FDA Accepts AstraZeneca's Regulatory Submission for TAGRISSO (Osimertinib) in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer,2017-12-18 07:17:00-05:00,AZN,negative
127661.0,AstraZeneca Announces  FDA Accepts Regulatory Submission for TAGRISSO in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer And Granted Priority Review,2017-12-18 07:01:00-05:00,AZN,negative
127662.0,AstraZeneca Announces CALQUENCE Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial at #ASH2017,2017-12-09 18:30:00-05:00,AZN,neutral
127663.0,Pfizer Reports Updated Data From Phase III Study On Ibrance,2017-12-08 12:40:00-05:00,AZN,neutral
127664.0,AstraZeneca Reports Tudorza Reduces Exacerbations; Demonstrates Cardiovascular Safety in COPD Patients,2017-12-04 04:46:00-05:00,AZN,positive
127665.0,FDA Decisions In November: The Month In Review,2017-12-01 14:05:00-05:00,AZN,neutral
127666.0,G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer,2017-11-28 07:02:00-05:00,AZN,negative
127667.0,AstraZeneca Tues. Afternoon Reported FDA Approval Of FASENRA For Severe Eosinophilic Asthma,2017-11-15 08:57:00-05:00,AZN,positive
127668.0,AstraZeneca Reports FASLODEX Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib,2017-11-15 07:00:00-05:00,AZN,negative
127669.0,AstraZeneca Announces Faslodex Receives FDA Approval for Treatment of Advanced Breast Cancer in Combination with Abemaciclib,2017-11-15 04:33:00-05:00,AZN,negative
127670.0,"Adam Feuerstein Tweets: $TSRO comments (negatively) on $AZN Lynparza Q3 sales. Interesting. Don't see this often, so publicly. Per Leerink note.",2017-11-09 12:21:00-05:00,AZN,positive
127671.0,"Earnings Scheduled For November 9, 2017",2017-11-09 04:08:00-05:00,AZN,neutral
127672.0,AstraZeneca Option Alert: Nov 17 $33.5 Puts Sweep (30) at the Ask: 2244 @ $0.45 vs 1704 OI; Ref=$34.22,2017-11-06 14:51:00-05:00,AZN,positive
127673.0,"Pharma Stock Roundup: Pfizer, Teva, Novartis, And More",2017-11-06 12:19:00-05:00,AZN,neutral
127674.0,Here's What Was Intriguing About Incyte's Q3 Report,2017-11-01 15:36:00-04:00,AZN,neutral
127675.0,AstraZeneca Completes Commercialization Agreement with Aspen,2017-11-01 04:35:00-04:00,AZN,positive
127676.0,"AstraZeneca Says Tralokinumab Phase III Programme in Severe, Uncontrolled Asthma did Not Achieve Primary Endpoint",2017-11-01 04:06:00-04:00,AZN,negative
127677.0,"Incyte, AstraZeneca Announce Clinical Trial Collaboration in Early Lung Cancer",2017-10-31 03:43:00-04:00,AZN,negative
127678.0,US FDA Approves AstraZeneca's Once-Weekly BYDUREON BCise Injectable Medicine for Patients with Type-2 Diabetes,2017-10-23 07:10:00-04:00,AZN,positive
127679.0,"AstraZeneca, Merck Rapidly Advance LYNPARZA in Japan With a NDA To Japan's Pharmaceuticals and Medical Devices Agency",2017-10-23 06:58:00-04:00,AZN,neutral
127680.0,AstraZeneca Reports New Data Showing Us Preterm Infants At Significantly Greater Risk Of RSV Hospitalizations Following 2014 Guidance Change,2017-10-18 13:06:00-04:00,AZN,positive
127681.0,"Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever",2017-10-18 09:07:00-04:00,AZN,positive
127682.0,"AstraZeneca Issues Release Highlighting FDA Acceptance Of Regulatory Submission For LYNPARZA, Has Granted Priority Review",2017-10-18 06:56:00-04:00,AZN,positive
127683.0,"AstraZeneca's Supplemental Biologics License Application for IMFINZI in Locally Advanced, Unresectable Non-Small Cell Lung Cancer is Accepted by the FDA",2017-10-17 07:12:00-04:00,AZN,negative
127684.0,Watch These 8 Huge Call Purchases In Tuesday Trade,2017-10-10 04:13:00-04:00,AZN,positive
127685.0,Benzinga's Option Alert Recap From October 9,2017-10-09 16:31:00-04:00,AZN,positive
127686.0,AstraZeneca Option Alert: Apr 20 $35 Calls at the Ask: 5000 @ $1.801 vs 671 OI; Ref=$34.465,2017-10-09 12:35:00-04:00,AZN,positive
127687.0,Hearing BNP Paribas Upgraded AstraZeneca From Neutral To Outperform,2017-09-25 12:05:00-04:00,AZN,neutral
127688.0,15 Biggest Mid-Day Gainers For Friday,2017-09-22 12:12:00-04:00,AZN,neutral
127689.0,"Benzinga's Top Upgrades, Downgrades For September 22, 2017",2017-09-22 09:59:00-04:00,AZN,positive
127690.0,"4 Reasons To Buy, 2 Controversies Surrounding AstraZeneca",2017-09-22 09:51:00-04:00,AZN,neutral
127691.0,The Market In 5 Minutes,2017-09-22 08:42:00-04:00,AZN,neutral
127692.0,Bernstein Upgrades Astrazeneca PLC Common Stock to Outperform,2017-09-22 06:13:00-04:00,AZN,neutral
127693.0,"Astrazeneca Reports BYDUREON EXSCEL Trial Demonstrates Favorable Safety Profile, Fewer CV Patients With ?Type-2 Diabetes At Wide Range Of CV Risk",2017-09-14 12:30:00-04:00,AZN,positive
127694.0,The Market In 5 Minutes,2017-09-14 10:07:00-04:00,AZN,neutral
127695.0,Liberum Downgrades Astrazeneca PLC Common Stock to Hold,2017-09-14 09:06:00-04:00,AZN,neutral
127696.0,Aspen to Acquire Residual Rights to Anesthetic Medicines from AstraZeneca,2017-09-14 04:44:00-04:00,AZN,neutral
127697.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-09-13 08:04:00-04:00,AZN,neutral
127698.0,"ACADIA Pharma Shares Indicated Up 0.5% Premarket As Traders Circulate Article From UK Paper, 'Market report: AstraZeneca in spotlight as traders revive chatter over bid for US firm Acadia'",2017-09-08 07:35:00-04:00,AZN,positive
127699.0,Watch These 8 Huge Call Purchases In Friday Trade,2017-09-08 04:03:00-04:00,AZN,positive
127700.0,Benzinga's Option Alert Recap From September 7,2017-09-07 16:37:00-04:00,AZN,positive
127701.0,15 Biggest Mid-Day Gainers For Thursday,2017-09-07 12:30:00-04:00,AZN,neutral
127702.0,AZN Option Alert: Sep 15 $31.5 Calls at the Bid: 1276 @ $0.451 vs 30 OI; Ref=$31.29,2017-09-07 09:42:00-04:00,AZN,positive
127703.0,"Benzinga's Top Upgrades, Downgrades For September 7, 2017",2017-09-07 09:25:00-04:00,AZN,positive
127704.0,"BMO Capital Initiates Coverage On Astrazeneca PLC Common Stock with Outperform Rating, Announces $38.00 Price Target",2017-09-07 07:43:00-04:00,AZN,neutral
127705.0,"A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Data, Fed Speakers",2017-09-07 07:20:00-04:00,AZN,neutral
127706.0,AstraZeneca  Phase III AMPLIFY trial for Duaklir Met Primary Endpoint,2017-09-07 06:23:00-04:00,AZN,neutral
127707.0,"Amgen and AstraZeneca's Press Release Announces PATHWAY Trial Of Tezepelumab Achieved Its Primary Efficacy Endpoint, Results Published Today In New England Journal of Medicine",2017-09-06 17:10:00-04:00,AZN,neutral
127708.0,"Wall Street's M&A Chatter From August 31: Barnes & Noble, Constellium, Daiichi Sankyo",2017-09-01 08:12:00-04:00,AZN,positive
127709.0,Watch These 8 Huge Call Purchases In Friday Trade,2017-09-01 04:00:00-04:00,AZN,positive
127710.0,Benzinga's Option Alert Recap From August 31,2017-08-31 16:22:00-04:00,AZN,positive
127711.0,Daiichi Sankyo Denies Nikkei Business Report That Co. Received An Acquisition Offer From AstraZeneca,2017-08-31 10:14:00-04:00,AZN,negative
127712.0,AstraZeneca Option Alert: Sep 15 $29.5 Calls Sweep (22) at the Ask: 3500 @ $0.6 vs 1081 OI; Ref=$29.75,2017-08-31 10:09:00-04:00,AZN,positive
127713.0,Japan's Daiichi Sankyo Rejected Takeover Bid from AstraZeneca Last Year -Nikkei Business,2017-08-31 04:45:00-04:00,AZN,negative
127714.0,"AstraZeneca,Takeda to Collaborate to Develop and Commercialize MEDI1341 for Parkinson's Disease; Takeda to Pay AstraZeneca Up to $400M",2017-08-29 04:22:00-04:00,AZN,negative
127715.0,"AstraZeneca's FASLODEX Gets FDA Approvalas Monotherapy for Expanded Use in HR+, HER2- Advanced Breast Cancer",2017-08-28 07:01:00-04:00,AZN,negative
127716.0,AstraZeneca Announces Extended Treatment With Brilinta Reduces Risk Of Cardiovascular Death By 29% In Patients With History Of Heart Attack,2017-08-24 05:59:00-04:00,AZN,negative
127717.0,"Ethris Announces Five-Year Strategic Collaboration with AstraZeneca, MedImmune to Develop mRNA Therapies for Respiratory Diseases",2017-08-21 04:23:00-04:00,AZN,neutral
127718.0,Astrazeneca Reports Additional FDA Acceptance For LYNPARZA,2017-08-17 16:31:00-04:00,AZN,positive
127719.0,"AstraZeneca, Merck Issue Release Confirming Added, Broad Approval Of LYNPARZA In US For Ovarian Cancer",2017-08-17 15:36:00-04:00,AZN,negative
127720.0,"AstraZeneca Shares Unaffected As Lynparza Receives Added, Broad US Approval For Ovarian Cancer Treatment",2017-08-17 15:33:00-04:00,AZN,neutral
127721.0,Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive',2017-08-16 11:59:00-04:00,AZN,neutral
127722.0,Investec Upgrades AstraZeneca to Buy from Hold; Lowers PT to 4900P from 5000P,2017-08-09 04:40:00-04:00,AZN,negative
127723.0,A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision,2017-08-08 14:36:00-04:00,AZN,positive
127724.0,AstraZeneca Reports FDA Granted Breakthrough Therapy Designation For Acalabrutinib,2017-08-01 07:18:00-04:00,AZN,positive
127725.0,AstraZeneca Reports durvalumab Granted Breakthrough Therapy Designation by US FDA,2017-07-31 07:05:00-04:00,AZN,positive
127726.0,Morgan Stanley Downgrades Astrazeneca PLC Common Stock to Equal-Weight,2017-07-28 09:15:00-04:00,AZN,neutral
127727.0,20 Biggest Mid-Day Losers For Thursday,2017-07-27 12:51:00-04:00,AZN,negative
127728.0,Mid-Day Market Update: ShoreTel Gains On Acquisition News; Neuralstem Shares Plunge,2017-07-27 12:06:00-04:00,AZN,positive
127729.0,Leerink Swann Downgrades Astrazeneca PLC Common Stock to Market Perform,2017-07-27 10:36:00-04:00,AZN,neutral
127730.0,Mid-Morning Market Update: Markets Open Higher; Facebook Beats Q2 Estimates,2017-07-27 10:33:00-04:00,AZN,neutral
127731.0,"AstraZeneca Shares Down 15% Pre-Market After Announcing Imfinzi Plus Tremelimumab Combination Did Not Meet Primary Endpoint, Despite News Of Strategic Oncology Collab Deal With Merck",2017-07-27 09:26:00-04:00,AZN,positive
127732.0,Why Is AstraZeneca Sinking Today?,2017-07-27 09:18:00-04:00,AZN,neutral
127733.0,20 Stocks Moving In Thursday's Pre-Market Session,2017-07-27 08:30:00-04:00,AZN,neutral
127734.0,"Earnings Scheduled For July 27, 2017",2017-07-27 05:07:00-04:00,AZN,neutral
127735.0,Astrazeneca Says Imfinzi Plus Tremelimumab Combination Did Not Meet Primary Endpoint of Progression-Free Survival Compared to Chemotherapy; Mystic Trial Continues as Planned to Assess Additional Primary Endpoints of Overall Survival,2017-07-27 04:19:00-04:00,AZN,neutral
127736.0,AstraZeneca CEO Declines Comment on Reports He is Leaving to Join Teva -Reuters,2017-07-27 04:14:00-04:00,AZN,positive
127737.0,"AstraZeneca, Merck Announce Strategic Oncology Collaboration; Merck to pay AstraZeneca up to $8.5B in Total Consideration",2017-07-27 03:41:00-04:00,AZN,negative
127738.0,AstraZeneca Faslodex Gets EU Approval For 1L Breast Cancer,2017-07-26 11:49:00-04:00,AZN,negative
127739.0,"AstraZeneca CEO Rumor Reportedly Ends, Shares Rise",2017-07-18 13:34:00-04:00,AZN,positive
127740.0,Fast Money Traders Share Their Picks That Could Make A Strong Move Higher,2017-07-17 07:04:00-04:00,AZN,positive
127741.0,Fast Money Traders Share Their Picks For The Week,2017-07-16 13:43:00-04:00,AZN,positive
127742.0,AstraZeneca Spokeswoman Declines Comment On Future Of CEO Following Report By Bloomberg Saying He's Not Leaving Company,2017-07-14 14:59:00-04:00,AZN,neutral
127743.0,AstraZeneca Shares Up ~$0.30 Over Last 15 Mins Following Report CEO Will Be Staying At Co.,2017-07-14 14:04:00-04:00,AZN,positive
127744.0,The Market In 5 Minutes,2017-07-14 09:05:00-04:00,AZN,neutral
127745.0,AstraZeneca Declines Comment on Report CEO is Leaving Co -Reuters,2017-07-14 04:41:00-04:00,AZN,neutral
127746.0,Analyst Wonders If AstraZeneca's CEO Would Be A Fit At Teva,2017-07-13 17:08:00-04:00,AZN,positive
127747.0,AstraZeneca Shares Down 8% From High Following Word That CEO Will Resign After The Close,2017-07-13 15:45:00-04:00,AZN,negative
127748.0,Hearing AstraZeneca CEO Said To Announce He Is Leaving Company After Market Close,2017-07-13 15:34:00-04:00,AZN,neutral
127749.0,"Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher",2017-07-13 14:43:00-04:00,AZN,positive
127750.0,Teva Spokesperson Declines Comment Following Calcalist Report Co. Could Hire AstraZeneca CEO Soriot,2017-07-13 12:43:00-04:00,AZN,neutral
127751.0,Teva Shares Up 2.2% Following News Of The Company Could Hire AstraZenneca CEO Soriot,2017-07-13 08:54:00-04:00,AZN,positive
127752.0,Hearing Teva Will Hearing AstraZeneca CEO Soriot,2017-07-12 15:18:00-04:00,AZN,neutral
127753.0,"Chi-Med, AstraZeneca Initiate SAVOIR Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma",2017-06-29 04:29:00-04:00,AZN,neutral
127754.0,Watch These 7 Huge Put Purchases In Wednesday Trade,2017-06-28 04:17:00-04:00,AZN,positive
127755.0,Benzinga's Option Alert Recap From June 27,2017-06-27 16:09:00-04:00,AZN,positive
127756.0,Option Alert: AstraZeneca Jul 32.5 Puts Sweep: 998 @  ASK  $0.80: 1673 traded vs 14k OI:  Earnings 7/27 Before Open  $34.64 Ref,2017-06-27 13:21:00-04:00,AZN,positive
127758.0,How Altimmune Is Trying To Get Ahead Of A Potentially Fatal 'Flu Pandemic',2017-06-23 08:15:00-04:00,AZN,negative
127759.0,AstraZeneca Faslodex CHMP Positive Opinion In 1L Breast Cancer,2017-06-23 07:54:00-04:00,AZN,negative
127760.0,"Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma",2017-06-22 07:06:00-04:00,AZN,neutral
127764.0,AstraZeneca Presents New Data on Safety of Farxiga,2017-06-12 07:02:00-04:00,AZN,positive
127767.0,"AstraZeneca Entered Agreement with Grünenthal for Global Rights to Zomig Outside Japan; AstraZeneca to Receive $200M Upon Completion, Up to $102M in Milestones",2017-06-07 04:49:00-04:00,AZN,positive
127768.0,AstraZeneca Reports Data from Trial of Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases: extended the length of time patients with CNS metastases live without disease worsening or death to 11.7 months...,2017-06-06 07:16:00-04:00,AZN,negative
127769.0,AstraZeneca Announces LYNPARZA Significantly Reduces the Risk of Disease Worsening or Death in Patients with BRCA-Mutated Metastatic Breast Cancer #ASCO17,2017-06-04 08:17:00-04:00,AZN,negative
127770.0,Orexo Receives $2.5M Milestone Payment from Astrazeneca; OX-CLI Advances into Clinical Trials,2017-06-02 04:53:00-04:00,AZN,neutral
127771.0,"Adam Feuerstein Tweets '$TSRO ""for sale"" news  good reminder: Plenty 'o PARP data coming.  

$AZN OlympiAD breast at #ASCO17 (plenary)

$CLVS ARIEL-3 end of June'",2017-05-31 16:33:00-04:00,AZN,positive
127772.0,Tracking The Busy June PDUFA Calendar,2017-05-30 08:58:00-04:00,AZN,neutral
127773.0,AstraZeneca Reports New Data Related to Expanded Portfolio of Cancer Medicines at ASCO: Highlights Key Trials of Tagrisso Have Shown Effects in Patients with EGFR,2017-05-26 08:46:00-04:00,AZN,negative
127774.0,AstraZeneca Initiates Voluntary Nationwide Recall Of One Lot Of BRILINTA 90mg Due To Report Of Another Medicine In One Bottle From That Lot,2017-05-25 17:30:00-04:00,AZN,neutral
127775.0,AstraZeneca Reports Bydureon EXSCEL Trial Met Primary Endpoint Objective in Type-2 Diabetes Patients with Cardiovascular Risk,2017-05-23 07:12:00-04:00,AZN,negative
127776.0,AstraZeneca Announces Phase III ZONDA Trial Achieved Its Primary Endpoint With Statistical Significance,2017-05-22 14:35:00-04:00,AZN,positive
127777.0,AstraZeneca Enters Agreement with Recordati for Seloken Commercial Rights in Europe; AstraZeneca to Receive $300M,2017-05-22 04:27:00-04:00,AZN,positive
127778.0,Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns,2017-05-16 11:15:00-04:00,AZN,neutral
127779.0,Credit Suisse Upgrades Astrazeneca PLC Common Stock to Neutral,2017-05-15 08:23:00-04:00,AZN,positive
127780.0,15 Biggest Mid-Day Gainers For Friday,2017-05-12 12:26:00-04:00,AZN,neutral
127781.0,AstraZeneca Sharply Higher Off Positive Data For Imfinzi,2017-05-12 10:29:00-04:00,AZN,positive
127782.0,22 Stocks Moving In Friday's Pre-Market Session,2017-05-12 08:03:00-04:00,AZN,neutral
127783.0,"AstraZeneca +5.73% Premarket @$32.82, Co Announced Imfinzi Met Primary Endpoint NSCLC",2017-05-12 07:27:00-04:00,AZN,neutral
127784.0,Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers,2017-05-06 09:03:00-04:00,AZN,negative
127785.0,"Pieris Pharmaceuticals +58% Premarket @$3.79; Co, AstraZeneca Collaborate to Develop, Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases",2017-05-03 07:22:00-04:00,AZN,neutral
127786.0,"Pieris Pharmaceuticals, AstraZeneca Collaborate to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases",2017-05-03 04:18:00-04:00,AZN,neutral
127787.0,AstraZeneca's IMFINZI Receives US FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer,2017-05-01 14:24:00-04:00,AZN,negative
127788.0,"AstraZeneca Shares at Session Highs, Up 0.7%; Traders Circulating Report FDA Has Approved IMFINZI for Locally-Advanced, Metastatic Urothelial Carcinoma",2017-05-01 12:40:00-04:00,AZN,positive
127789.0,Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space,2017-04-27 12:55:00-04:00,AZN,negative
127790.0,Astrazeneca Shareholders Vote To Approve Directors' Remuneration Policy,2017-04-27 12:45:00-04:00,AZN,neutral
127791.0,"Companies Holding Shareholder Meetings Today Include: Akorn, AstraZeneca, HCA Holdings, Johnson & Johnson, & Lockheed Martin",2017-04-27 08:41:00-04:00,AZN,neutral
127792.0,AstraZeneca Shares Volatile Over Last Few Mins as Traders Circulating FDA Confidential Form 483 Doc with Date of Inspection Jan. 18-30,2017-04-19 14:35:00-04:00,AZN,positive
127793.0,Cardiovascular Players Could Be Eyeing Esperion,2017-04-10 11:53:00-04:00,AZN,neutral
127794.0,Anthrax And Government Contracts: PharmAthene And Altimmune Ahead Of Merger,2017-04-06 16:01:00-04:00,AZN,neutral
127795.0,FibroGen Reports China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat,2017-03-31 07:09:00-04:00,AZN,positive
127796.0,AstraZeneca Announces FDA Grants Full Approval For TAGRISSO,2017-03-31 07:00:00-04:00,AZN,positive
127797.0,AstraZeneca's Inebilizumab for Neuromyelitis Optica Spectrum Disorder Receives Orphan Designation from EMA,2017-03-29 06:44:00-04:00,AZN,negative
127798.0,"Tesaro Gets Approval For Zejula, Expect U.S. Launch Late April",2017-03-28 10:26:00-04:00,AZN,positive
127799.0,AstraZeneca Data Shows RSV Immunoprophylaxis With palivizumab Could Result In Reduced Overall Costs In Infants Born At 29-32 wGA,2017-03-28 09:02:00-04:00,AZN,neutral
127800.0,How The Market For Tesaro's Niraparib Plays Out Following Early FDA Approval,2017-03-28 08:46:00-04:00,AZN,positive
127801.0,'Spider-Man' Glenn King Hopes His Potential Stroke-Saving Arachnid Molecule Makes It To Market,2017-03-24 13:50:00-04:00,AZN,positive
127802.0,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,2017-03-20 09:17:00-04:00,AZN,neutral
127803.0,AstraZeneca Announces CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Hospitalizations for Heart Failure and Death vs Other Type-2 Diabetes Medicines,2017-03-19 15:24:00-04:00,AZN,negative
127804.0,Astrazeneca Receives CRL from FDA for ZS-9 for Hyperkalaemia,2017-03-17 06:09:00-04:00,AZN,neutral
127805.0,"AstraZeneca, Circassia Enter Strategic Collaboration in Respiratory Disease; AstraZeneca to Receive $50M in Ordinary Shares of Circassia, Milestone Payments Up to $180M",2017-03-17 06:06:00-04:00,AZN,positive
127806.0,Lynparza Vs. Niraparib,2017-03-15 08:32:00-04:00,AZN,neutral
127807.0,Clovis Shares Reiterated As A Sell Following 10% Rally,2017-03-15 08:08:00-04:00,AZN,positive
127808.0,Watch These 8 Huge Call Purchases In Wednesday Trade,2017-03-15 05:02:00-04:00,AZN,positive
127809.0,Benzinga's Option Alert Recap From March 14,2017-03-14 17:00:00-04:00,AZN,positive
127810.0,Option Alert: AstraZeneca Mar 30.0 Calls: 1400 @  ASK  $0.60: 4610 traded vs 8208 OI:  Earnings 4/28 Before Open (est)  $30.34 Ref,2017-03-14 15:22:00-04:00,AZN,positive
127811.0,"AstraZeneca's Lynparza Ovarian Cancer Drug shows Investigator-Assessed Progression-Free Survival Of 19.1 Months, 30.2M Months PFS Based On Independent Central Review",2017-03-14 14:36:00-04:00,AZN,negative
127812.0,"Adam Feuerstein Tweets: $AZN Takes PARP Inhibitor Fight to Rival $TSRO with Strong Ovarian Cancer Study Results —> thestreet.com/story/14043007… $CLVS, too.",2017-03-14 14:30:00-04:00,AZN,negative
127813.0,"Adam Feuerstein Tweet $AZN Lynparza SOLO-2 ovarian cancer maintenance therapy data in 10 minutes. Watch $TSRO $CLVS for reaction, as well. Battle of the PARPs.",2017-03-14 14:21:00-04:00,AZN,negative
127814.0,How The Ultra-Wealthy Are Helping Advance Health And Life Sciences,2017-03-10 15:58:00-05:00,AZN,positive
127815.0,"Exclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market",2017-03-03 16:09:00-05:00,AZN,negative
127816.0,"Sanofi Pasteur, MedImmune Collaborate on Monoclonal Antibody to Prevent Illnesses Associated with RSV; Sanofi Pasteur to Make Upfront Payment of €120M, Pay up to €495M upon Achievement of Certain Milestones",2017-03-03 04:26:00-05:00,AZN,negative
127817.0,"Synergy's Safety Profile Should Boost Trulance Uptake, Takeover Prospects Remain Favorable",2017-03-02 14:53:00-05:00,AZN,positive
127818.0,AstraZeneca Announces FDA Approves Once-Daily QTERN Tablets for Adults with Type-2 Diabetes,2017-02-28 04:07:00-05:00,AZN,positive
127819.0,Carl Icahn's Track Record In Big Pharma,2017-02-24 09:40:00-05:00,AZN,neutral
127820.0,Eu Medicines Agency Recommends Approval Of AstraZeneca's ZS-9 For High Potassium Levels,2017-02-24 07:26:00-05:00,AZN,positive
127821.0,Analyst: Buy AstraZeneca On The Turnaround Story,2017-02-22 07:29:00-05:00,AZN,neutral
127822.0,AstraZeneca Reports LYNPARZA Met Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer,2017-02-17 07:01:00-05:00,AZN,negative
127823.0,AstraZeneca Reports Lynparza Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer,2017-02-17 06:38:00-05:00,AZN,negative
127824.0,"After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?",2017-02-16 16:13:00-05:00,AZN,negative
127825.0,Hearing AstraZeneca Holder Woodford Added to Holding on Recent Share Price Weakness,2017-02-16 10:53:00-05:00,AZN,negative
127826.0,Price Bump From M&A Rumors Earns Acadia A Vetr Downgrade,2017-02-15 17:03:00-05:00,AZN,neutral
127827.0,"Chi-Med, AstraZeneca to Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium",2017-02-14 04:17:00-05:00,AZN,neutral
127828.0,FDA Watch: February's Notable PDUFA Dates,2017-02-06 14:42:00-05:00,AZN,neutral
127829.0,The Market In 5 Minutes: One For The Thumb,2017-02-06 09:03:00-05:00,AZN,neutral
127830.0,Wall Street's M&A Chatter From February 3-6,2017-02-06 06:40:00-05:00,AZN,neutral
127831.0,ACADIA Spokesperson Tells Benzinga The Company Does Not Comment On Rumors In The Marketplace,2017-02-03 16:12:00-05:00,AZN,neutral
127832.0,"Earnings Scheduled For February 2, 2017",2017-02-02 04:57:00-05:00,AZN,neutral
127833.0,Q4 2016 Real-Time Call Brief,2017-02-01 19:00:00-05:00,AZN,neutral
127834.0,How Pharmacy Benefit Managers Add To The Cost Of Your Prescription,2017-01-26 11:14:00-05:00,AZN,positive
127835.0,Which Pharma Players Dominate The Lung Cancer Space?,2017-01-25 14:40:00-05:00,AZN,negative
127836.0,The Best BioPharma Plays Amid Uncertainty From Trump Comments,2017-01-12 13:58:00-05:00,AZN,positive
127837.0,Here's What Merck's Keytruda News Means For Bristol-Myers,2017-01-11 14:26:00-05:00,AZN,neutral
127838.0,Watch These 5 Huge Call Purchases In Friday Trade,2016-12-30 04:00:00-05:00,AZN,positive
127839.0,Option Alert: AZN Jul17 30.0 Calls: 550 @  ASK  $1.65: 10k traded vs 34k OI:  Earnings 2/2 Before Open  $27.47 Ref,2016-12-29 12:17:00-05:00,AZN,positive
127840.0,6 Worst Biotech Stocks Of 2016,2016-12-23 11:50:00-05:00,AZN,negative
127841.0,Breaking Down The Crowded Novel Ovarian Cancer Treatment Space,2016-12-21 09:19:00-05:00,AZN,negative
127842.0,"UPDATE: Ionis Says Earns $25M Milestone Payment, Eligible to Receive Up to $300M in Added Development, Regulatory Milestones",2016-12-19 16:04:00-05:00,AZN,neutral
127843.0,"Ionis, AstraZeneca Advance First Generation 2.5 LICA Drug into Preclinical Development to Treat Cardiovascular Disease",2016-12-19 16:04:00-05:00,AZN,positive
127844.0,Adam Feuerstein Tweets '$CLVS Rubraca approval has little bearing on $TSRO given different ovarian cancer pat pops. Rubraca more competes w/ $AZN Lynparza.',2016-12-19 13:08:00-05:00,AZN,negative
127845.0,Jefferies' 2017 Global Pharma Outlook,2016-12-19 10:56:00-05:00,AZN,neutral
127846.0,"Jefferies' Huge Pharma Pair Trade: Bristol-Myers Upgraded To Buy, Merck Downgraded To Sell",2016-12-19 09:09:00-05:00,AZN,positive
127847.0,"Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer, AstraZeneca Excercises Option To License IONIS-KRAS-2.5 Rx",2016-12-16 07:01:00-05:00,AZN,negative
127848.0,AstraZeneca's Movantik to be Marketed in Canada and Israel by Knight Therapeutics,2016-12-15 07:32:00-05:00,AZN,neutral
127849.0,"Cramer Gives His Opinion On Reynolds American, AstraZeneca And Sony",2016-12-14 06:58:00-05:00,AZN,neutral
127850.0,Alexion Management Changes Overshadow Potentially Positive Audit Results,2016-12-12 09:28:00-05:00,AZN,positive
127851.0,AstraZeneca Higher Off Drug News And Upgrade,2016-12-09 11:47:00-05:00,AZN,neutral
127852.0,Option Alert: AZN Jan 2018 $30 Put; 4000 @Bid @$5.80; Ref=$27.20,2016-12-09 10:35:00-05:00,AZN,positive
127853.0,"AstraZeneca Shares Resume Trade, Now Up 4%",2016-12-09 10:26:00-05:00,AZN,positive
127854.0,AstraZeneca Shares Indicated in $27-$29 Range; Stock Was Halted at $27.11,2016-12-09 10:21:00-05:00,AZN,positive
127855.0,"AstraZeneca Shares Trading in London Pull Back from Intraday Highs But Still Up ~5.5% for Session Following News FDA Has Accepted Co.s Durvalumab for BLA, Priority Review",2016-12-09 10:15:00-05:00,AZN,positive
127856.0,"UPDATE: FDA Has Granted AstraZeneca's Durvalumab for Priority Review Status, Sees PDUFA Date in Q2'17",2016-12-09 10:08:00-05:00,AZN,positive
127857.0,AstraZeneca FDA Accepts Durvalumabe For BLA In Bladder Cancer,2016-12-09 10:06:00-05:00,AZN,negative
127858.0,AstraZeneca Shares Trading in London Up ~3.3% Since Shares Trading on NYSE Were Halted; Up 5.5% for Session,2016-12-09 10:02:00-05:00,AZN,positive
127859.0,"Novartis, Biomarin, Alexion Shares All Moving Higher On AstraZeneca Halt",2016-12-09 09:57:00-05:00,AZN,positive
127860.0,AstraZeneca Halted News Pending,2016-12-09 09:54:00-05:00,AZN,neutral
127861.0,Benzinga's Top Upgrades,2016-12-09 08:39:00-05:00,AZN,positive
127862.0,"AstraZeneca Says Tagrisso Reduced Risk Of Disease Progression By 70%, From AURA3 Phase III Trial On Tagrisso",2016-12-09 08:04:00-05:00,AZN,negative
127863.0,Eli Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease,2016-12-09 07:01:00-05:00,AZN,neutral
127864.0,Leerink Swann Upgrades Astrazeneca PLC Common Stock to Outperform,2016-12-09 06:26:00-05:00,AZN,neutral
127865.0,"UPDATE: AstraZeneca FALCON Trial Met Primary Endpoint, Revealed Median PFS of 16.6 Months vs. ARIMIDEX Arm PFS Of 13.8 Months",2016-12-08 08:33:00-05:00,AZN,neutral
127866.0,AstraZeneca Announces Subgroup Analysis from FALCON Trial Comparing FASLODEX To ARIMIDEX,2016-12-08 08:33:00-05:00,AZN,neutral
127867.0,AstraZeneca Presents AURA3 Trial Data Which Shows Statistically Significant Improvement In PFS vs. Doublet Chemotherapy,2016-12-06 07:02:00-05:00,AZN,positive
127868.0,AstraZeneca +3.3% Premarket @$27.24; Liberium Upgraded Friday from Hold to Buy,2016-11-25 09:22:00-05:00,AZN,neutral
127869.0,Stocks Hitting 52-Week Lows,2016-11-23 10:27:00-05:00,AZN,negative
127870.0,AstraZeneca Announces FDA Lifted Partial Clinical Hold on Enrollment of New Patients with HNSCC for Clinical Trials of Durvalumab as Monotherapy and in Combination with Tremelimumab,2016-11-22 04:44:00-05:00,AZN,neutral
127871.0,Novartis Tells Benzinga On Intereconomia Article Suggesting Deal With AstraZeneca 'Novartis Doesn't Comment On Market Rumor Or Speculation',2016-11-11 12:02:00-05:00,AZN,neutral
127872.0,BZ NOTE: Watch for Near-Term Profit Taking in AstraZeneca Shares Following Intereconomia Report of Takeover Interest; Traders Often Times Show Skepticism About Rumors Coming from This Publication,2016-11-11 11:50:00-05:00,AZN,positive
127873.0,Hearing Intereconomia Reporting Novartis To Acquire AstraZeneca,2016-11-11 11:48:00-05:00,AZN,neutral
127874.0,AstraZeneca Reports Study Results Show SYMBICORT Improves Lung Funcation in Pediatric Asthma Patients,2016-11-11 08:01:00-05:00,AZN,positive
127875.0,AstraZeneca Reports Q3 EPS $1.32 vs $0.74 Est; Revenue $5.699B vs $5.95B Est,2016-11-10 04:57:00-05:00,AZN,neutral
127876.0,"Earnings Scheduled For November 10, 2016",2016-11-10 04:16:00-05:00,AZN,neutral
127877.0,Watch These 4 Huge Put Purchases In Thursday Trade,2016-11-10 01:14:00-05:00,AZN,positive
127878.0,Option Alert: AZN Nov16 28.0 Puts Sweep: 3700 @  ASK  $0.45: 3879 traded vs 3564 OI:  Earnings tmrrw Before Open  $29.11 Ref,2016-11-09 14:36:00-05:00,AZN,positive
127879.0,"Amazon's Price Target Reduced To A Measly $1,000 At Credit Suisse",2016-10-28 12:20:00-04:00,AZN,positive
127880.0,"Incyte Shares Recently Pulled Back from $88 Level; Hearing News Astra, FDA Made Deal for Partial Clinical Hold is Negative for Incyte",2016-10-27 11:42:00-04:00,AZN,negative
127881.0,Bloomberg Confirms AstraZeneca Spoke To FDA Recently And Agreed To Partial Clinical Halt,2016-10-27 11:40:00-04:00,AZN,positive
127882.0,Hearing Astrazeneca Has Stopped Recruitment In Trial Evaluating IO Combination In Head And Neck Cancer,2016-10-27 11:14:00-04:00,AZN,negative
127883.0,LYNPARZATM (olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit,2016-10-26 07:00:00-04:00,AZN,positive
127884.0,6 Big Pharma Companies Left To Report September Quarterly Figures,2016-10-25 13:45:00-04:00,AZN,neutral
127885.0,AstraZeneca Spokesperson Declines Comment Following Unconfirmed Report of Roche Interest,2016-10-17 14:46:00-04:00,AZN,positive
127886.0,Shares of AstraZeneca Trading Higher Over Past Few Minutes On Rumor Of Potential Roche Acquisition of AstraZeneca,2016-10-17 10:01:00-04:00,AZN,positive
127887.0,Insmed Reports Global License Deal with AstraZeneca for Oral DPP1 Inhibitor,2016-10-05 06:58:00-04:00,AZN,negative
127888.0,AstraZeneca Drug Trial Failure Has Major Implications To Its Pipeline,2016-10-04 10:14:00-04:00,AZN,negative
127889.0,Aralez Pharma Shares Up ~9 Percent in Premarket on News of Beta Blocker Toprol-XL Acquisition from AstraZeneca,2016-10-04 08:28:00-04:00,AZN,positive
127890.0,A Peek Into The Markets: U.S. Stock Futures Edge Higher; Crude Oil Drops,2016-10-04 07:53:00-04:00,AZN,negative
127891.0,AstraZeneca's Brilinta Didn't Meet Primary Endpoint,2016-10-04 07:40:00-04:00,AZN,neutral
127892.0,AstraZeneca Announces Agreement with Aralez for Toprol-XL in US; Aralez will Pay AstraZeneca $175M to Acquire Rights,2016-10-04 04:26:00-04:00,AZN,positive
127893.0,AstraZeneca Announces Top-line EUCLID Results in PAD;  Brilinta did Not Meet Primary Endpoint,2016-10-04 04:23:00-04:00,AZN,neutral
127894.0,Allergan Announces Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program,2016-10-03 04:07:00-04:00,AZN,positive
127895.0,Brean Likes Nektar Therapeutics' Upcoming Launches; Assumes Coverage At Buy,2016-09-30 08:34:00-04:00,AZN,positive
127896.0,AstraZeneca Gets FDA Approval for Tagrisso,2016-09-29 07:06:00-04:00,AZN,positive
127897.0,"vTv Therapeutics Shares Initiated With Buy Rating, $13 Target",2016-09-26 11:46:00-04:00,AZN,positive
127898.0,PiperJaffray Initiates Coverage on AstraZeneca at Overweight,2016-09-23 06:46:00-04:00,AZN,negative
127899.0,"Citi Research Reevaluates Bristol-Myers, Lowers Price Target",2016-09-20 09:13:00-04:00,AZN,negative
127900.0,"Phase III Combination Trial of BYDUREON and FARXIGA Shows Significant Blood Sugar Reduction in Patients with Type 2 Diabetes, Met Primary And Secondary Endpoints",2016-09-16 08:01:00-04:00,AZN,positive
127901.0,AstraZeneca Says Combination of Diabetes Drugs Bydureon and Forxiga Shows Promise in Study -Bloomberg,2016-09-16 06:35:00-04:00,AZN,positive
127902.0,What To Watch For In Autozone's Upcoming Earnings Release,2016-09-15 17:10:00-04:00,AZN,neutral
127903.0,Option Alert: AZN Fri 10/28 31.5 Calls (Wkly): 500 @  ASK  $2.65: 3117 traded vs 4001 OI:  Earnings 11/3  $33.54 Ref,2016-09-15 12:34:00-04:00,AZN,positive
127904.0,Watch These 7 Huge Call Purchases In Thursday Trade,2016-09-15 02:16:00-04:00,AZN,positive
127905.0,Option Alert: AZN Apr17 32.5 Calls: 500 @  ASK  $2.80: 2000 traded vs 53 OI:  Earnings 11/3  $33.21 Ref,2016-09-14 11:24:00-04:00,AZN,positive
127906.0,"The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A",2016-09-14 09:17:00-04:00,AZN,positive
127907.0,Benzinga's Top Downgrades,2016-09-14 09:16:00-04:00,AZN,positive
127908.0,Exane BNP Paribas Downgrades AstraZeneca to Neutral,2016-09-14 04:58:00-04:00,AZN,neutral
127909.0,"Jefferies Sees Much Larger Market Opportunity For AstraZeneca, Upgrades To Buy",2016-09-12 09:33:00-04:00,AZN,positive
127910.0,Benzinga's Top Upgrades,2016-09-12 09:21:00-04:00,AZN,positive
127911.0,The Market In 5 Minutes: Hillary Clinton Falls Ill With The Global Stock Markets,2016-09-12 08:55:00-04:00,AZN,negative
127912.0,Jefferies Upgrades AstraZeneca to Buy,2016-09-12 03:43:00-04:00,AZN,neutral
127913.0,Astrazeneca Says Benralizumab Phase III Trials Show Positive Results,2016-09-06 08:01:00-04:00,AZN,positive
127914.0,Aspen Pharmacare to Acquire Exclusive Rights to Commercialize Astrazeneca's Anaesthetics Portfolio; Terms Not Disclosed,2016-09-01 05:11:00-04:00,AZN,positive
127915.0,UPDATE: AstraZeneca Announces SYMBICORT Demonstrated Comparable Risk of Serious Asthma-Related Events and Lower Risk of Asthma Exacerbations Compared to Budesonide Alone,2016-08-31 17:06:00-04:00,AZN,negative
127916.0,AstraZeneca Announces Symbicort Demonstrated Comparable Risk Of Serious Asthma-Related Events Compared To Budesonide,2016-08-31 17:05:00-04:00,AZN,negative
127917.0,"Argus Upgrades AstraZeneca To Buy, Says Discount Is Too Steep Against Pipeline Potential",2016-08-29 10:39:00-04:00,AZN,neutral
127918.0,"The Market In 5 Minutes: Icahn, Netflix And A Quiet Market",2016-08-29 08:57:00-04:00,AZN,neutral
127919.0,Benzinga's Top Upgrades,2016-08-29 08:49:00-04:00,AZN,positive
127920.0,"Argus Research Upgrades AstraZeneca to Buy, Announces $38.00 PT",2016-08-29 07:10:00-04:00,AZN,neutral
127921.0,Here Are All The Big Biotech Mergers In 2016,2016-08-27 18:36:00-04:00,AZN,neutral
127922.0,Pfizer's $1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre-Split Prep?,2016-08-24 14:42:00-04:00,AZN,neutral
127923.0,Option Alert: AZN Sep16 35.0 Calls Sweep: 2158 @  ASK  $0.45: 2212 traded vs 9614 OI: $34.10 Ref,2016-08-24 09:40:00-04:00,AZN,positive
127924.0,The Market In 5 Minutes: Stocks Trading Higher As Earnings Season Quiets Down,2016-08-24 09:07:00-04:00,AZN,neutral
127925.0,Pfizer to Acquire Small Molecule Anti-Infective Business from AstraZeneca for Up to $1.575B,2016-08-24 04:19:00-04:00,AZN,neutral
127926.0,Pfizer Has Had A Busy M&A Year...Or Has It?,2016-08-23 08:58:00-04:00,AZN,neutral
127927.0,Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293,2016-08-22 06:01:00-04:00,AZN,neutral
127928.0,AstraZeneca Makes $140M Investment in Moderna; Now has 9% Stake,2016-08-10 09:45:00-04:00,AZN,neutral
127929.0,"AstraZeneca Reports Positive Top-Line Data from Two Phase III SYMBICORT Studies, Achieved Primary Endpoints In Both Studies",2016-08-10 08:06:00-04:00,AZN,positive
127930.0,AstraZeneca Announces Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint,2016-08-09 04:05:00-04:00,AZN,negative
127931.0,Citi Doesn't See Merck's Lung Cancer Success Lasting Long,2016-08-08 07:36:00-04:00,AZN,negative
127932.0,"Benzinga's M&A Chatter for Thursday August 4, 2016",2016-08-04 21:11:00-04:00,AZN,neutral
127933.0,Generics Keeping The Pressure On Big Pharma,2016-08-03 17:13:00-04:00,AZN,negative
127934.0,"Legg Mason Introduces International High Dividend, Low Vol ETF",2016-07-29 15:27:00-04:00,AZN,negative
127935.0,Option Alert: AZN Oct16 35.0 Calls Sweep: 749 @  ASK  $0.75: 1015 traded vs 312 OI:  Earnings today Before Open  $33.70 Re,2016-07-28 11:52:00-04:00,AZN,positive
127936.0,The Market In 5 Minutes: Facebook Crushes Earnings,2016-07-28 08:55:00-04:00,AZN,negative
127937.0,AstraZeneca CEO Declines Comment on Possibility Co Might Become Takeover Target Again -Reuters,2016-07-28 04:53:00-04:00,AZN,neutral
127938.0,"Earnings Scheduled For July 28, 2016",2016-07-28 04:03:00-04:00,AZN,neutral
127939.0,AstraZeneca Says Phase III Aura3 Trial Met Its Primary Endpoint,2016-07-18 04:38:00-04:00,AZN,neutral
127940.0,Argus Concerned With Near-Term Challenges At AstraZeneca,2016-07-12 09:37:00-04:00,AZN,positive
127941.0,Benzinga's Top Initiations,2016-07-12 09:33:00-04:00,AZN,positive
127942.0,Argus Research Initiates Coverage on AstraZeneca at Hold,2016-07-12 07:05:00-04:00,AZN,neutral
127943.0,Believe It: Brexit Isn't All Bad For U.K. ETFs,2016-07-11 08:41:00-04:00,AZN,positive
127944.0,Astra Zeneca's Tagrisso Approved By Heath Canada As Treatment For Lung Cancer Patients,2016-07-11 08:05:00-04:00,AZN,negative
127945.0,What's The Market Potential For Relypsa Now That AstraZeneca's ZS-9 Is Indefinitely On Hold?,2016-07-08 14:33:00-04:00,AZN,neutral
127946.0,FibroGen Receives $62M License Payment from AstraZeneca,2016-07-08 04:34:00-04:00,AZN,neutral
127947.0,Medivation Bidders Will Have To Price In Talazoparib; BMO Sees $68-$76 Takeout Price,2016-07-07 15:33:00-04:00,AZN,neutral
127948.0,Here's Why Valeant Is Happy To Relinquish Its European Brodalumab Rights,2016-07-07 10:21:00-04:00,AZN,positive
127949.0,Jefferies Downgrades Tesaro Following 108% Stock Move,2016-06-30 13:11:00-04:00,AZN,neutral
127951.0,AstraZeneca Announces Zavicefta Approved in EU for Patients With Serious Bacterial Infections,2016-06-28 05:45:00-04:00,AZN,positive
127952.0,AstraZeneca Announces Zavicefta Approved in EU for Patients With Serious Bacterial Infections,2016-06-28 05:45:00-04:00,AZN,positive
127953.0,Chinese Expats Revolutionizing China's Homegrown Biopharma Sector,2016-06-27 09:41:00-04:00,AZN,neutral
127954.0,Active Premarket Stocks,2016-06-24 04:19:00-04:00,AZN,positive
127955.0,Don't Bother Using FluMist; It Just Doesn't Work,2016-06-23 14:00:00-04:00,AZN,positive
127956.0,"Antares Pharma Reports Settlement of Patent Litigation for Key Alliance Business Product, Settlement Between AstraZeneca and Teva Allows Teva to Commercialize Its Generic Version of BYETTA on October 15, 2017",2016-06-23 10:55:00-04:00,AZN,negative
127957.0,Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta in the United States,2016-06-23 08:30:00-04:00,AZN,positive
127958.0,"Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators",2016-06-13 09:37:00-04:00,AZN,negative
127959.0,The Market In 5 Minutes: Gotta Get Down On Friday,2016-06-10 08:46:00-04:00,AZN,neutral
127960.0,"Benzinga's M&A Chatter for Thursday June 9, 2016",2016-06-09 20:48:00-04:00,AZN,neutral
127961.0,StreetSweeper On Relypsa: 8 Reasons 'We Wouldn't Run Away & Join This Circus',2016-06-09 10:49:00-04:00,AZN,negative
127962.0,Aspen to Acquire Commercialization Rights to Astrazeneca's Anaesthetic Medicines Portfolio for $520M Upfront Payment,2016-06-09 04:17:00-04:00,AZN,neutral
127963.0,"Morgan Stanley Downgrades Relypsa, Expects Focus To Return To The Challenged Veltassa Launch & Cash Burn",2016-06-07 08:39:00-04:00,AZN,negative
127964.0,Acadia Pharmaceuticals May Be Subject Of A Bidding War,2016-06-06 12:21:00-04:00,AZN,negative
127965.0,"The Market In 5 Minutes: Float Like A Butterfly, Sting Like A Bee",2016-06-06 08:57:00-04:00,AZN,positive
127966.0,"Must Watch Stocks for June 6, 2016",2016-06-06 04:36:00-04:00,AZN,neutral
127967.0,Benzinga's Weekend M&A Chatter,2016-06-05 20:21:00-04:00,AZN,neutral
127968.0,"Foundation Medicine, AstraZeneca Announce Strategic Collaboration for Lynparza Companion Diagnostic Assay",2016-06-04 09:43:00-04:00,AZN,neutral
127969.0,"AstraZeneca, Teva, Biogen, Allergan Said to be Potential Bidders for Acadia -Daily Mail",2016-06-03 18:38:00-04:00,AZN,neutral
127970.0,Ironwood Pharmaceuticals Closes Transaction with AstraZeneca for US Rights to Lesinurad,2016-06-03 04:18:00-04:00,AZN,neutral
127971.0,"Grünenthal, AstraZeneca Enter License Agreement for Gout Treatment Zurampic for Europe, Latin America",2016-06-02 04:54:00-04:00,AZN,positive
127972.0,5 Other Times Relypsa Gained 10% In A Day This Year,2016-05-27 13:55:00-04:00,AZN,positive
127973.0,Benzinga's Volume Movers,2016-05-27 10:37:00-04:00,AZN,neutral
127974.0,Mid-Morning Market Update: Markets Edge Higher; Big Lots Beats Q1 Estimates,2016-05-27 10:11:00-04:00,AZN,neutral
127975.0,5 Gainers And Losers In The Pre-Market Today,2016-05-27 10:07:00-04:00,AZN,negative
127976.0,"Overhang For Relypsa Remains, Morgan Stanley Says",2016-05-27 09:04:00-04:00,AZN,neutral
127977.0,15 Stocks Moving In Friday's Pre-Market Session,2016-05-27 08:17:00-04:00,AZN,neutral
127978.0,Relypsa Surges 30% Following Setback From Rival AstraZeneca,2016-05-27 08:09:00-04:00,AZN,neutral
127979.0,AstraZeneca Remains Committed To Development Of ZS-9 Despite Letter From FDA,2016-05-27 07:47:00-04:00,AZN,positive
127980.0,AstraZeneca's ZS-9 Delay Highlights Broader Risk Of Pipeline-Led EPS Growth Outlook,2016-05-27 07:31:00-04:00,AZN,negative
127981.0,Relypsa +28% Premarket @$21.30 as FDA Sends CRL for AstraZeneca's Hyperkalaemia Treatment,2016-05-27 07:26:00-04:00,AZN,neutral
127982.0,"AstraZeneca Reports Positive Phase 3 Falcon Trial Results, Met Primary Endpoint; Trial Showed An Adverse Event Profile Consistent With Current Knowledge Of The Safety Profile Of The Medicines",2016-05-27 07:05:00-04:00,AZN,positive
127983.0,AstraZeneca's Fulvestrant Met Its Primary Endpoint,2016-05-27 07:00:00-04:00,AZN,neutral
127984.0,AstraZeneca Receives CRL from FDA for Sodium Zirconium Cyclosilicate for Oral Suspension for Treatment of Hyperkalaemia,2016-05-27 04:54:00-04:00,AZN,neutral
127985.0,AstraZeneca's Faslodex Met Primary Endpoint of Extended Progression-free Survival in Advanced Breast Cancer,2016-05-27 04:52:00-04:00,AZN,negative
127986.0,The Market In 5 Minutes: Where's The Oil?,2016-05-24 08:44:00-04:00,AZN,neutral
127987.0,AstraZeneca's Multi-Tumor Opportunity Still Exists,2016-05-18 13:43:00-04:00,AZN,positive
127988.0,A Look At All Of Pfizer's Acquisitions Over The Past 2 Years,2016-05-17 11:22:00-04:00,AZN,neutral
127989.0,"As Veltassa Continues To Grow, BTIG Still Buying Relypsa",2016-05-17 08:12:00-04:00,AZN,neutral
127990.0,AstraZeneca Reports They Met Primary Endpoint In 2 Phase III Trials For SIROCCO and CALIMA Showing Significant Reductions In Asthma Exacerbation Rate vs. Placebo,2016-05-17 07:03:00-04:00,AZN,positive
127991.0,"UPDATE: AstraZeneca CEO Says Expects Progression-Free Survival Data from Mystic Immuno-Oncology Trial in Early 2017, With Overall Survival Data in Q2/Q3 2017",2016-05-13 09:11:00-04:00,AZN,neutral
127992.0,"AstraZeneca CEO, in Interview Says DDR Drugs Could Treat Up to 40% of Ovarian/Breast Cancers; Also Promising In Lung Cancer -Reuters",2016-05-13 09:10:00-04:00,AZN,neutral
127993.0,The Market In 5 Minutes: Don't Stop Me Now,2016-05-11 09:34:00-04:00,AZN,positive
127994.0,"AstraZeneca Launche, Prices €2.2B of Bonds; Proceeds to be Used for General Corporate Purposes, Including Repayment of Debt",2016-05-09 12:47:00-04:00,AZN,negative
127995.0,"Benzinga's M&A Chatter for Tuesday May 3, 2016",2016-05-03 18:52:00-04:00,AZN,neutral
127996.0,Benzinga's Weekend M&A Chatter,2016-05-01 20:36:00-04:00,AZN,neutral
127997.0,FDA Approves First Generic Crestor-DJ,2016-04-29 12:57:00-04:00,AZN,positive
127998.0,"Hearing Medivation Seeking Bids of At Least $65/Share, AstraZeneca, Pfizer Mentioned as Weigh Bids",2016-04-29 12:32:00-04:00,AZN,neutral
127999.0,"Earnings Scheduled For April 29, 2016",2016-04-29 04:07:00-04:00,AZN,neutral
128000.0,Why Medivation Will Likely Reject Sanofi's $52.50/Share Buyout Offer,2016-04-28 16:37:00-04:00,AZN,negative
128001.0,Why Are Medivation Shares Trading Sharply Above The $52.50 Offer?,2016-04-28 13:45:00-04:00,AZN,positive
128002.0,Astrazeneca Announces US Licensing Agreement With Ironwood; Includes US Rights to Zurampic; Lesinurad/Allopurinol Fixed-Dose Combination in Gout,2016-04-26 04:34:00-04:00,AZN,positive
128003.0,"Leerink: Medivation Buyout 'Inevitable,' AstraZeneca And AbbVie Most Likely Buyers",2016-04-25 10:51:00-04:00,AZN,neutral
128004.0,"The Market In 5 Minutes: Brazil, Doha, And Earnings Season",2016-04-18 09:44:00-04:00,AZN,neutral
128005.0,"Medivation Ticks Up 3%, AstraZeneca Said To Be Also Interested In Acquisition",2016-04-18 08:31:00-04:00,AZN,positive
128006.0,10 Stocks Moving In Monday's Pre-Market Session,2016-04-18 08:22:00-04:00,AZN,neutral
128007.0,Benzinga's Weekend M&A Chatter,2016-04-17 19:28:00-04:00,AZN,neutral
128008.0,Morgan Stanley's Berens Highlights Greater Payor Pushback For Relypsa's Veltassa,2016-04-15 09:54:00-04:00,AZN,positive
128009.0,"SunTrust: Medivation M&A Chatter Highlights Value, Company's 'Unique' Industry Position",2016-04-13 13:44:00-04:00,AZN,positive
128010.0,Cancer Drug Stocks Are The Picture Of Health,2016-04-12 17:12:00-04:00,AZN,negative
128011.0,Benzinga's Top Downgrades,2016-04-12 09:16:00-04:00,AZN,positive
128012.0,"Goldman Sachs Downgrades AstraZeneca To Sell, Cites High Pipeline Expectations",2016-04-12 07:57:00-04:00,AZN,neutral
128013.0,Goldman Sachs Downgrades AstraZeneca to Sell,2016-04-11 22:48:00-04:00,AZN,neutral
128014.0,"Eli Lilly, AstraZeneca Report Continuation of Pivotal Trial for People with Early Alzheimer's Disease; Will Continue to Phase 3 After Positive Interim Safety Data",2016-04-08 07:03:00-04:00,AZN,positive
128015.0,Stifel Comments On Relypsa M&A Rumors: 'Timing Could Be Tricky',2016-04-07 16:52:00-04:00,AZN,negative
128016.0,Cantor: Relypsa Sale Makes Sense,2016-04-07 15:10:00-04:00,AZN,neutral
128017.0,"BZ NOTE: Relypsa Has Been Mentioned In Rumors Over Past 7 Months In Possible M&A Talk With Sanofi, Merck, Astra Zeneca",2016-04-07 13:05:00-04:00,AZN,positive
128018.0,"PPH May Be Home To Hedge Fund Hotels, But This ETF Can Endure",2016-04-06 14:26:00-04:00,AZN,neutral
128019.0,SocGen Picks New Favorites In Big Pharma,2016-04-06 13:44:00-04:00,AZN,positive
128020.0,WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP,2016-04-06 04:52:00-04:00,AZN,positive
128021.0,Evidence Pfizer Could Revisit GlaxoSmithKline Or AstraZeneca Deals If Allergan Falls Through,2016-04-05 12:30:00-04:00,AZN,neutral
128022.0,"The Market In 5 Minutes: Tuesday, April 5, 2016",2016-04-05 10:38:00-04:00,AZN,neutral
128023.0,"Credit Suisse: Medivation Could Be Worth $54 To $75 In Takeout, But Management Won't Sell",2016-03-31 11:27:00-04:00,AZN,positive
128024.0,Citi Downgrades Novartis Following SAG Investigation,2016-03-29 10:10:00-04:00,AZN,neutral
128025.0,Inovio Gives Update On INO-3112 HPV Immunotherapy Development Plan,2016-03-29 08:03:00-04:00,AZN,neutral
128026.0,AstraZeneca Says Tagrisso Approved in Japan for Cancer Patients,2016-03-29 05:07:00-04:00,AZN,negative
128027.0,Medivation Up As Triple M&A Interest Rumor Circulates,2016-03-22 11:47:00-04:00,AZN,positive
128028.0,"The Market In 5 Minutes: Tuesday, March 22, 2016",2016-03-22 11:15:00-04:00,AZN,neutral
128029.0,Stocks Hitting 52-Week Lows,2016-03-22 10:09:00-04:00,AZN,negative
128030.0,Intercept Shares Move to High; Hearing Unconfirmed Market Chatter of Offer from AstraZeneca,2016-03-18 11:18:00-04:00,AZN,positive
128031.0,AstraZeneca Acquires All Rights to Orexo's OX-CLI Project,2016-03-17 09:47:00-04:00,AZN,neutral
128032.0,Stocks Hitting 52-Week Lows,2016-03-16 10:10:00-04:00,AZN,negative
128033.0,Benzinga's Top Downgrades,2016-03-15 09:08:00-04:00,AZN,positive
128034.0,"Amid Few Catalysts, Jefferies Downgrades AstraZeneca",2016-03-15 08:07:00-04:00,AZN,neutral
128035.0,"Jefferies Downgrades AstraZeneca To Hold, Says FY 2016 Catalysts Are Limited, Sees LT Upside Potential From IO Pipeline But Cautions Driving Catalysts May Not Manifest Until 2017",2016-03-15 06:38:00-04:00,AZN,negative
128036.0,Jefferies Downgrades AstraZeneca to Hold,2016-03-15 04:04:00-04:00,AZN,neutral
128037.0,"In The Fight Against Cancer, Roche And AstraZeneca Are Looking At Trillions Of Bacteria That Live In The Body",2016-03-14 14:37:00-04:00,AZN,negative
128038.0,AstraZeneca Looks to Link Executive Compensation to $45B Revenue Target -Bloomberg,2016-03-13 17:17:00-04:00,AZN,neutral
128039.0,"Jim Cramer Advises Viewers On AstraZeneca, Juno Therapeutics, Enbridge Energy Partners, Lockheed Martin And Microsoft",2016-03-09 07:02:00-05:00,AZN,positive
128040.0,"Watch Pharma Names Following FDA Issuance Of New Mandatory Clinical Study For Bayer's 'Essure', Requires Product Labeling, Including Box Warnings And Patient Decision Checklist",2016-02-29 15:39:00-05:00,AZN,negative
128041.0,6-K Confirms AstraZeneca Failed Trial For Tremelimumab,2016-02-29 10:41:00-05:00,AZN,negative
128042.0,Benzinga's Top Initiations,2016-02-29 09:51:00-05:00,AZN,positive
128043.0,UPDATE: AZN Says Top-Line Tremelimumab Trial Did Not Meet Primary Endpoint Of Improving Overall Survival In Mesothelioma Patients,2016-02-29 08:54:00-05:00,AZN,positive
128044.0,Hearing AstraZeneca Top-Line Results of Tremelimumab Trial Did Not Meet Primary Endpoint,2016-02-29 08:53:00-05:00,AZN,neutral
128045.0,Tibet Rhodiola Pharmaceutical Says it and Partners Sign Agreement to Acquire Imdur Related Assets from Astrazeneca for $190M -Reuters,2016-02-29 06:09:00-05:00,AZN,positive
128046.0,Drexel Hamilton Initiates Coverage on AstraZeneca at Buy,2016-02-29 05:53:00-05:00,AZN,neutral
128047.0,AstraZeneca Announces Licensing Agreement with China Medical System Holdings for commercialization Rights in China to Plendil; CMS to pay AstraZeneca $310M for License to Sell Plendil in China,2016-02-29 04:27:00-05:00,AZN,positive
128048.0,Cantor Fitzgerald Initiates Coverage on AstraZeneca at Buy,2016-02-26 06:21:00-05:00,AZN,neutral
128049.0,"AstraZeneca's Acalabrutinib Receives Orphan Drug Designation in Europe for Treatment of Cll/Sll, Mantle Cell Lymphoma MCL and Lymphoplasmacytic Lymphoma -Reuters",2016-02-25 05:20:00-05:00,AZN,neutral
128050.0,UPDATE: AstraZeneca Release Was Posted Earlier To Day,2016-02-17 11:56:00-05:00,AZN,neutral
128051.0,Durvalumab Granted Breakthrough Therapy Designation By US FDA,2016-02-17 11:55:00-05:00,AZN,positive
128052.0,"BIND Therapeutics, AstraZeneca Report Publishing of Preclinical Data Showing ACCURINS Ability to Utilize Proprietary Hydrophobic Ion Pairing to Increase Biodistribution to Tumor Sites of Molecularly Targeted Agents",2016-02-10 16:01:00-05:00,AZN,positive
128053.0,CentreView Partners Said to be Advising on Sale of Intercept to Astrazeneca,2016-02-09 09:47:00-05:00,AZN,neutral
128054.0,Benzinga's Top Downgrades,2016-02-08 09:38:00-05:00,AZN,positive
128055.0,HBSC Downgrades AstraZeneca to Hold,2016-02-08 05:41:00-05:00,AZN,neutral
128056.0,AstraZeneca Falls More Than 5% Following Q4 Print,2016-02-04 08:03:00-05:00,AZN,neutral
128057.0,AstraZeneca Q4Q EPS $0.94 vs $0.88 Est; Revenue $6.39B vs $6.27B Est,2016-02-04 05:30:00-05:00,AZN,neutral
128058.0,"Earnings Scheduled For February 4, 2016",2016-02-04 04:13:00-05:00,AZN,neutral
128059.0,"Alleran, AstraZeneca Partner To Commercialize ATM-AVI For Gram-Negative Antibiotic Resistant Infections",2016-01-29 07:07:00-05:00,AZN,neutral
128060.0,"Oddo Securities Upgrades AstraZeneca to Top Pick, Says Co Pipeline Well Positioned In Terms Of Newsflow",2016-01-26 08:56:00-05:00,AZN,positive
128061.0,Why Shares Of Valeant Pharmaceuticals Spiked,2016-01-25 13:17:00-05:00,AZN,positive
128062.0,"Dynavax, AstraZeneca Report Amended Deal for Asthma Drug Candidate",2016-01-19 16:00:00-05:00,AZN,neutral
128063.0,AstraZeneca Shares Higher Following Barclays Upgrade,2016-01-19 09:42:00-05:00,AZN,positive
128064.0,Benzinga's Top Upgrades,2016-01-19 09:16:00-05:00,AZN,positive
128065.0,"Barclays Upgrades AstraZeneca to Equal-weight, Raises PT to $50.00",2016-01-19 05:38:00-05:00,AZN,neutral
128066.0,"Empire Analyst: Sell Sucampo Pharma, It Has 50% Downside",2016-01-12 10:45:00-05:00,AZN,negative
128067.0,Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration,2016-01-11 07:00:00-05:00,AZN,negative
128068.0,Must Watch Stocks for Today,2015-12-28 03:42:00-05:00,AZN,neutral
128069.0,Benzinga's Volume Movers,2015-12-24 10:33:00-05:00,AZN,neutral
128070.0,Here's What's Been Going On With Relypsa,2015-12-24 10:06:00-05:00,AZN,neutral
128071.0,Benzinga's Top #PreMarket Gainers,2015-12-24 08:19:00-05:00,AZN,positive
128072.0,Report: AstraZeneca Eyes Acquisition Of Relypsa For $46 Per Share,2015-12-24 07:53:00-05:00,AZN,positive
128074.0,AstraZeneca Said to Bid $46/Share for Relypsa -Daily Mail,2015-12-23 17:22:00-05:00,AZN,neutral
128075.0,Hearing FDA Has Approved Zurampic for Treatment of High Blood Uric Acid Levels Related to Gout,2015-12-22 17:46:00-05:00,AZN,positive
128076.0,Watch Stocks of Co.'s with Flu-Related Solutions; Macquarie Note Earlier Highlighted 'Early Flu Results Lagging,2015-12-22 12:06:00-05:00,AZN,negative
128077.0,"Jim Cramer Gives His Opinion On AstraZeneca, Cummins And Dow Chemical",2015-12-20 18:55:00-05:00,AZN,neutral
128078.0,"Regulus Therapeutics Announces Initial Dosing In Phase 1 Clinical Study Of RG-125 By Partner AstraZeneca, Regulus Earns $10M Milestone Payment",2015-12-18 08:02:00-05:00,AZN,neutral
128079.0,"Hearing AstraZeneca Has Received Positive CHMP Opinions on Lesinurad for Gout, Brilique, Tagrissot",2015-12-18 07:43:00-05:00,AZN,positive
128080.0,EMA Grants Conditional Marketing Authorization for Astrazeneca's Lung Cancer Drug Osimertinib,2015-12-18 07:19:00-05:00,AZN,negative
128081.0,EMA Recommends Astrazeneca's Gout Drug Lesinurad,2015-12-18 07:17:00-05:00,AZN,positive
128082.0,"Benzinga's M&A Chatter for Thursday December 17, 2015",2015-12-17 18:41:00-05:00,AZN,neutral
128083.0,"Early Global News: Obama Meets Bloomberg, Microsoft Supplying Chinese Government With Windows 10, And More",2015-12-17 07:28:00-05:00,AZN,neutral
128084.0,AstraZeneca toAcquire 55% Stake in Acerta for Upfront Payment of $2.5B,2015-12-17 05:30:00-05:00,AZN,neutral
128085.0,"Benzinga's M&A Chatter for Wednesday December 16, 2015",2015-12-16 18:47:00-05:00,AZN,neutral
128086.0,AstraZeneca to Acquire Respiratory Portfolio from Takeda for $575M,2015-12-16 04:26:00-05:00,AZN,neutral
128087.0,"Hearing AstraZeneca Has Reported Closing of Deal with Perrigo, Says Deal Does Not Impact Outlook",2015-12-15 10:08:00-05:00,AZN,neutral
128088.0,"M&A In Small-, Mid-Cap Biotechs Isn't Slowing Down",2015-12-14 11:59:00-05:00,AZN,neutral
128089.0,AstraZeneca Confirms Exploring Potential Strategic Options With Acerta Pharma,2015-12-14 04:51:00-05:00,AZN,neutral
128090.0,"Must Watch Stocks for December 14, 2015",2015-12-14 04:41:00-05:00,AZN,neutral
128091.0,Benzinga's Weekend M&A Chatter,2015-12-13 19:01:00-05:00,AZN,neutral
128092.0,"Several Pharma/Biotech Names Spiking on AstraZeneca Rumor: Baxter, Shire, Baxalta",2015-12-11 12:41:00-05:00,AZN,neutral
128093.0,UPDATE:  Astrazeneca Could Pay $5B+ for Acerta,2015-12-11 12:40:00-05:00,AZN,negative
128094.0,Astrazeneca In Talks To Acquire Acerta Pharma  -DJ,2015-12-11 12:39:00-05:00,AZN,neutral
128095.0,Credit Suisse Desk Lists Best Names To Buy/Sell Today,2015-12-08 10:40:00-05:00,AZN,positive
128096.0,These Currency Hedged ETFs Could Enjoy 2016,2015-12-07 09:34:00-05:00,AZN,positive
128097.0,"UPDATE: Celgene, Astrazeneca Fusion Program Partnership Is To Develop & Commercialize durvalumab Across A Range Of Blood Cancers",2015-12-07 07:32:00-05:00,AZN,neutral
128098.0,"Celgene, Astrazeneca Report Start Of Fusion Clincial Development Program In Immuno-Oncology",2015-12-07 07:30:00-05:00,AZN,neutral
128099.0,The Rare Double Upgrade: Why Morgan Stanley Loves AstraZeneca After Hating It,2015-12-01 14:13:00-05:00,AZN,positive
128100.0,Morgan Stanley Confirms Shares of AstraZeneca Upgraded Mid-Day,2015-12-01 11:46:00-05:00,AZN,positive
128101.0,"Shares of AstraZeneca Spike Over $34.20 Level, Up ~1.3% Over Last Few Mins; Some Traders Attributing Move Higher to Mid-Day Upgrade from Morgan Stanley",2015-12-01 11:41:00-05:00,AZN,positive
128102.0,6 Buys And 5 Value Traps Hiding In The European Stock Market,2015-11-30 08:32:00-05:00,AZN,positive
128103.0,"Early Global News: Alibaba Startup Stake, Commercial Drones & Under Armour-Lululemon Rumor",2015-11-23 09:37:00-05:00,AZN,neutral
128104.0,"Perrigo Reports Purchase of Entocort Capsules, Authorized Generic Capsules Marketed by Par Pharma from AstraZeneca for $380M",2015-11-23 07:58:00-05:00,AZN,neutral
128105.0,Diplomat to Dispense AstraZeneca Drug TAGRISSO(TM) (osimertinib),2015-11-16 16:01:00-05:00,AZN,neutral
128106.0,Benzinga's Volume Movers,2015-11-16 12:17:00-05:00,AZN,neutral
128107.0,AstraZeneca's Targisso Approved By FDA For Patients With EGFR T790M Mutation-Positive Metastic Non-Small Cell Lung Cancer-Reuters,2015-11-13 10:13:00-05:00,AZN,positive
128108.0,Why These Two Firms Downgraded ZS Pharma Stock,2015-11-09 08:38:00-05:00,AZN,neutral
128109.0,"AstraZeneca Presents Positive Update On Lesinurad Renal Data In Gout Patients; PDUFA Date December 29, 2015",2015-11-09 08:07:00-05:00,AZN,positive
128110.0,AstraZeneca Presents Positive Update on Lesinurad Renal Data in Gout Patients,2015-11-09 08:00:00-05:00,AZN,positive
128111.0,Mid-Afternoon Market Update: Sierra Wireless Drops On Downbeat Earnings; TrueCar Shares Spike Higher,2015-11-06 15:09:00-05:00,AZN,positive
128112.0,Mid-Day Market Update: ZS Pharma Jumps On Acquisition News; Men's Wearhouse Shares Slide,2015-11-06 12:26:00-05:00,AZN,positive
128113.0,Could Relypsa Be The Next Big Pharma Buyout Target?,2015-11-06 11:03:00-05:00,AZN,neutral
128114.0,Benzinga's Volume Movers,2015-11-06 10:23:00-05:00,AZN,neutral
128115.0,Stocks Hitting 52-Week Highs,2015-11-06 10:13:00-05:00,AZN,neutral
128116.0,Mid-Morning Market Update: Markets Decline; Humana Earnings Beat Estimates,2015-11-06 10:03:00-05:00,AZN,neutral
128117.0,Morning Market Gainers,2015-11-06 09:43:00-05:00,AZN,neutral
128118.0,Why ZS Pharma Isn't Game-Changing For AstraZeneca,2015-11-06 09:17:00-05:00,AZN,neutral
128119.0,Benzinga's Top #PreMarket Gainers,2015-11-06 08:09:00-05:00,AZN,positive
128120.0,US Stock Futures Mostly Flat; All Eyes On Jobs Report,2015-11-06 07:02:00-05:00,AZN,neutral
128121.0,"Morgan Stanley Says AstraZeneca Acquisition Of ZS Pharma is 'not game-changing', Deal Fits Well Into AstraZeneca's Portfolio",2015-11-06 05:37:00-05:00,AZN,positive
128122.0,AstraZeneca to Acquire ZS Pharma for $90/Share in Cash,2015-11-06 05:19:00-05:00,AZN,neutral
128124.0,Inovio's INO-3112 Demonstrates Robust Immune Responses in Patients With Head & Neck Cancer,2015-11-05 08:10:00-05:00,AZN,negative
128125.0,AstraZeneca Reports Q3 EPS $0.61 vs $0.77 Est; Revenue $5.945B vs $5.90B Est,2015-11-05 05:35:00-05:00,AZN,neutral
128126.0,"AstraZeneca CEO Says Nothing Has Changed in Partnership With Valeant on Brodalumab, Despite Issues at Valeant -Reuters",2015-11-05 05:23:00-05:00,AZN,neutral
128127.0,"Earnings Scheduled For November 5, 2015",2015-11-05 04:29:00-05:00,AZN,neutral
128128.0,How Allergan Could Be Pfizer's Rocket Ship,2015-10-29 12:19:00-04:00,AZN,neutral
128129.0,FDA Panel Votes Unanimously In Favor Of Clinical Benefit Of Astrazeneca's Gout Drug In Combination With Febuxostat,2015-10-23 14:56:00-04:00,AZN,positive
128130.0,10 Giant M&A Deals That Almost Happened...But Fell Through At The Last Minute,2015-10-22 10:02:00-04:00,AZN,neutral
128131.0,Benzinga's Top Downgrades,2015-10-20 10:03:00-04:00,AZN,positive
128132.0,Credit Suisse Downgrades AstraZeneca to Underperform,2015-10-20 07:34:00-04:00,AZN,positive
128133.0,"6-K from AstraZeneca Reports FDA Issues CRL Related to NDA for Investigational Fixed-Dose Combo of Saxagliptin, Dapagliflozin fro Treatment of Adults with Type 2 Diabetes",2015-10-16 07:36:00-04:00,AZN,neutral
128134.0,Peregrine Pharmaceuticals +20% Premarket Following Announcement of Collaboration With AstraZeneca,2015-10-15 08:07:00-04:00,AZN,neutral
128135.0,"Savolitinib, AstraZeneca Complete Enrolment for Phase II Clinical Trial in Papillary Renal Cell Carcinoma",2015-10-13 04:31:00-04:00,AZN,neutral
128136.0,AstraZeneca Halts 2 Lung Cancer Drug Combo Trials,2015-10-09 08:24:00-04:00,AZN,negative
128137.0,Option Alert: $AZN Jan $35 Call; 4000 Contracts above Ask @$0.65; Now $32/15,2015-10-08 12:17:00-04:00,AZN,positive
128138.0,AstraZeneca Presents Respiratory Syncytial Virus (RSV) Study Results at IDWeek 2015,2015-10-08 08:01:00-04:00,AZN,neutral
128139.0,AstraZeneca to Present Data Demonstrating Diversity of Its Portfolio of Innovative Formulations and Devices at the European Respiratory Society International Congress 2015,2015-09-22 08:10:00-04:00,AZN,positive
128140.0,Biotechs Coming Off One Of The Busiest Weeks In Recent Memory,2015-09-14 13:44:00-04:00,AZN,neutral
128141.0,Benzinga's Top Upgrades,2015-09-14 09:25:00-04:00,AZN,positive
128142.0,Deutsche Bank Upgrades AstraZeneca to Buy,2015-09-14 07:16:00-04:00,AZN,neutral
128143.0,US Stock Futures Decline Ahead Of Economic Data,2015-09-11 07:35:00-04:00,AZN,neutral
128144.0,AstraZeneca Purchases US Biologics Manufacturing Facility to Support Growing Pipeline,2015-09-11 07:00:00-04:00,AZN,positive
128145.0,"AstraZeneca Buys Boulder, CO Manufacturing Facility from Amgen -Reuters",2015-09-11 04:49:00-04:00,AZN,neutral
128146.0,Starpharma Signs Drug Delivery License with AstraZeneca,2015-09-07 06:59:00-04:00,AZN,neutral
128147.0,AstraZeneca to Update on Leading Lung Cancer Portfolio at WCLC 2015,2015-09-04 08:00:00-04:00,AZN,negative
128149.0,US Stock Futures Tumble Ahead Of Economic Data,2015-09-01 07:34:00-04:00,AZN,neutral
128150.0,"Valeant, AstraZeneca to Partner on Brodalumab; Valeant to Make Upfront Payment to AstraZeneca of $100M; Up to $345M in Milestone Payments",2015-09-01 04:35:00-04:00,AZN,neutral
128151.0,"US Stock Futures Tumble, China's Shanghai Plunges 8.5%",2015-08-24 07:28:00-04:00,AZN,neutral
128152.0,AstraZeneca Names Sean Bohen as Chief Medical Officer,2015-08-24 05:08:00-04:00,AZN,neutral
128153.0,"AstraZeneca, Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial",2015-08-24 04:27:00-04:00,AZN,neutral
128154.0,O'Leary's O'Shares Triples The Size Of Its ETF Stable,2015-08-19 15:22:00-04:00,AZN,positive
128155.0,"Juno Therapeutics Could Nearly Double On Data, Multiple Catalysts, Say FBR Analysts",2015-08-18 09:38:00-04:00,AZN,neutral
128156.0,Diplomat To Dispense AstraZeneca Drug IRESSA,2015-08-10 17:13:00-04:00,AZN,neutral
128157.0,Mid-Day Market Update: Dow Surges Over 200 Points; Dean Foods Shares Decline On Downbeat Sales,2015-08-10 13:34:00-04:00,AZN,positive
128158.0,"Mid-Day Market Update: Monday's Movers, China's Trade, Oil And More",2015-08-10 12:29:00-04:00,AZN,neutral
128159.0,Mid-Morning Market Update: Markets Open Higher; Berkshire Hathaway To Acquire Precision Castparts For $37.2B,2015-08-10 10:50:00-04:00,AZN,neutral
128160.0,Morning Market Gainers,2015-08-10 09:45:00-04:00,AZN,neutral
128161.0,Benzinga's Top #PreMarket Gainers,2015-08-10 08:12:00-04:00,AZN,positive
128162.0,"Inovoio +9% Premarket on Light Trading, Following Announcement of Licensing Deal With AstraZeneca Unit; Inovio to Receive Up to $700M in Payments",2015-08-10 04:49:00-04:00,AZN,neutral
128163.0,Inovio Pharmaceuticals Announces Strategic Cancer Vaccine Collaboration and License Agreement With AstraZeneca's MedImmune Unit,2015-08-10 04:16:00-04:00,AZN,negative
128164.0,"Sosei Subsidiary Heptares, AstraZeneca Announce Agreement to Develop Novel Immuno-Oncology Treatments for Range of Cancers",2015-08-06 04:11:00-04:00,AZN,positive
128165.0,"AstraZeneca's MedImmune, Mirati Therapeutics Partner on Immuno-oncology Combination in Lung Cancer",2015-08-05 04:27:00-04:00,AZN,negative
128166.0,"Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease",2015-08-03 06:33:00-04:00,AZN,positive
128167.0,"AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases",2015-08-03 04:23:00-04:00,AZN,neutral
128168.0,AstraZeneca CEO Says Looking at M&A Deals But Prices are Pretty Hefty -Reuters,2015-07-30 08:29:00-04:00,AZN,positive
128169.0,"Charles River Laboratories, AstraZeneca Renew Strategic Partnership Agreement",2015-07-30 07:09:00-04:00,AZN,positive
128170.0,US Stock Futures Signal Lower Start On Wall Street,2015-07-27 07:07:00-04:00,AZN,negative
128171.0,AstraZeneca to Sell Caprelsa to Sanofi's Genzyme for Up to $300M,2015-07-27 05:29:00-04:00,AZN,neutral
128172.0,Celgene's Q2 Earnings Call: Highlights & Analyst Commentary,2015-07-23 13:04:00-04:00,AZN,neutral
128173.0,Morning Market Losers,2015-07-22 09:58:00-04:00,AZN,negative
128174.0,Benzinga's Top #PreMarket Losers,2015-07-22 08:28:00-04:00,AZN,negative
128175.0,US Stock Futures Down; Apple Shares Slide After Weak Sales Forecast,2015-07-22 07:47:00-04:00,AZN,negative
128176.0,Array BioPharma Shares Fall 20% Premarket Following AstraZeneca Report of Phase 3 SUMIT Metastatic Uveal Melanoma Study,2015-07-22 07:27:00-04:00,AZN,positive
128177.0,AstraZeneca Phase 3 SUMIT Study of Selumetinib in Combination with Dacarbazine Did Not Meet Primary Endpoint,2015-07-22 05:54:00-04:00,AZN,neutral
128178.0,"Clovis Oncology, FibroGen Are Key Biotech Names For Goldman Sachs",2015-07-20 07:56:00-04:00,AZN,neutral
128179.0,Hearing FDA Has Approved Target Therapies For First-Time Patients Seeking Treatment For Types Of Metastic Lung Cancer,2015-07-13 13:33:00-04:00,AZN,negative
128180.0,New Studies And Research Evaluating Stem Cell Therapy Treatments for Bone Marrow Diseases & Conditions Look to Identify Next-Generation Therapies For New Pre-Clinical and Phase I/II Clinical Trials,2015-07-09 08:30:00-04:00,AZN,neutral
128181.0,"AstraZeneca, Ironwood Announce Positive Top-Line Data from Phase III IBS-C Trial Designed to Support Linaclotide Approval in China",2015-07-08 08:00:00-04:00,AZN,positive
128182.0,Benzinga's Top Upgrades,2015-07-02 09:22:00-04:00,AZN,positive
128183.0,Berenberg Upgrades AstraZeneca To  Buy,2015-07-02 08:51:00-04:00,AZN,neutral
128184.0,Berenberg Upgrades AstraZeneca to Buy,2015-07-02 06:09:00-04:00,AZN,neutral
128185.0,"Eolas Therapeutics, AstraZeneca Announce Partnership to Develop Orexin-1 Receptor Antagonist for Multiple Indications",2015-06-30 10:19:00-04:00,AZN,negative
128186.0,"AstraZeneca Changes Ratio To NYSE-Listed ADS, New Ratio Will Be Two ADS For One Ordinary Share, Prior Ratio Was 1:1",2015-06-26 07:45:00-04:00,AZN,positive
128187.0,Biotech Stocks Worth Taking A Look At,2015-06-19 06:56:00-04:00,AZN,positive
128188.0,The Note Moving Pharma Giants Today,2015-06-17 16:06:00-04:00,AZN,neutral
128189.0,New Report: Abbvie Is Jefferies' Top Global Pharma Stock,2015-06-16 12:15:00-04:00,AZN,positive
128190.0,AstraZeneca Presents Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at EULAR 2015,2015-06-13 09:27:00-04:00,AZN,neutral
128191.0,Highlights From ISIS Pharmaceuticals At Goldman Sachs Healthcare Conference,2015-06-11 13:36:00-04:00,AZN,neutral
128192.0,AstraZeneca Shares Spike Lower; May be Attributed to Unconfirmed Market Chatter R&D Chief is Leaving,2015-06-10 10:38:00-04:00,AZN,negative
128193.0,"Benzinga's M&A Chatter for Tuesday June 9, 2015",2015-06-09 19:18:00-04:00,AZN,neutral
128194.0,Rumor Receptos Rejected $200/Share AstraZeneca Bid,2015-06-09 10:33:00-04:00,AZN,negative
128195.0,"US Stock Futures Surge Ahead Of ADP Report, Beige Book",2015-06-03 07:30:00-04:00,AZN,neutral
128196.0,"Ardelyx Regains Worldwide Development, Commercialization Rights for Tenapanor and Related Portfolio of NHE3 Compounds",2015-06-03 06:23:00-04:00,AZN,neutral
128197.0,"Astrazeneca, Innate Pharma Announce Global Co-Development and Commercialisation Collaboration for IPH2201 in Immuno-Oncology",2015-06-03 05:32:00-04:00,AZN,neutral
128198.0,Juno Shares Falling; May be Attributed to Bloomberg Correcting Earlier Story of AstraZeneca CEO Saying Would Buy Co Such as Juno,2015-06-02 13:47:00-04:00,AZN,positive
128199.0,Report: AstraZeneca Might Bid On Juno Therapeutics,2015-06-02 12:28:00-04:00,AZN,neutral
128200.0,AstraZeneca CEO Soriot Said CAR T Therapy Candidates Would Need to Be Able to Manage Side Effects Before Co. Would Be Interested in Deal,2015-06-02 10:30:00-04:00,AZN,positive
128201.0,"Hearing AstraZeneca CEO Pascal Soriot Has Suggested Co. 'Would Consider' Cos. Like Juno, Will Partner for Further Immunotherapy Trials",2015-06-02 10:27:00-04:00,AZN,positive
128202.0,"Shares of Ziopharm, Juno Moving Higher; Note Being Circulated Says Juno, Ziopharm Potential Targets of AstraZeneca",2015-06-02 10:23:00-04:00,AZN,positive
128203.0,16 Biotech Stocks Moving Off The ASCO Conference,2015-06-01 15:51:00-04:00,AZN,neutral
128204.0,AstraZeneca Presents Positive Data on AZD9291 in First-Line EGFR Mutated NSCLC at ASCO,2015-05-31 09:45:00-04:00,AZN,positive
128205.0,"AstraZeneca, MedImmune Present Positive Immuno-Oncology Combination Data at ASCO",2015-05-30 10:25:00-04:00,AZN,positive
128206.0,"Lilly, AstraZeneca to Partner on Immuno-Oncology Combination Clinical Trial in Solid Tumors",2015-05-29 08:04:00-04:00,AZN,positive
128207.0,CNBC's Stock Pops & Drops From May 26,2015-05-27 07:48:00-04:00,AZN,neutral
128208.0,"Amgen, AstraZeneca End Development Pact; Shares Sink",2015-05-26 20:56:00-04:00,AZN,positive
128209.0,DoJ Says Express Scripts' Medco Health Unit to Pay $7.9M to Settle Kickback Allegations Involving AstraZeneca -Retuers,2015-05-20 11:11:00-04:00,AZN,negative
128210.0,LBBW Upgrades AstraZeneca to Hold,2015-05-19 09:39:00-04:00,AZN,neutral
128211.0,US Stock Futures Edge Lower Ahead Of Housing Market Index,2015-05-18 07:11:00-04:00,AZN,negative
128212.0,AstraZeneca to Invest in New Biological Manufacturing Facility in Sweden; To Create 150-250 Jobs By 2019,2015-05-18 04:49:00-04:00,AZN,positive
128213.0,Barclays Hopes Pulmicort Is 'Back For Good' At Actavis,2015-05-08 10:22:00-04:00,AZN,positive
128214.0,Actavis Earlier After-Hours Release Announced Co. to Immediately Re-Launch Generic Version of AstraZeneca's Pulmicort RESPULES,2015-05-07 16:58:00-04:00,AZN,neutral
128215.0,AstraZeneca Has Lost Appeal Related to Pulmicort Respules Being Invalid; BZ NOTE: Actavis Winner Here,2015-05-07 10:01:00-04:00,AZN,positive
128216.0,"Goldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis Oncology",2015-05-06 08:46:00-04:00,AZN,negative
128217.0,"Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestle Health Science and Bayer CropScience",2015-05-05 07:17:00-04:00,AZN,positive
128218.0,"AstraZeneca, Starpharma Sign Extension to Existing Collaboration; AstraZeneca to Develop Oncology Drug Using Stapharma's DEP Technology -Reuters",2015-05-03 18:49:00-04:00,AZN,neutral
128219.0,Morgan Stanley On What 'Should Be Rewarded' At Gilead,2015-05-01 07:14:00-04:00,AZN,positive
128220.0,US Stock Futures Slip Ahead Of Fed Decision,2015-04-29 07:50:00-04:00,AZN,neutral
128221.0,AstraZeneca Reports FDA Grants Priority Review for Potential New Indication for BRILINTA,2015-04-29 07:04:00-04:00,AZN,positive
128222.0,Oppenheimer Comments On 2 Biotech Stocks,2015-04-27 06:39:00-04:00,AZN,neutral
128223.0,"AstraZeneca CEO Declines Comment on Pfizer, Says Completely Focused on Developing Pipeline -Reuters",2015-04-24 04:34:00-04:00,AZN,positive
128224.0,Innate Pharma and AstraZeneca announce global agreement for IPH2201 in immuno-oncology,2015-04-24 04:23:00-04:00,AZN,positive
128225.0,"Earnings Scheduled For April 24, 2015",2015-04-24 04:19:00-04:00,AZN,neutral
128226.0,SunTrust's Latest Comments On Merck,2015-04-15 15:32:00-04:00,AZN,neutral
128227.0,SocGen Initiates Big Drug/Pharma Names,2015-04-15 12:07:00-04:00,AZN,neutral
128228.0,"PatientsLikeMe, AstraZeneca Announce Global Research Collaboration",2015-04-13 08:21:00-04:00,AZN,neutral
128229.0,Morning Market Gainers,2015-04-08 09:40:00-04:00,AZN,neutral
128230.0,"Regulus Therapeutics, Healthcare Stocks Are Big Movers In Tuesday's After Hours Trading",2015-04-07 20:39:00-04:00,AZN,neutral
128231.0,UPDATE: Regulus Therapeutics Says Expect to Initiate Phase I Study of RG-125 in Humans by End of 2015,2015-04-07 16:15:00-04:00,AZN,neutral
128232.0,"RG-125 (AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Chosen As Clinical Candidate by AstraZeneca",2015-04-07 16:11:00-04:00,AZN,neutral
128233.0,"Myriad, AstraZeneca Expand Research Collaboration on Lynparza",2015-04-01 07:09:00-04:00,AZN,positive
128234.0,AstraZeneca Reports Launch of MOVANTIK in US,2015-03-31 09:04:00-04:00,AZN,neutral
128235.0,"AstraZeneca Announces FDA Approval For BRILINTA, New Administration Option",2015-03-30 09:03:00-04:00,AZN,positive
128236.0,The Marijuana CARERS Act: What You Need To Know,2015-03-19 15:12:00-04:00,AZN,neutral
128237.0,Nektar Announces Partner AstraZeneca Reported Co-Commercialization Deal with Daiichi Sankyo for MOVANTIK in US,2015-03-19 08:34:00-04:00,AZN,neutral
128238.0,US Stock Futures Down; All Eyes On Fed Decision,2015-03-18 07:24:00-04:00,AZN,neutral
128239.0,"AstraZeneca Announces Positive Phase III Top-line Results for PT003 from PINNACLE 1, PINNACLE 2 Studies in COPD",2015-03-18 05:34:00-04:00,AZN,positive
128240.0,AstraZeneca Announces Positive BRILINTA Results in PEGASUS-TIMI 54 Study,2015-03-14 21:41:00-04:00,AZN,positive
128241.0,"AstraZeneca's MedImmune Reports Co., Joslin Diabetes Center to Offer New Research Collaboration Focused on Advancing Metabolic Disease Research",2015-03-10 08:26:00-04:00,AZN,positive
128242.0,"Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices",2015-02-20 13:10:00-05:00,AZN,positive
128243.0,AstraZeneca Says US Court Rules Pulmicort Respules Patent Invalid; Strongly Disagrees With Court Decision; Considering Appeal,2015-02-16 06:41:00-05:00,AZN,negative
128244.0,"Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, Trims McDonald's In Q4",2015-02-13 14:19:00-05:00,AZN,neutral
128245.0,Astrazeneca to Pay $7.9M to Settle Kickback Allegations -Reuters,2015-02-11 09:53:00-05:00,AZN,negative
128246.0,"After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?",2015-02-06 15:28:00-05:00,AZN,positive
128247.0,"Amid The Pfizer-Hospira Deal, Are Healthcare ETFs In Play?",2015-02-06 12:48:00-05:00,AZN,positive
128248.0,UPDATE: AstraZeneca Board Declared Second Interim Dividend of $1.90/Share,2015-02-05 08:08:00-05:00,AZN,neutral
128249.0,US Stock Futures Surge Ahead Of Jobless Claims Data,2015-02-05 07:26:00-05:00,AZN,neutral
128250.0,AstraZeneca Q4 Profit Misses Estimates,2015-02-05 05:27:00-05:00,AZN,positive
128251.0,"Earnings Scheduled For February 5, 2015",2015-02-05 05:05:00-05:00,AZN,neutral
128252.0,AstraZeneca Reports Q4 Adj EPS $0.76 vs $0.85 Est; Revenue $6.68B vs $6.75B Est,2015-02-05 05:05:00-05:00,AZN,neutral
128253.0,SEB Equity Research Upgrades AstraZeneca to Buy,2015-02-03 04:48:00-05:00,AZN,neutral
128254.0,Ardelyx Says Astrazeneca's Phase 2b Clinical Trial Evaluating Tenapanor Met Primary Endpoint,2015-02-02 07:22:00-05:00,AZN,neutral
128255.0,Benzinga's Volume Movers,2015-01-27 10:42:00-05:00,AZN,neutral
128256.0,Leerink Raises AstraZeneca Price Target,2015-01-22 12:15:00-05:00,AZN,neutral
128257.0,AstraZeneca Announces EMA Accepted Marketing Authorization Application for Lesinurad 200mg Tablets,2015-01-22 04:59:00-05:00,AZN,positive
128258.0,"Barclays Issues 3 Upgrades, 1 Downgrade On Pharma Stocks",2015-01-16 15:12:00-05:00,AZN,neutral
128259.0,Barclays Downgrades AstraZeneca to Underweight,2015-01-16 07:16:00-05:00,AZN,neutral
128260.0,AstraZeneca Announces Pegasus Meets Primary Endpoint,2015-01-14 07:02:00-05:00,AZN,neutral
128261.0,"AstraZeneca Announces PEGASUS-TIMI 54 Study of BRILINTA Met Primary Endpoint in 60mg, 90mg Doses",2015-01-14 04:48:00-05:00,AZN,neutral
128262.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3,2015-01-13 10:58:00-05:00,AZN,neutral
128263.0,QIAGEN Announces First-ever Regulatory Registration of a Lung Cancer Companion Diagnostic Based on Liquid Biopsies in Collaboration With AstraZeneca,2015-01-12 04:51:00-05:00,AZN,negative
128264.0,What Investors Are Expecting Ahead Of Multiple Nektar Therapeutics Catalysts,2015-01-09 12:53:00-05:00,AZN,neutral
128265.0,FDA Approves Lynparza to Treat Advanced Ovarian Cancer,2014-12-19 11:43:00-05:00,AZN,positive
128266.0,AstraZeneca's Lynparza Approved In EU for Ovarian Cancer,2014-12-18 05:21:00-05:00,AZN,negative
128267.0,"Dynavax, AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma into Phase 2a Clinical Study; AstraZeneca to Fully Fund Trial",2014-12-08 06:06:00-05:00,AZN,neutral
128268.0,Actavis' Antibiotic Ceftazidime/avibactam Receives Partial FDA Panel Backing,2014-12-05 15:00:00-05:00,AZN,neutral
128269.0,Jury Verdict in Favor of AstraZeneca in Nexium Patent Litigation -Reuters,2014-12-05 12:04:00-05:00,AZN,positive
128270.0,"Option Alert: Ariad May $10 Call; 1,000 Contract Trade at Ask @$0.70; Currently $7.44",2014-12-04 09:41:00-05:00,AZN,positive
128271.0,"Ariad Shares Up 1% Premarket on Rumor of Potential Bids from AstraZeneca, Shire",2014-12-04 08:26:00-05:00,AZN,positive
128272.0,Morgan Stanley Pair Trade On Novartis And AstraZeneca,2014-12-02 14:01:00-05:00,AZN,neutral
128273.0,Morgan Stanley Downgrades Astrazeneca PLC to Underweight,2014-12-02 11:42:00-05:00,AZN,neutral
128274.0,AstraZeneca Shares Spike Lower; May be Attributed to Morgan Stanley Downgrade,2014-12-02 11:40:00-05:00,AZN,neutral
128275.0,AstraZeneca NDA for IRESSA Accepted by FDA,2014-12-02 05:57:00-05:00,AZN,positive
128276.0,Lilly Announces Co. AstraZeneca Report Enrollment of First Patient Into AMARANTH,2014-12-01 07:01:00-05:00,AZN,neutral
128277.0,AstraZeneca CEO: We Will Achieve Our Targets Through Our Drug Pipeline,2014-11-28 10:53:00-05:00,AZN,neutral
128278.0,CNBC'S Catherine Boyle Doesn't Think A Pfizer/AstraZeneca Deal Will Happen Soon,2014-11-26 14:20:00-05:00,AZN,neutral
128279.0,"Amgen, AstraZeneca Reports Positive Results from Third, Final Pivotal Phase 3 Study of Brodalumab In Patients with Moderate-to-Severe Plaque Psoriasis",2014-11-25 16:02:00-05:00,AZN,positive
128280.0,AstraZeneca's Duaklir Genuair Receives Marketing Authorization from EC,2014-11-24 05:15:00-05:00,AZN,neutral
128281.0,AstraZeneca Announces Plans For Maryland Manufacturing Center Expansion,2014-11-21 11:11:00-05:00,AZN,neutral
128282.0,Fitch Downgrades AstraZenaca to 'A+'; Outlook Stable,2014-11-21 11:04:00-05:00,AZN,positive
128283.0,ISIS-STAT3 Rx And ISIS-AR Rx Data Presented By AstraZeneca At European Cancer Symposium,2014-11-20 16:48:00-05:00,AZN,negative
128284.0,Astrazeneca PLC Sees FY2023 Sales $45.0B,2014-11-18 05:08:00-05:00,AZN,neutral
128285.0,Bank Of America Believes DAPT Adds To Precedent For PEGASUS Success For AstraZeneca,2014-11-17 10:29:00-05:00,AZN,positive
128286.0,AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at ACR,2014-11-16 09:55:00-05:00,AZN,neutral
128287.0,Report: Pfizer 'Unlikely' To Pursue Acquisition Of AstraZeneca,2014-11-14 09:38:00-05:00,AZN,neutral
128288.0,AstraZeneca Shares Fall 2% Premarket on Reuters Report Pfizer Unlikely to Bid Again,2014-11-14 07:34:00-05:00,AZN,positive
128289.0,AstraZeneca Announces Initiation of Development Program for BRILINTA (ticagrelor) Reversal Agent,2014-11-13 07:01:00-05:00,AZN,neutral
128290.0,"AstraZeneca, Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods",2014-11-13 05:10:00-05:00,AZN,neutral
128291.0,Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis,2014-11-11 16:03:00-05:00,AZN,positive
128292.0,"#PreMarket Primer: Friday, November 7: Boehner Reveals Intentions To Modify Obamacare",2014-11-07 07:50:00-05:00,AZN,neutral
128293.0,"#PreMarket Primer: Thursday, November 6: Obama, McConnell Prepare For Rocky Road Ahead",2014-11-06 08:08:00-05:00,AZN,neutral
128294.0,AstraZeneca Raises 2014 Outlook,2014-11-06 06:14:00-05:00,AZN,neutral
128295.0,Aegerion Acquires Myalept from AstraZeneca for $325M Upfront Payment,2014-11-06 05:39:00-05:00,AZN,neutral
128296.0,Astrazeneca PLC Reports Q3 EPS of $1.05 vs $1.04 Est; Revenue of $6.54B vs $6.28B Est,2014-11-06 05:30:00-05:00,AZN,neutral
128297.0,Isis Pharmaceuticals Earns $7.5M Milestone Payment from AstraZeneca for Advancement of ISIS-STAT3Rx,2014-11-05 07:05:00-05:00,AZN,neutral
128298.0,"AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA ",2014-11-04 08:24:00-05:00,AZN,neutral
128299.0,"AstraZeneca Says Medimmune to Acquire Definiens for Initial Payment of $150M, Plus Milestone Payments",2014-11-04 05:33:00-05:00,AZN,neutral
128300.0,Markets Rally On Better Than Expected GDP; Dow Has Best Close In More Than A Month,2014-10-30 17:09:00-04:00,AZN,positive
128301.0,AstraZeneca Announces FDA Approves Once-Daily XIGDUO™ XR Tablets ,2014-10-30 07:03:00-04:00,AZN,positive
128302.0,8-K from Targacept Shows AstraZeneca Has Ended Collaborative Research Deal,2014-10-09 08:33:00-04:00,AZN,neutral
128303.0,AstraZeneca Reports BRILINTA Preferred Over Clopidogrel in '14 AHA/ACC Guideline for Mgmt,2014-10-06 07:32:00-04:00,AZN,neutral
128304.0,What Are The Best-Selling Drugs Of 2014?,2014-10-03 11:34:00-04:00,AZN,neutral
128305.0,AstraZeneca Expects to File Lung Cancer Pill for US Regulatory Approval in H2 2015 -Reuters ,2014-09-29 05:32:00-04:00,AZN,negative
128306.0,AstraZeneca Reports CHMP Recommends Constipation Drug Moventig for Approval,2014-09-26 06:50:00-04:00,AZN,positive
128307.0,"8-K from IGI Labs Shows Co. Paid ~$500K for 18 Products from AstraZeneca, Co. Required to Pay Up to $6M in Added Milestones",2014-09-25 09:34:00-04:00,AZN,negative
128308.0,"Benzinga's M&A Chatter for Tuesday September 23, 2014",2014-09-23 18:35:00-04:00,AZN,neutral
128309.0,Pfizer Inc. Is Kicking The Tires At Actavis PLC,2014-09-23 14:45:00-04:00,AZN,neutral
128310.0,UPDATE: Pfizer Has Weighed Other Options Including an Offer for AstraZeneca,2014-09-23 14:12:00-04:00,AZN,neutral
128311.0,AstraZeneca Spikes to High,2014-09-23 14:11:00-04:00,AZN,neutral
128312.0,UPDATE: Pfizer Seeking Friendly Inversion Deal,2014-09-23 14:11:00-04:00,AZN,positive
128313.0,Inversion Crackdown Leaves Several Deals In Limbo,2014-09-23 12:41:00-04:00,AZN,neutral
128314.0,"Midday Losers From September 23 - Alco Stores Inc, CarMax, Inc And More",2014-09-23 12:37:00-04:00,AZN,negative
128315.0,Markets Mixed; Carnival Profit Tops Street View,2014-09-23 11:20:00-04:00,AZN,positive
128316.0,"Robert Willens Commenting to Bloomberg: Treasury's New Rules Do Not Strike a Mortal Blow to Inversion Deals, Believes Deals Should Be Completed Without Missing a Beat",2014-09-23 10:06:00-04:00,AZN,positive
128317.0,AstraZeneca's Medimmune Has Received Fast Track Designation for MEDI3902 for Prevention of Nosocomial Pneumonia,2014-09-23 08:09:00-04:00,AZN,neutral
128318.0,Citi Says New Tax Inversion Measures Should have Little Impact on Pfizer Deal for AstraZeneca,2014-09-23 06:48:00-04:00,AZN,neutral
128319.0,"AstraZeneca, Shire Shares Fall 5% Premarket on Proposed New US Rules Affecting Tax Inversion Deals",2014-09-23 06:29:00-04:00,AZN,positive
128320.0,AstraZeneca Confirms FDA Approval of MOVANTIK Tablets,2014-09-16 14:00:00-04:00,AZN,positive
128321.0,UPDATE: FDA Posts Approval of 'Movantik for Opioid-Induced Constipation',2014-09-16 10:20:00-04:00,AZN,positive
128322.0,FDA Has Issued Approval for Nektar's Movantik for Opioid-Induced Constipation,2014-09-16 10:15:00-04:00,AZN,positive
128323.0,"Eli Lilly, AstraZeneca Report Alliance to Co-Develop Potential Treatment for Alzheimer's, Lilly to Pay Up to $500M in Milestones",2014-09-16 07:01:00-04:00,AZN,negative
128324.0,Teva Announces Positive Judgment in Company's Patent Case vs AstraZeneca by UK High Court ,2014-09-03 05:26:00-04:00,AZN,positive
128325.0,Teva Announces UK High Court Gives Positive Judgment In The Company's Patent Case Against AstraZeneca,2014-09-03 05:10:00-04:00,AZN,positive
128326.0,SunTrust Sees Further Pfizer Inc. Bid For AstraZeneca PLC (ADR) 'Highly Likely',2014-09-02 15:35:00-04:00,AZN,neutral
128327.0,AstraZeneca CEO Says Back to Normal Despite Pfizer Rumors -Reuters,2014-09-02 09:08:00-04:00,AZN,neutral
128328.0,AstraZeneca Moves MEDI-4736 into Mid-Stage Study in Colorectal Cancer -Reuters,2014-08-29 06:57:00-04:00,AZN,negative
128329.0,Deutsche Bank Says Pfizer Has A Strong Financial Position And Attractive Pipeline,2014-08-27 11:25:00-04:00,AZN,positive
128330.0,The 4 Companies Teaming Up For A New Tool To Fight Cancer,2014-08-25 16:03:00-04:00,AZN,negative
128331.0,Markets Continue To Rally Ahead Of Yellen's Speech At Jackson Hole,2014-08-21 17:16:00-04:00,AZN,neutral
128332.0,Pfizer Could Revive AstraZeneca Bid As Early As Tuesday,2014-08-21 11:39:00-04:00,AZN,positive
128333.0,"Illumina Announces Strategic Partnerships with AstraZeneca, Janssen, Sanofi",2014-08-21 05:21:00-04:00,AZN,neutral
128334.0,"Pfizer Could Be Exploring Alternatives to Deal with AstraZeneca, May Consider Other Targets, Including Actavis - Bloomberg",2014-08-20 19:02:00-04:00,AZN,neutral
128335.0,AztraZeneca Reports DOJ Closes Investigation Into PLATO Clinical Trial for BRILINTA,2014-08-19 07:05:00-04:00,AZN,neutral
128336.0,Stocks Mixed Despite Better Than Expected GDP,2014-07-30 16:43:00-04:00,AZN,negative
128337.0,Citigroup Comments On Potential Pfizer/AstraZeneca Acquisition,2014-07-29 11:49:00-04:00,AZN,neutral
128338.0,Pfizer CEO Says Best to Remain Silent About AstraZeneca Due to UK Takeover Rules -Reuters,2014-07-29 11:16:00-04:00,AZN,positive
128339.0,Pfizer CEO Says Still Interested In Acquisitions ,2014-07-29 10:42:00-04:00,AZN,positive
128340.0,QIAGEN Announces Collaboration Agreement with AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic,2014-07-28 05:33:00-04:00,AZN,positive
128341.0,Benzinga Weekly Preview: FOMC In Focus As Earnings Season Progresses,2014-07-26 13:58:00-04:00,AZN,neutral
128342.0,5 British Blue Chips For Your Portfolio,2014-07-11 09:20:00-04:00,AZN,neutral
128343.0,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,2014-07-11 04:14:00-04:00,AZN,positive
128344.0,"Dow Trades Above 17,000 While S&P 500 Inches Closer To 2,000",2014-07-03 13:20:00-04:00,AZN,neutral
128345.0,JP Morgan Reinstates Underweight on Astrazeneca PLC,2014-07-03 07:57:00-04:00,AZN,positive
128346.0,"UPDATE: FDA Panel Says Safety, Efficacy Results for AstraZeneca's Olaparib Did Not Support Accelerated Approval - Reuters",2014-06-25 14:38:00-04:00,AZN,negative
128347.0,"AstraZeneca, Pfizer Shares Volatile Over Last Few Mins as Reuters Reporting FDA Panel Has Voted 11-2 Admin Should Wait for Study Known as Solo-2 Before Granting Approval of Olaparib",2014-06-25 14:38:00-04:00,AZN,positive
128348.0,Left Behind In The Rally: Pfizer,2014-06-25 13:47:00-04:00,AZN,neutral
128349.0,Rumor Of Massive Monsanto-Syngenta Deal Gets Agriculture Sector Moving,2014-06-23 14:06:00-04:00,AZN,neutral
128350.0,FT Reports AstraZeneca Considering Plan to Sell Some Rights to Future Revenue on Existing Drugs ,2014-06-20 14:38:00-04:00,AZN,neutral
128351.0,UPDATE: AstraZeneca Reports PDUFA Date for Movantik Now Sept. 16th,2014-06-19 14:45:00-04:00,AZN,neutral
128352.0,AstraZeneca Announces 12.5mg Dose in Kodiac-5 Trial Did Not Meet Statistical Significance,2014-06-19 14:43:00-04:00,AZN,negative
128353.0,"Dow Jones Reports AstraZeneca Hires Centerview to Advise on Potential Deal,, According to Sources",2014-06-16 12:43:00-04:00,AZN,neutral
128354.0,AstraZeneca Spikes Higher,2014-06-16 12:40:00-04:00,AZN,neutral
128355.0,"AstraZeneca Issues Clarification on AXA Stake, Says AXA Investment Has 0.93% Voting Rights, AXA SA Has 0.06% Voting Rights, AllianceBernstein 0.08% Voting Rights - Bloomberg",2014-06-13 10:01:00-04:00,AZN,neutral
128356.0,Amgen Announces Study of Brodalumab Showed Achieving of Primary Endpoint,2014-06-11 17:02:00-04:00,AZN,neutral
128357.0,Pfizer's D'Amelio Will Not Comment on Whether Co. Will Continue to Engage AstraZeneca,2014-06-11 11:11:00-04:00,AZN,positive
128358.0,Pfizer's D'Amelio Said Co. Allowed to Again Approach AstraZeneca Following Regulatory Period,2014-06-11 11:09:00-04:00,AZN,neutral
128359.0,UPDATE: Pfizer's D'Amelio Speaking at Goldman's Healthcare Conference Disclosed Reason Deal with AstraZeneca Didn't Happen Was Price,2014-06-11 11:08:00-04:00,AZN,neutral
128360.0,Pfizer CEO Frank D'Amelio Says Strong Hand on AstraZeneca,2014-06-11 11:06:00-04:00,AZN,positive
128361.0,AstraZeneca Spikes Higher,2014-06-11 11:03:00-04:00,AZN,neutral
128362.0,Morning Market Movers ,2014-06-10 09:39:00-04:00,AZN,neutral
128363.0,Isis Pharmaceutics Gets $15M From AstraZeneca For Phase 1 Study Initiation,2014-06-10 07:01:00-04:00,AZN,neutral
128364.0,"Cancer Genetics Reports Partnership with AstraZeneca for Providing Biomarker, Molecular Based Testing",2014-06-09 08:01:00-04:00,AZN,negative
128365.0,ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy,2014-06-04 10:32:00-04:00,AZN,neutral
128366.0,ASCO Meeting Day 1: Preserving Fertility And Reducing Side Effects,2014-06-04 10:11:00-04:00,AZN,neutral
128367.0,AstraZeneca Announces Enlarged Recruitment For Tremelimumab Phase II,2014-06-03 11:03:00-04:00,AZN,neutral
128368.0,AstraZeneca Announces Announces Positive AZD9291 Trial Results,2014-06-03 11:02:00-04:00,AZN,positive
128369.0,Cigna Enters Contract with AstraZeneca for CRESTOR,2014-06-02 10:59:00-04:00,AZN,neutral
128370.0,Pfizer Jilted By AstraZeneca; Analyst Sees Break-Up,2014-05-27 14:41:00-04:00,AZN,neutral
128371.0,Benzinga's Weekend M&A Chatter,2014-05-26 19:15:00-04:00,AZN,neutral
128372.0,"UPDATE: Pfizer Won't Bid for for Astrazeneca, Still Believes Final Proposal was Compelling ",2014-05-26 17:50:00-04:00,AZN,positive
128373.0,Pfizer Reportedly to Abandon Bid for AstraZeneca -BBC,2014-05-25 21:40:00-04:00,AZN,negative
128374.0,SkyNews Reporting BlackRock Has Urged AstraZeneca Board to Hold New Talks,2014-05-22 08:49:00-04:00,AZN,neutral
128375.0,"Benzinga's M&A Chatter for Wednesday May 21, 2014",2014-05-21 19:37:00-04:00,AZN,neutral
128376.0,Market Wrap For May 21: Fed's Minutes Support Wednesday's Bull Run,2014-05-21 16:37:00-04:00,AZN,positive
128377.0,AstraZeneca's Board Feeling Pressure From Stockholders Following Pfizer Bid Rejection,2014-05-21 14:18:00-04:00,AZN,negative
128378.0,UPDATE: AstraZeneca Says Won't Reopen Talks with Pfizer Before May 26 Deadline -FT,2014-05-21 14:11:00-04:00,AZN,neutral
128379.0,AstraZeneca Spikes Lower on Volume,2014-05-21 14:10:00-04:00,AZN,negative
128380.0,AstraZeneca Shares Spiking on Volume,2014-05-21 10:54:00-04:00,AZN,positive
128381.0,Axa Says Astrazeneca Board Should Not Stop Pfizer £55/Share Bid from Being Presented to Investors -Reuters,2014-05-21 09:48:00-04:00,AZN,positive
128382.0, Shareholder Threadneedle Investments Supports Astrazeneca Board Decision Regarding Pfizer Bid -Reuters,2014-05-21 09:42:00-04:00,AZN,positive
128383.0,"Dow Jones Reports Large AstraZeneca Shareholder Urges Board to Open Talks With Pfizer, According to Sources",2014-05-21 06:04:00-04:00,AZN,neutral
128384.0,"Benzinga's M&A Chatter for Tuesday May 20, 2014",2014-05-20 17:55:00-04:00,AZN,neutral
128385.0,"Market Wrap For May 20: Markets Sharply Lower On Fed Talk, Disappointing Earnings",2014-05-20 16:42:00-04:00,AZN,negative
128386.0,"Reuters Reports Pfizer Unlikely to Pay Fees to Advisers on Astrazenaca Bid, According to Source",2014-05-20 14:06:00-04:00,AZN,negative
128387.0,AstraZeneca Says Shareholders are Strongly Advised to Take No Action,2014-05-20 13:23:00-04:00,AZN,neutral
128388.0,Astrazeneca Says Pfizer Must Either Announce a Recommended Firm Offer or State It Does Not Intend to Make an Offer for Astrazeneca,2014-05-20 13:22:00-04:00,AZN,positive
128389.0,AstraZeneca Notes Announcement Made By Pfizer  Dated 19 May 2014 Seeking To Clarify Certain Matters Set Out In Its Announcement,2014-05-20 13:21:00-04:00,AZN,positive
128390.0,AstraZeneca Shareholders Have Mixed Feelings On Board's Quick Refusal,2014-05-20 11:36:00-04:00,AZN,neutral
128391.0,Fidelity Worldwide Investment Says Astrazeneca Was Right to Reject Pfizer Bid -Reuters,2014-05-20 10:09:00-04:00,AZN,negative
128392.0,Morning Market Movers ,2014-05-20 09:45:00-04:00,AZN,neutral
128393.0,Benzinga's Top #PreMarket Gainers ,2014-05-20 08:20:00-04:00,AZN,positive
128394.0,AstraZeneca Shares Gain 2% Premarket on Investor Call for Talks with Pfizer,2014-05-20 07:14:00-04:00,AZN,positive
128395.0,AstraZeneca Shareholder Schroders Calls on Board to Reopen Talks with Pfizer Regarding Proposal -Reuters,2014-05-20 05:48:00-04:00,AZN,neutral
128396.0,"Benzinga's M&A Chatter for Monday May 19, 2014",2014-05-19 17:45:00-04:00,AZN,neutral
128397.0,"Bloomberg Headlines Suggest Pfizer's New Bid for AstraZeneca Likely to Fail, AstraZeneca Said Does Not Intend to Reevaluate Pfizer's Latest Offer",2014-05-19 16:38:00-04:00,AZN,negative
128398.0,Market Wrap for May 19: Markets Finish Higher On M&A Monday,2014-05-19 16:31:00-04:00,AZN,neutral
128399.0,Mid-Day Market Movers,2014-05-19 15:40:00-04:00,AZN,neutral
128400.0,Mid-Afternoon Market Update: Markets Drift Higher Amid A Flurry Of Weekend M&A Activity,2014-05-19 15:33:00-04:00,AZN,neutral
128401.0,ISI Says AstraZeneca Needs To 'Speak Up For Increased Bid',2014-05-19 14:49:00-04:00,AZN,positive
128402.0,#Premarket Prep Technical Update - Pfizer Inc. Higher,2014-05-19 14:27:00-04:00,AZN,neutral
128403.0,"AT&T, DirecTV, Pfizer And AstraZeneca Dominate M&A Headlines Over The Weekend",2014-05-19 13:54:00-04:00,AZN,negative
128404.0,Mid-Day Market Update: Campbell Soup Slides After Weak Forecast; InterMune Shares Spike Higher,2014-05-19 12:33:00-04:00,AZN,negative
128405.0,Mid-Morning Market Update: Markets Mixed; AT&T To Buy DirecTV For $48.5B,2014-05-19 10:24:00-04:00,AZN,neutral
128406.0,Morning Market Losers ,2014-05-19 09:54:00-04:00,AZN,negative
128407.0,UPDATE: AsraZeneca's Johansson Sees No Prospect of Pfizer Deal Before May 26 Deadline or Extension of Deadline,2014-05-19 09:13:00-04:00,AZN,neutral
128408.0,AstraZeneca Chairman Says Spoke on Phone with Pfizer for More than One Hour on Sunday; Says Pfizer Shut Down Discussions -Reuters ,2014-05-19 09:11:00-04:00,AZN,neutral
128409.0,Benzinga's Top #PreMarket Losers,2014-05-19 08:13:00-04:00,AZN,negative
128410.0,Benzinga's Top #PreMarket Gainers,2014-05-19 08:08:00-04:00,AZN,positive
128411.0,"DirecTV Imminent Takeover By AT&T, Pfizer To AstraZeneca: 'Take It Or Leave It'",2014-05-19 07:41:00-04:00,AZN,negative
128412.0,UPDATE: AstraZeneca Shares Fall 11% Premarket on Rejection of Final Pfizer Offer,2014-05-19 06:11:00-04:00,AZN,negative
128413.0,Jupiter Fund Manager Alastair Gunn Disappointed With Astrazeneca Rejection of Pfizer Proposal -Reuters,2014-05-19 06:00:00-04:00,AZN,negative
128414.0,UPDATE: AstraZeneca Board Rejects Pfizer's Final Proposal,2014-05-19 05:34:00-04:00,AZN,negative
128415.0,AstraZeneca Rejects Pfizer's Final Offer of £55/Share,2014-05-19 05:31:00-04:00,AZN,negative
128416.0,"Stocks To Watch For May 19, 2014",2014-05-19 04:51:00-04:00,AZN,neutral
128417.0,Benzinga's Weekend M&A Chatter,2014-05-18 19:56:00-04:00,AZN,neutral
128418.0,UPDATE: Pfizer Makes Final Proposal to AstraZeneca of £55/Share,2014-05-18 17:05:00-04:00,AZN,neutral
128419.0,UPDATE: Pfizer Raises Bid for AstraZeneca to £55/Share,2014-05-18 16:47:00-04:00,AZN,neutral
128420.0,Mark Kleinman Sky News Tweet: ' Latest intell on AstraZeneca is that Pfizer may offer up to £55-a-share but would walk away from the situation if that proposal is rejected',2014-05-18 14:17:00-04:00,AZN,negative
128421.0,"DAVID FABER Tweet: 'Looks like a busy afternoon for all you merger fans. Expect we will have a $T, $DTV deal later today and Pfizer will raise for $AZN'",2014-05-18 13:59:00-04:00,AZN,positive
128422.0,Pfizer Expected to Raise Bid for AstraZeneca -FT,2014-05-18 13:38:00-04:00,AZN,neutral
128423.0,"Shares of AstraZeneca Down ~1% Over Last 45 Mins, Spiked Down to $79.65 Right as Pfizer Shares Were Halted",2014-05-16 12:09:00-04:00,AZN,positive
128424.0,Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss,2014-05-15 16:41:00-04:00,AZN,negative
128425.0,Ardelyx Recives $25M Milestone from AstraZeneca For Tenapanor,2014-05-15 08:05:00-04:00,AZN,neutral
128426.0,UPDATE: Astrazeneca CEO Says Not One Shareholder Said Board Should Have Accepted £50/Share Offer,2014-05-14 11:17:00-04:00,AZN,positive
128427.0,Reuters Reports Astrazeneca CEO Says Would Engage With Pfizer if Offer Reflected Value of Company and Implementation Risks ,2014-05-14 11:16:00-04:00,AZN,positive
128428.0,UPDATE: Ligand Signs Research and Licensing Agreement with Omthera Pharmaceuticals for Dyslipidemia-related Diseases,2014-05-14 08:35:00-04:00,AZN,positive
128429.0,UK PM Cameron Says Want More Assurances from Pfizer on AstraZeneca Deal,2014-05-14 07:11:00-04:00,AZN,positive
128430.0,"Ligand Enters into Research and License Agreement with Omthera Pharmaceuticals, a Wholly-owned Subsidiary of AstraZeneca -8-K",2014-05-14 06:58:00-04:00,AZN,positive
128431.0,"Incyte, MedImmune Collaborate on Immuno-Oncology Combination Clinical Trial ",2014-05-14 05:51:00-04:00,AZN,neutral
128432.0,Market Wrap For May 13: Markets Close Again At Record Highs,2014-05-13 16:36:00-04:00,AZN,neutral
128433.0,7 Stocks For Your Retirement Portfolio,2014-05-13 09:26:00-04:00,AZN,neutral
128434.0,UPDATE: Astrazeneca Issues Statement Regarding Pfizer Announcement,2014-05-13 06:41:00-04:00,AZN,neutral
128435.0,AstraZeneca Says Pfizer's Announcement Contains No New Proposal,2014-05-13 06:38:00-04:00,AZN,negative
128436.0,Market Wrap For May 12: Dow And S&P Close At Record Highs,2014-05-12 16:37:00-04:00,AZN,neutral
128437.0,Astrazeneca's Mavrilimumab and Sifalimumab Met Primary Endpoints,2014-05-12 11:09:00-04:00,AZN,neutral
128438.0,"FDA Panel for Mu Opioid Atangonists Scheduled for June 11, According to Bloomberg",2014-05-12 10:56:00-04:00,AZN,neutral
128439.0, Pfizer Submits Statement Supporting AstraZeneca Buy to UK Govt Committ,2014-05-12 05:35:00-04:00,AZN,positive
128440.0,Benzinga's Weekend M&A Chatter,2014-05-11 22:28:00-04:00,AZN,neutral
128441.0,"Amgen, AstraZeneca Offer Positive Results from Phase 3 Study of Brodalumab, Study Met Primary, Secondary Endpoints",2014-05-09 16:02:00-04:00,AZN,positive
128442.0,"AstraZeneca Shares Now Have Almost Fully Recovered Losses Following 'Blocking' Report, More Recent Headline Suggests UK's Business Department is Neutral on Deal with Pfizer",2014-05-09 13:00:00-04:00,AZN,negative
128443.0,Will The U.K.'s Business Department Block Pfizer's Bid?,2014-05-09 12:33:00-04:00,AZN,negative
128444.0,Bloomberg Reporting UK Business Department Could Be Looking at Ways to Block Pfizer's Bid,2014-05-09 11:46:00-04:00,AZN,negative
128445.0,"Benzinga's M&A Chatter for Thursday May 8, 2014",2014-05-08 19:05:00-04:00,AZN,neutral
128446.0,Pfizer's Heart Races Of AstraZeneca Amidst Rumored Deal & Drug Approval,2014-05-08 15:23:00-04:00,AZN,positive
128447.0,Pfizer Holders Could Face Tax Hit in AstraZeneca Deal -DJ,2014-05-08 15:12:00-04:00,AZN,neutral
128448.0,Reuters Reports Pfizer Could Raise Bid for AstraZeneca to $89.90/Share,2014-05-08 07:42:00-04:00,AZN,neutral
128449.0,Astrazeneca Initiates Phase Iii Study for Medi4736,2014-05-08 07:36:00-04:00,AZN,neutral
128450.0,"CEOs at Pfizer, AstraZeneca Will Testify to UK Regulators on May 14th - Bloomberg",2014-05-07 09:07:00-04:00,AZN,neutral
128451.0,"Market Wrap For May 6: Dow Suffers Triple-Digit Point Loss, Nasdaq Underperforms Once Again",2014-05-06 16:42:00-04:00,AZN,negative
128452.0,"Astrazeneca CEO Says Range of Opinion on Pfizer Offer from Shareholders, Overall Feedback Supportive -Reuters",2014-05-06 10:28:00-04:00,AZN,positive
128453.0,Spokesperson for British PM Cameron Says Significant that Pfizer has Chosen to Engage With Britain Over Potential Takeover of AstraZeneca -Reuters,2014-05-06 07:42:00-04:00,AZN,positive
128454.0,"British Parliament Science Committee Requests Meeting with Pfizer, Astrazeneca Management to Discuss Potential Takeover",2014-05-06 07:02:00-04:00,AZN,neutral
128455.0,AstraZeneca Announces FDA Approval of EPANOVA for Treatment of Adults with Severe Hypertriglyceridemia ,2014-05-06 05:29:00-04:00,AZN,positive
128456.0,Danske Downgrades Astrazeneca PLC to Sell,2014-05-05 07:44:00-04:00,AZN,neutral
128457.0,Benzinga's Weekend M&A Chatter,2014-05-04 19:49:00-04:00,AZN,neutral
128458.0,Market Wrap For May 2: Markets Slip On Ukraine Tensions Despite Positive Jobs Data ,2014-05-02 16:58:00-04:00,AZN,negative
128459.0,"Option Alert: Pfizer Jun $29 Put; 20,000 Contract Trade Between Bid and Ask @$0.44 vs 8,453 OI; Currently $30.67",2014-05-02 11:37:00-04:00,AZN,positive
128460.0,Moody's Says Pfizer's New Proposal for Astrazeneca is Credit-Positive,2014-05-02 10:26:00-04:00,AZN,neutral
128461.0,UPDATE: AstraZeneca CEO Says New Pfizer Offer Underappreciated AstraZeneca Drug Pipeline -DJ,2014-05-02 08:18:00-04:00,AZN,neutral
128462.0,"UK Government Says Letter from Pfizer CEO a Positive Sign, Will Consider Proposals to See if they Offer Sufficient Protection of Priorities",2014-05-02 08:05:00-04:00,AZN,positive
128463.0,"#PreMarket Primer: Friday, May 2: Nonfarm Payrolls Data Expected To Impress",2014-05-02 07:30:00-04:00,AZN,positive
128464.0,"UPDATE: AstraZeneca Board Says Terms of Pfizer Proposal are Inadequate, Undervalue Astrazeneca",2014-05-02 05:53:00-04:00,AZN,negative
128465.0,UPDATE Astrazeneca Board Rejects Pfizer Proposal,2014-05-02 05:51:00-04:00,AZN,negative
128466.0,UPDATE: Pfizer Sends Letter to UK PM Cameron Regarding Commitments If Proposed Combination with AstraZeneca is Completed,2014-05-02 05:40:00-04:00,AZN,positive
128467.0,"UPDATE: Pfizer Confirms Delivery of Increased Proposal to AstraZeneca, Offer Represents Value of £50.00 ($84.47)/Share ",2014-05-02 05:38:00-04:00,AZN,positive
128468.0," Pfizer Confirms Increased Offer for Astrazeneca, 1.845 Shares, 1,598P Cash/Share",2014-05-02 05:35:00-04:00,AZN,positive
128469.0,"Benzinga's M&A Chatter for Thursday May 1, 2014",2014-05-01 18:51:00-04:00,AZN,neutral
128470.0,Market Wrap For May 1: Markets Mixed To Start The New Month,2014-05-01 16:35:00-04:00,AZN,neutral
128471.0,"Pfizer Could Weigh New Bid for AstraZeneca as Earlier as Next Week, May Be Over £50/Share - Bloomberg",2014-05-01 11:35:00-04:00,AZN,neutral
128472.0,"Option Alert: AstraZenca Oct $90 Call; 4,072 Contracts Traded vs 33 OI: Currently $78.99",2014-04-30 11:06:00-04:00,AZN,positive
128473.0,Express Scripts Received Subpoena from NJ AG in March Related to Relationship with AstraZeneca,2014-04-29 16:54:00-04:00,AZN,neutral
128474.0,"Option Alert: Pfizer Jun $33 Call; 25,350 Contracts Traded vs 16,043 OI; Currently $31.64",2014-04-29 10:46:00-04:00,AZN,positive
128475.0,S&P Says Pfizer Ratings Unaffected by Proposd AstraZeneca Merger,2014-04-29 10:13:00-04:00,AZN,neutral
128476.0,"ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, TWTR)",2014-04-29 09:48:00-04:00,AZN,neutral
128477.0,"Fitch Says Pfizer, AstraZeneca Combination Would Achieve Strategic Aims",2014-04-29 09:07:00-04:00,AZN,neutral
128478.0,Panmure Upgrades Astrazeneca PLC to Buy,2014-04-29 08:56:00-04:00,AZN,neutral
128479.0,Kepler Cheuvreux Upgrades Astrazeneca PLC to Hold,2014-04-29 08:56:00-04:00,AZN,neutral
128480.0,"Benzinga's M&A Chatter for Monday April 28, 2014",2014-04-28 18:50:00-04:00,AZN,neutral
128481.0,Market Wrap For April 28: Apple Hits New 52-Week Highs In a Volatile Start To the Trading Week,2014-04-28 16:34:00-04:00,AZN,neutral
128482.0,Mid-Afternoon Market Update: Markets Trade in Swing-Prone Session as J.C. Penney Rallies,2014-04-28 15:44:00-04:00,AZN,neutral
128483.0,Mid-Day Market Update: NASDAQ Drops 0.8%; Susser Shares Surge On Acquisition News,2014-04-28 12:19:00-04:00,AZN,positive
128484.0,BBC's Kamal Ahmed Tweet: 'Am told Pfizer has been in touch with Vince Cable & David Willett's office on AstraZeneca. Gov looking for 'jobs and investment' assurances',2014-04-28 11:14:00-04:00,AZN,positive
128485.0,Benzinga's Volume Movers,2014-04-28 10:50:00-04:00,AZN,neutral
128486.0,Pfizer Courts AstraZeneca (Again) With $100 Billion Offer,2014-04-28 10:39:00-04:00,AZN,neutral
128487.0,Mid-Morning Market Update: Markets Open Higher; Forest Labs To Acquire Furiex For $1.1B In Cash,2014-04-28 10:22:00-04:00,AZN,neutral
128488.0,Stocks Hitting 52-Week Highs,2014-04-28 10:16:00-04:00,AZN,neutral
128489.0,Morning Market Movers ,2014-04-28 09:43:00-04:00,AZN,neutral
128490.0,From Pfizer Call to Discuss AstraZeneca Potential Deal: CEO Ian Read Says Co. is Reconsidering Options Related to AstraZeneca,2014-04-28 08:36:00-04:00,AZN,neutral
128491.0,Benzinga's Top #PreMarket Gainers,2014-04-28 08:05:00-04:00,AZN,positive
128492.0,Societe Generale Upgrades Astrazeneca PLC to Hold,2014-04-28 07:52:00-04:00,AZN,neutral
128493.0,UPDATE: AstraZeneca Shares Rise 16% Premarket Following Rejection of Pfizer's $76.62/Share Bid,2014-04-28 07:09:00-04:00,AZN,negative
128494.0,"UPDATE: Pfizer CEO Says Can't Make Firm Commitments on UK Investment, Jobs",2014-04-28 06:51:00-04:00,AZN,negative
128495.0,UPDATE: Pfizer CEO Says Will Continue to Invest In US,2014-04-28 06:49:00-04:00,AZN,neutral
128496.0,"UPDATE: AstraZeneca Board Says Not Appropriate to Engage in Discussions with Pfizer, Says Pfizer Proposal Undervalues AstraZeneca",2014-04-28 06:32:00-04:00,AZN,negative
128497.0,UPDATE: Pfizer Confirms $76.62/Share Offer for AstraZeneca,2014-04-28 06:27:00-04:00,AZN,neutral
128498.0,Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Merger,2014-04-28 06:15:00-04:00,AZN,neutral
128499.0,Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns,2014-04-24 16:41:00-04:00,AZN,neutral
128500.0,Astrazeneca PLC Reports Q1 Adjusted EPS of $1.17 vs $1.22 Est; Revenue of $6.42B vs $6.29B Est,2014-04-24 05:42:00-04:00,AZN,neutral
128501.0,"Drug ETFs Surge On M&A Activity (AGN, VRX, IHE, XPH, PPH, AZN)",2014-04-22 13:24:00-04:00,AZN,neutral
128502.0,Astrazeneca Down 3% Despite Citigroup Upgrade,2014-04-22 13:16:00-04:00,AZN,neutral
128503.0,Citigroup Upgrades Astrazeneca PLC to Buy,2014-04-22 08:24:00-04:00,AZN,neutral
128504.0,"DAVID FABER Tweet: 'So Ackman can buy $3b in $AGN stock, which he will sell to $VRX for a lot more if it succeeds in an offer Ackman knew was coming'",2014-04-21 17:36:00-04:00,AZN,positive
128505.0,"Market Wrap For April 21: S&P 500 Extends Winning Streak To Five Days, Dow & Nasdaq Also Positive",2014-04-21 16:37:00-04:00,AZN,positive
128506.0,Mid-Day Market Update: AMD Surges After Upbeat Results; Acacia Research Shares Decline,2014-04-21 12:42:00-04:00,AZN,positive
128507.0,Benzinga's Volume Movers,2014-04-21 11:00:00-04:00,AZN,neutral
128508.0,Mid-Morning Market Update: Markets Rise; Halliburton Posts Q1 Profit,2014-04-21 10:27:00-04:00,AZN,positive
128509.0,Morning Market Movers ,2014-04-21 09:47:00-04:00,AZN,neutral
128510.0,Rumor: Pfizer Planning $100 Billion Bid For AstraZeneca,2014-04-21 09:03:00-04:00,AZN,neutral
128511.0,Benzinga's Top #PreMarket Gainers,2014-04-21 08:08:00-04:00,AZN,positive
128512.0,UPDATE: AstraZeneca  Shares Rise 8% Premarket on Report of Potential Acquisition by Pfizer,2014-04-21 07:47:00-04:00,AZN,positive
128513.0,Benzinga's Weekend M&A Chatter,2014-04-20 19:47:00-04:00,AZN,neutral
128514.0,Sunday Times Reports Pfizer Considering $100B Offer for AstraZeneca,2014-04-20 07:04:00-04:00,AZN,neutral
128515.0,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield ,2014-04-08 04:50:00-04:00,AZN,positive
128516.0,Panmure Upgrades Astrazeneca PLC to Hold,2014-04-01 07:42:00-04:00,AZN,neutral
128517.0,"AstraZeneca, Nektar Therapeutics: FDA Meeting to Review  Mu Opioid Antagonists Is Tentatively Scheduled for June 11-12",2014-03-17 17:04:00-04:00,AZN,negative
128518.0,Astrazeneca Shares Push Below $66 Level as JP Morgan Downgrades to Underweight,2014-03-13 12:51:00-04:00,AZN,positive
128519.0,Market Wrap For March 7: Markets Cap Off Positive Week With Small Gains,2014-03-07 16:31:00-05:00,AZN,positive
128520.0,Adam Feuerstein Tweet: '$AMRN new strategy — patent trolling. Sues $AZN over pending Epanova launch',2014-03-04 06:26:00-05:00,AZN,neutral
128521.0,Bank of America Downgrades Astrazeneca PLC to Underperform,2014-03-03 07:28:00-05:00,AZN,neutral
128522.0,AstraZeneca Announces FDA Approves Bydureon Pen for Once-Weekly Treatment of Adults with Type 2 Diabetes ,2014-03-03 05:42:00-05:00,AZN,positive
128523.0,"Dow Jones Reports AstraZeneca Proposed $70.00/Share Bid for Forest Laboratories, According to Sources",2014-02-25 17:00:00-05:00,AZN,neutral
128524.0,UPDATE: AstraZeneca Announces  FDA Approves Orphan Drug Myalept ,2014-02-25 14:10:00-05:00,AZN,positive
128525.0,AstraZeneca Shares Briefly Spike Higher But Now Unaffected as Bloomberg Now Highlighting Earlier News of FDA Orphan Drug Approval of Myalept,2014-02-25 13:31:00-05:00,AZN,positive
128526.0,EMA Isuses New Compassionate-Use Programme,2014-02-21 08:09:00-05:00,AZN,neutral
128527.0,FDA Site Shows AstraZeneca Receives FDA Orphan Drug Designation for Crestor,2014-02-14 14:05:00-05:00,AZN,neutral
128528.0,AstraZeneca Announces 2nd Interim Dividend of $1.90/Share,2014-02-06 06:31:00-05:00,AZN,neutral
128529.0,Astrazeneca Reports Q4 Adjusted EPS of $1.23 vs $1.22 Est; Revenue of $6.84B vs $6.91B Est,2014-02-06 06:30:00-05:00,AZN,neutral
128530.0,Bristol-Myers Squibb Completes Sale of Global Diabetes Business to AstraZeneca ,2014-02-03 05:45:00-05:00,AZN,neutral
128531.0,Market Wrap For January 22: Earnings Season Continues To Come In Mixed,2014-01-22 16:58:00-05:00,AZN,neutral
128532.0,Danske Bank Upgrades Astrazeneca PLC to Buy,2014-01-15 07:26:00-05:00,AZN,neutral
128533.0,Market Wrap For January 14: Markets Rebound On Earnings Season Kickoff,2014-01-14 17:19:00-05:00,AZN,neutral
128534.0,Morgan Stanley Upgrades Astrazeneca PLC to Equalweight,2014-01-14 11:38:00-05:00,AZN,neutral
128535.0,Stocks Hitting 52-Week Highs,2014-01-14 10:39:00-05:00,AZN,neutral
128536.0,Jefferies Upgrades Astrazeneca PLC to Hold,2014-01-09 08:21:00-05:00,AZN,neutral
128537.0,"AstraZeneca, Bristol-Myers Report FDA Approval of Farxiga",2014-01-08 17:12:00-05:00,AZN,positive
128538.0,"Maeil Reporting AstraZeneca, Teva, Roche Are Considering Buying a Celltrion Stake",2014-01-07 17:40:00-05:00,AZN,neutral
128539.0,Benzinga's Top Downgrades,2013-12-20 08:41:00-05:00,AZN,positive
128540.0,Bryan Garnier & Cie Downgrades Astrazeneca PLC to Neutral,2013-12-20 07:49:00-05:00,AZN,neutral
128541.0,Market Wrap For December 18: Markets Flat During Day One Post Fed Taper,2013-12-19 16:47:00-05:00,AZN,neutral
128542.0,"Bristol-Myers, AstraZeneca Shares Higher Following Confirmation AstraZeneca Will Buy JV Diabetes Stake for Up to $4.3B",2013-12-19 07:57:00-05:00,AZN,positive
128543.0,WSJ Reporting Bristol Myers Could Be Near a Deal to Sell Diabetes JV Stake to AstraZeneca in $3B Deal,2013-12-18 18:23:00-05:00,AZN,neutral
128544.0,"AstraZeneca Issues Response to Launch of Esomeprazole Strontium in US, Says 2013 Views Unch",2013-12-17 13:32:00-05:00,AZN,neutral
128545.0,"Genpact, AstraZeneca Extend Finance and Accounting Services Agreement ",2013-12-12 08:48:00-05:00,AZN,positive
128546.0,"Bloomberg First Word Reporting Bristol Myers, AstraZeneca Have Won FDA Panel Support for Metreleptin in Lipodystrophy",2013-12-11 16:21:00-05:00,AZN,positive
128547.0,FDA Posts Staff Review of AstraZeneca/Bristol's Metreleptin on Website,2013-12-09 07:49:00-05:00,AZN,neutral
128548.0,UPDATE: AstraZeneca Says Awarded Damages Will Have No Effect on 2013 Earnings,2013-12-03 15:10:00-05:00,AZN,negative
128549.0,AstraZeneca Announces Awarded $76M in Damages Related to Prilosec Patent Litigation,2013-12-03 15:09:00-05:00,AZN,negative
128550.0,"Hearing Unconfirmed Takeover Chatter in Forest Labs, AstraZeneca Rumored Buyer",2013-12-03 10:23:00-05:00,AZN,negative
128551.0,Horizon to Acquire US Rights for VIMOVO from Pozen,2013-11-19 06:18:00-05:00,AZN,neutral
128552.0,Benzinga's Top Upgrades,2013-11-15 08:37:00-05:00,AZN,positive
128553.0,Liberum Upgrades Astrazeneca PLC to Buy,2013-11-15 07:21:00-05:00,AZN,neutral
128554.0,Panmure Downgrades Astrazeneca PLC to Sell,2013-11-13 07:29:00-05:00,AZN,neutral
128555.0,UBS Downgrades Astrazeneca PLC to Neutral,2013-11-04 07:22:00-05:00,AZN,neutral
128556.0,UPDATE: Bank of America Upgrades AstraZeneca plc on Slightly Better Outlook,2013-10-28 09:02:00-04:00,AZN,positive
128557.0,Benzinga's Top Upgrades,2013-10-28 08:29:00-04:00,AZN,positive
128558.0,Bank of America Upgrades Astrazeneca PLC to Neutral,2013-10-28 06:32:00-04:00,AZN,neutral
128559.0,"Earnings Expectations For The Week Of October 28: Apple, Facebook, GM and More",2013-10-27 19:10:00-04:00,AZN,neutral
128560.0,FDA Says AstraZeneca's Drug for Systemic Sclerosis Wins Orphan Drug Designation,2013-10-25 12:05:00-04:00,AZN,positive
128561.0,Acacia Subsidiary Enters into Settlement Agreement with AstraZeneca,2013-10-21 06:07:00-04:00,AZN,positive
128562.0,AstraZeneca Shares Unch Following FDA's Orphan Drug Designation for Olaparib in Ovarian Cancer,2013-10-16 15:12:00-04:00,AZN,negative
128563.0,"AstraZeneca Reports New Safety Data for Naloxegol, Says Most Naloxegol-Emergent AES Early in Treatment",2013-10-14 10:27:00-04:00,AZN,positive
128564.0,Jefferies Downgrades Astrazeneca PLC to Underperform,2013-10-11 07:38:00-04:00,AZN,neutral
128565.0,MainFirst Initiates Coverage on Astrazeneca PLC at Underperform,2013-10-09 06:57:00-04:00,AZN,neutral
128566.0,"Amgen, AstraZeneca Highlight Brodalumab Data to be Presented at EADV",2013-10-03 06:06:00-04:00,AZN,positive
128567.0,"Shares of Clovis Oncology Down 4+% Following Mixed Ariad Data on AP26113, Data on AZD9291 from AstraZeneca",2013-09-30 09:30:00-04:00,AZN,positive
128568.0,"AstraZeneca, Bristol-Myers Squibb Announce Positive Phase III Dapagliflozin Data",2013-09-24 06:01:00-04:00,AZN,positive
128569.0,US Stock Futures Edge Higher; All Eyes On Fed,2013-09-18 07:16:00-04:00,AZN,neutral
128570.0,FDA Accepts NDA for AstraZeneca's Epanova,2013-09-18 06:24:00-04:00,AZN,positive
128571.0,"Form 8-K Filing from Nektar Therapeutics Shows AstraZeneca Filed NDA with FDA, AstraZeneca Will Pay Nektar $70M Milestone on Acceptance of NDA",2013-09-16 16:22:00-04:00,AZN,positive
128572.0,Nordea Upgrades Astrazeneca PLC to Buy,2013-09-16 07:49:00-04:00,AZN,neutral
128573.0,AstraZeneca Shares Spike Higher,2013-09-11 14:00:00-04:00,AZN,positive
128574.0,US Stock Futures Flat; Apple Shares Drop In Pre-Market Trading,2013-09-11 07:07:00-04:00,AZN,neutral
128575.0,"Merck, AstraZeneca Announce License Agreement for MK-1775",2013-09-11 05:39:00-04:00,AZN,positive
128576.0,"Myriad Genetics, AstraZeneca Expand Collaboration on Olaparib Phase 3 Clinical Trials ",2013-09-04 06:05:00-04:00,AZN,positive
128577.0,Form 8-K from Nektar Therapeutics Shows AstraZeneca Filed NDS with HC for Naloxegol on Aug. 26th,2013-08-28 17:05:00-04:00,AZN,neutral
128578.0,"Benzinga's M&A Chatter for Monday August 26, 2013",2013-08-26 16:33:00-04:00,AZN,neutral
128579.0,Amgen and Onyx Finally Ink Deal Two Months In The Making,2013-08-26 07:27:00-04:00,AZN,neutral
128580.0,AstraZeneca's MedImmune Division to Acquire Amplimmune for up to $500M,2013-08-26 06:32:00-04:00,AZN,neutral
128581.0,Morgan Stanley Downgrades Astrazeneca PLC to Underweight,2013-08-15 08:35:00-04:00,AZN,neutral
128582.0,How Much Does It Cost To Develop A New Drug?,2013-08-14 09:32:00-04:00,AZN,neutral
128583.0,"AstraZeneca Will Pay Nektar $25M Milestone if MAA Accepted by EMA, $70M Milestone if NDA Accepted by FDA",2013-08-08 16:54:00-04:00,AZN,positive
128584.0,Swedbank Upgrades Astrazeneca PLC to Reduce,2013-08-02 07:41:00-04:00,AZN,neutral
128585.0,Swedbank Upgrades Astrazeneca PLC to Reduce,2013-08-02 06:28:00-04:00,AZN,neutral
128586.0,Astrazeneca PLC Reports Q2 EPS of $1.20 vs $1.16 Est; Revenue of $6.23B vs $6.24B Est,2013-08-01 06:06:00-04:00,AZN,neutral
128587.0,Earnings Expectations for the Week of July 29,2013-07-28 14:00:00-04:00,AZN,neutral
128588.0,"Weekly Preview: Earnings Season Continues, Fed In Focus, Economic Maelstrom Expected",2013-07-26 16:05:00-04:00,AZN,neutral
128589.0,U.S. FDA Acknowledges Receipt of Resubmission of the New Drug Application From AstraZenenca,2013-07-25 17:02:00-04:00,AZN,neutral
128590.0,"Benzinga's M&A Chatter for Monday July 22, 2013",2013-07-22 17:12:00-04:00,AZN,neutral
128591.0,"Bloomberg Reporting Pfizer, Novartis, AstraZeneca Said to Be Preparing Onyx Pharma Bids",2013-07-22 12:10:00-04:00,AZN,neutral
128592.0,"Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)",2013-07-02 08:58:00-04:00,AZN,neutral
128593.0,Big Pharma's Next Blockbuster is Fish Oil?,2013-06-28 11:42:00-04:00,AZN,positive
128594.0,"EMA Gives Positive Recommendations For AstraZeneca's Nexium Control, Extension of Onglyza",2013-06-28 07:56:00-04:00,AZN,positive
128595.0,ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM),2013-06-24 15:16:00-04:00,AZN,positive
128596.0,"AstraZeneca, Bristol-Myers Squibb, Announce Results from Phase IIa Study Assessing Safety and Tolerability of Dapagliflozin",2013-06-22 11:10:00-04:00,AZN,positive
128597.0,"AstraZeneca's MedImmune, and NGM Biopharmaceuticals Announce Agreement to Develop Therapies for Diabetes and Obesity ",2013-06-17 06:33:00-04:00,AZN,positive
128598.0,"Astrazeneca, Bristol-Myers Squibb Release Statement to American Diabetes Association",2013-06-12 13:13:00-04:00,AZN,neutral
128599.0,"Benzinga's M&A Chatter for Monday June 10, 2013",2013-06-10 17:57:00-04:00,AZN,neutral
128600.0,AstraZeneca to Buy Pearl Therapeutics to Gain Lung Medicine,2013-06-10 14:53:00-04:00,AZN,positive
128601.0,"AstraZeneca to Acquire Pearl Therapeutics to Gain Foothold into Lucrative Market (AZN, GSK, NVS)",2013-06-10 09:18:00-04:00,AZN,positive
128602.0,A Peek Into The Market Before The Trading Starts,2013-06-10 07:16:00-04:00,AZN,neutral
128603.0,AstraZeneca to Acquire Pearl Therapeutics for Up to $1.15B,2013-06-10 06:39:00-04:00,AZN,neutral
128604.0,US Stock Futures Signal Higher Start On Wall Street,2013-06-10 06:18:00-04:00,AZN,neutral
128605.0,"Stocks To Watch For June 10, 2013",2013-06-10 04:14:00-04:00,AZN,neutral
128606.0,"Market Wrap for Tuesday, June 4: Stocks Retreat as Uncertainty Rises ",2013-06-04 16:16:00-04:00,AZN,negative
128607.0,Traders Passing Around Fool Article 'AstraZeneca Writes Off $140 Million Following Product Trial' Related to Results from Fostamatinib,2013-06-04 11:27:00-04:00,AZN,negative
128608.0,Stocks Hitting 52-Week Lows,2013-06-04 10:46:00-04:00,AZN,negative
128609.0,"Oppenheimer Downgrades Rigel Pharmaceuticals, Inc. to Perform, Removes $10.00 PT",2013-06-04 10:35:00-04:00,AZN,neutral
128610.0,Morning Market Losers,2013-06-04 10:18:00-04:00,AZN,negative
128611.0,"U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy ",2013-06-04 09:03:00-04:00,AZN,positive
128612.0,Benzinga's Top Pre-Market Losers,2013-06-04 08:18:00-04:00,AZN,negative
128613.0,"Rigel, AstraZeneca Announce Topline Results from OSKIRA-2 and OSKIRA-3 Phase 3 Clinical Trials Investigating Fostamatinib",2013-06-04 06:02:00-04:00,AZN,neutral
128614.0,Isis Pharma Announces $10M Milestone Payment from AstraZeneca for ISIS-AR,2013-06-03 07:22:00-04:00,AZN,neutral
128615.0,"Benzinga's M&A Chatter for Tuesday May 28, 2013",2013-05-28 17:39:00-04:00,AZN,neutral
128616.0,Morning Market Movers,2013-05-28 10:00:00-04:00,AZN,neutral
128617.0,Benzinga's Top Pre-Market Gainers,2013-05-28 08:06:00-04:00,AZN,positive
128618.0,"Benzinga Market Primer: Tuesday, May 28",2013-05-28 06:50:00-04:00,AZN,neutral
128619.0,AstraZeneca To Acquire Omthera Pharmaceuticals For $12.70/Share,2013-05-28 04:30:00-04:00,AZN,neutral
128620.0,"Stocks To Watch For May 28, 2013",2013-05-28 04:01:00-04:00,AZN,neutral
128621.0,Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013 ,2013-05-21 09:26:00-04:00,AZN,neutral
128622.0,"U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying",2013-05-18 15:54:00-04:00,AZN,neutral
128623.0,Impax Labs Launches Authorized Generic of Zomig in US,2013-05-17 08:33:00-04:00,AZN,neutral
128624.0,Optimer Spokesperson Declines Comment on Rumor of Cubist Bid,2013-05-15 18:57:00-04:00,AZN,neutral
128625.0,"Benzinga's M&A Chatter for Wednesday May 15, 2013",2013-05-15 18:52:00-04:00,AZN,neutral
128626.0,UPDATE: Cubist Reportedly Bid $20/Share for Optimer -Reuters,2013-05-15 15:51:00-04:00,AZN,neutral
128627.0,Hearing Cubist Bid Near $1B for Optimer,2013-05-15 15:50:00-04:00,AZN,neutral
128628.0,Optimer Spikes Higher ,2013-05-15 15:48:00-04:00,AZN,neutral
128629.0,"Benzinga's M&A Chatter for Monday May 13, 2013",2013-05-13 17:55:00-04:00,AZN,neutral
128630.0,"Hearing Chatter of Bids for Optimer from AstraZeneca, Cubist",2013-05-13 15:56:00-04:00,AZN,neutral
128631.0,Astrazeneca PLC Reports Q1 EPS of $1.41 vs $1.33 Est; Revenue of $6.39B vs $6.53B Est,2013-04-25 05:59:00-04:00,AZN,neutral
128632.0,Under The Hood: An ETF For International Income,2013-04-18 15:33:00-04:00,AZN,neutral
128633.0,Bloomberg First Word Reporting AstraZeneca Gets Further Delay in Generic Pulmicort Repsules,2013-04-10 15:50:00-04:00,AZN,negative
128634.0,S&P Lowers Outlook on AstraZeneca from Stable to Negative,2013-04-08 09:37:00-04:00,AZN,negative
128635.0,A Peek Into The Market Before The Trading Starts,2013-04-05 07:17:00-04:00,AZN,neutral
128636.0,AstraZeneca Announces Results from OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis ,2013-04-05 05:58:00-04:00,AZN,neutral
128637.0,A Peek Into The Market Before The Trading Starts,2013-04-03 07:39:00-04:00,AZN,neutral
128638.0,Astrazeneca's Medimmune Biologics Unit Acquires Alphacore Pharma,2013-04-03 07:02:00-04:00,AZN,neutral
128639.0,Actavis Confirms Court Issues TRO Preventing Distribution of Generic Pulmicort RESPULES,2013-04-03 06:37:00-04:00,AZN,neutral
128640.0,Benzinga's Top Upgrades,2013-04-02 07:10:00-04:00,AZN,positive
128641.0,JP Morgan Upgrades Astrazeneca PLC to Neutral,2013-04-02 06:33:00-04:00,AZN,positive
128642.0,Actavis Confirms Favorable Court Ruling in Patent Suit Involving Generic Version of AstraZeneca's Pulmicort RESPULES,2013-04-01 19:14:00-04:00,AZN,positive
128643.0,EMA Investigating Pancreatic Risks with GLP-1 Diabetes Drugs,2013-03-26 11:19:00-04:00,AZN,negative
128644.0,Natixis Upgrades Astrazeneca PLC to Neutral,2013-03-22 08:53:00-04:00,AZN,neutral
128645.0,AstraZeneca to Resubmit Dapagliflozin Dossier in Germany,2013-03-21 09:34:00-04:00,AZN,neutral
128646.0,"AstraZeneca to Reduce Global SG&A Workforce by 2,300",2013-03-21 07:11:00-04:00,AZN,neutral
128647.0,"AstraZeneca to Open Strategic R&D Center in Maryland, Sees $1.4B in One-Time Restructuring Charges",2013-03-18 09:10:00-04:00,AZN,negative
128648.0,UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure,2013-03-08 07:34:00-05:00,AZN,negative
128649.0,Swedbank Downgrades Astrazeneca PLC to Sell,2013-03-08 06:21:00-05:00,AZN,neutral
128650.0,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,2013-03-08 06:15:00-05:00,AZN,positive
128651.0,"Targacept, AstraZeneca Amend Pact, Targacept Wins Right to Pursue Any Alpha7 NNR Modulator",2013-03-05 07:10:00-05:00,AZN,positive
128652.0,These ETFs Have Moving Average Problems,2013-02-27 15:23:00-05:00,AZN,negative
128653.0,Are Global Health Care ETFs Worth Prescribing?,2013-02-22 11:24:00-05:00,AZN,positive
128654.0,Mylan Loses Bid to Challenge AstraZeneca Patent on Seroquel XR,2013-02-14 12:06:00-05:00,AZN,negative
128655.0,Astrazeneca PLC Reports Q4 EPS of $1.56 vs $1.41 Est; Revenue of $7.28B vs $7.17B Est,2013-01-31 07:03:00-05:00,AZN,neutral
128656.0,Astrazeneca Says Got Updated Guidelines on Stemi,2012-12-17 15:53:00-05:00,AZN,neutral
128657.0,AstraZeneca Wins Appeals Court Ruling on Crestor Payment,2012-12-14 11:43:00-05:00,AZN,positive
128658.0,Societe Generale Downgrades Astrazeneca PLC to Sell,2012-12-14 06:50:00-05:00,AZN,neutral
128659.0,Rigel Pharma Shares Sink as Fostamatinib Fails to Hit Secondary Endpoint,2012-12-13 12:12:00-05:00,AZN,negative
128660.0,Par Pharma Begins Shipping Generic Atacand HCT,2012-12-05 17:08:00-05:00,AZN,neutral
128661.0,"From Earlier: Optimer, AstraZeneca Collaborate to Commercialize Fidaxomicin for Clostridium Difficile Infection in LatAm",2012-12-03 09:17:00-05:00,AZN,neutral
128662.0,AstraZeneca Spokesperson Declines Comment on Rumored Amarin Interest,2012-11-15 07:54:00-05:00,AZN,positive
128663.0,Amarin Rises 12% Pre-Market on Takeover Rumor,2012-11-15 07:22:00-05:00,AZN,neutral
128664.0,"Teva, AstraZeneca May Bid for Amarin -Calcalist",2012-11-15 07:21:00-05:00,AZN,neutral
128665.0,"Bristol-Myers, AstraZeneca's Forxiga Wins EU Approval for Treatment of Type 2 Diabetes",2012-11-14 11:56:00-05:00,AZN,positive
128666.0,"Nektar Therapeutics Plunges on FDA Worries, Downgrade",2012-11-12 15:42:00-05:00,AZN,negative
128667.0,AstraZeneca Announces Positive Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation ,2012-11-12 06:39:00-05:00,AZN,positive
128668.0,AstraZeneca Begins Phase III Study of FASLODEX Injection in Patients with Hormone Receptor-Positive Advanced Breast Cancer ,2012-10-29 07:07:00-04:00,AZN,negative
128669.0,UPDATE: Pareto Securities Downgrades AstraZeneca to Sell,2012-10-26 07:15:00-04:00,AZN,positive
128670.0,UPDATE: Swedbank Downgrades AstraZeneca to Reduce on Valuation  ,2012-10-26 07:15:00-04:00,AZN,neutral
128671.0,Swedbank Downgrades AstraZeneca from Neutral to Reduce,2012-10-26 05:55:00-04:00,AZN,neutral
128672.0,Pareto Securities Downgrades AstraZeneca from Hold to Sell,2012-10-26 05:52:00-04:00,AZN,positive
128673.0,Charles River Laboratories Enters Strategic Partnership with AstraZeneca,2012-10-17 08:04:00-04:00,AZN,neutral
128674.0,SumTotal Systems Appoints Holly Rollo as CMO,2012-10-08 09:02:00-04:00,AZN,neutral
128675.0,"Benzinga's M&A Chatter for Wednesday October 3, 2012",2012-10-03 18:30:00-04:00,AZN,neutral
128676.0,Hearing Unconfirmed Takeover Chatter in Forest Labs,2012-10-03 12:25:00-04:00,AZN,negative
128677.0,"Benzinga's M&A Chatter for Monday October 1, 2012",2012-10-01 21:37:00-04:00,AZN,neutral
128678.0,AstraZeneca Suspends Share Repurchase Program,2012-10-01 09:05:00-04:00,AZN,positive
128679.0,Benzinga's Top Upgrades,2012-09-19 07:13:00-04:00,AZN,positive
128680.0,UPDATE: Bank of America Downgrades AstraZeneca to Underperform Following Recent Gain  ,2012-09-10 08:47:00-04:00,AZN,positive
128681.0,Bank of America Downgrades AstraZeneca from Neutral to Underperform,2012-09-10 05:51:00-04:00,AZN,neutral
128682.0,Benzinga's Top Upgrades,2012-09-07 07:12:00-04:00,AZN,positive
128683.0,Morgan Stanley Upgrades AstraZeneca from Underweight to Equal-weight,2012-09-07 05:42:00-04:00,AZN,neutral
128684.0,Seven Cheap Large-Caps Yielding Over 4% ,2012-09-06 14:07:00-04:00,AZN,neutral
128685.0,Pharma Companies Switch Drugs to OTC Market,2012-08-30 16:15:00-04:00,AZN,neutral
128686.0,AstraZeneca Appoints Pascal Soriot As New CEO,2012-08-28 05:00:00-04:00,AZN,neutral
128687.0,JP Morgan Downgrades AstraZeneca from Neutral to Underweight,2012-08-20 08:12:00-04:00,AZN,positive
128688.0,"Option Alert: AstraZeneca Call Volume at 3,232% of Average Ahead of Wednesday's Ex-Dividend; Currently $48.25",2012-08-07 12:29:00-04:00,AZN,positive
128689.0,AstraZeneca Reports Q2 EPS $1.53 vs $1.36 Est; Revenues $6.66B vs $6.78B Est,2012-07-26 06:44:00-04:00,AZN,neutral
128690.0,From Earlier: AstraZeneca to Initiate a New Study of BRILINTA (Ticagrelor) in Patients with PAD,2012-07-17 07:40:00-04:00,AZN,neutral
128691.0,BRILINTA Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of UA/NSTEMI Patients,2012-07-16 18:41:00-04:00,AZN,neutral
128692.0,AstraZeneca Acquires Neuroscience Assets From Link Medicine; Terms Not Disclosed  ,2012-07-12 08:02:00-04:00,AZN,positive
128693.0,Hearing dealReporter Saying AstraZeneca Could Have Interest in Amarin,2012-07-05 10:05:00-04:00,AZN,positive
128694.0,Bristol-Myers to Acquire Amylin,2012-07-02 13:45:00-04:00,AZN,neutral
128695.0,AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis  ,2012-07-02 08:05:00-04:00,AZN,neutral
128696.0,Bristol-Myers Squibb to Acquire Amylin Pharmaceuticals for $31/Share,2012-06-30 09:11:00-04:00,AZN,neutral
128697.0,J.P. Morgan Cazenove Reiterates Neutral Rating for AstraZeneca,2012-06-27 09:24:00-04:00,AZN,neutral
128698.0,A Peek Into The Market Before The Trading Starts,2012-06-27 07:22:00-04:00,AZN,neutral
128699.0,Merck and AstraZeneca Agree to Amend Partnership   ,2012-06-27 07:01:00-04:00,AZN,positive
128700.0,"Benzinga's M&A Chatter for Tuesday June 26, 2012",2012-06-26 18:04:00-04:00,AZN,neutral
128701.0,Spokesperson for Amylin Pharmaceuticals Won't Comment on Rumor of Bids from Pharma Companies,2012-06-26 13:17:00-04:00,AZN,neutral
128702.0,Amylin Pharmaceuticals Spiking to Highs on Earlier Bid Reports,2012-06-26 11:57:00-04:00,AZN,neutral
128703.0,"Novartis, Sanofi, Merck, Bristol, AstraZeneca Weigh Amylin Final Bids; Amylin Expects Final Bids Starting End of the Week -Reuters ",2012-06-26 11:38:00-04:00,AZN,neutral
128704.0,EMA: Positive Recommendations On New Generic Medicine Zyclara,2012-06-22 07:38:00-04:00,AZN,positive
128705.0,AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma  ,2012-06-19 08:04:00-04:00,AZN,positive
128706.0,"Benzinga's M&A Chatter for  Friday June 1, 2012",2012-06-03 10:47:00-04:00,AZN,neutral
128707.0,"Amylin Shares Jump as Sanofi, Merck Sumbit Bids",2012-05-25 15:15:00-04:00,AZN,positive
128708.0,GlaxoSmithKline to Get Hostile with Offer for Human Genome,2012-05-09 09:15:00-04:00,AZN,negative
128709.0,"Benzinga's Top Upgrades with Color for May 1, 2012",2012-05-01 10:15:00-04:00,AZN,positive
128710.0,AstraZeneca LUNAR Examines Cholesterol-Lowering Effects of CRESTOR Compared with Atorvastatin in Patients with Acute Coronary Syndrome ,2012-05-01 09:12:00-04:00,AZN,neutral
128711.0,UPDATE: Bank of America Upgrades AstraZeneca ,2012-05-01 08:02:00-04:00,AZN,neutral
128712.0,"Financial Breakfast: Morning News Summary for May 1, 2012",2012-05-01 07:29:00-04:00,AZN,neutral
128713.0,"Bank of America Upgrades AstraZeneca from Underperform to Neutral, Maintains PO at $49.2",2012-05-01 06:13:00-04:00,AZN,negative
128714.0,FDA Considering Letting Patients Purchase Drugs Without Prescriptions,2012-04-30 12:09:00-04:00,AZN,neutral
128715.0,Benzinga's Top Upgrades,2012-04-30 07:25:00-04:00,AZN,positive
128716.0,"Benzinga's M&A Chatter for Friday April 27, 2012",2012-04-28 20:31:00-04:00,AZN,neutral
128717.0,"AstraZeneca's CEO Quits As Earnings, Revenue Drop - IBD",2012-04-26 12:35:00-04:00,AZN,negative
128718.0,"Earnings Recap for April 26, 2012",2012-04-26 09:50:00-04:00,AZN,neutral
128719.0,From Earlier: Astrazeneca's CEO Will Retire June 1,2012-04-26 08:58:00-04:00,AZN,neutral
128720.0,AstraZeneca Reports Q1 EPS $1.81 vs $1.78 Est; Revenues $7.35B vs $7.85B Est,2012-04-26 08:56:00-04:00,AZN,neutral
128721.0,"Benzinga's M&A Chatter for Wednesday April 25, 2012",2012-04-25 17:21:00-04:00,AZN,neutral
128722.0,AstraZeneca and The Medicines Company Announce Global Collaboration in Acute Ischemic Heart Disease   ,2012-04-25 12:31:00-04:00,AZN,neutral
128723.0,"Financial Breakfast: Morning News Summary for April 24, 2012",2012-04-24 07:41:00-04:00,AZN,neutral
128724.0,"Benzinga's M&A Chatter for Monday April 23, 2012",2012-04-23 17:32:00-04:00,AZN,neutral
128725.0,Ardea Biosciences Surges 51% After Buyout,2012-04-23 09:50:00-04:00,AZN,neutral
128726.0,"Financial Breakfast: Morning News Summary for April 23, 2012",2012-04-23 08:21:00-04:00,AZN,neutral
128727.0,Benzinga's Top Pre-Market Gainers,2012-04-23 08:12:00-04:00,AZN,positive
128728.0,From Earlier: AstraZeneca to Acquire Ardea Biosciences for $1.26B Including Lead Product Lesinurad in Phase III Development for Gout  ,2012-04-23 07:50:00-04:00,AZN,neutral
128729.0,US Stock Futures Signal Lower Start On Wall Street ,2012-04-23 06:06:00-04:00,AZN,negative
128730.0,AstraZeneca To Acquire Ardea Biosciences For $32/Share,2012-04-23 03:06:00-04:00,AZN,neutral
128731.0,"Benzinga's M&A Chatter for Thursday April 12, 2012",2012-04-12 18:19:00-04:00,AZN,neutral
128732.0,AstraZeneca Spokesperson Won't Comment on Earlier UBS Note Saying Mylan Could be a Takeover Target,2012-04-12 10:19:00-04:00,AZN,neutral
128733.0,Positive Rumors Circulate About Mylan,2012-04-12 09:37:00-04:00,AZN,positive
128734.0,AstraZeneca Launches DUTOPROL,2012-04-12 09:07:00-04:00,AZN,neutral
128735.0,AstraZeneca Launches DUTOPROL,2012-04-12 09:03:00-04:00,AZN,neutral
128736.0,Amgen,2012-04-02 18:47:00-04:00,AZN,neutral
128737.0,Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio ,2012-04-02 16:02:00-04:00,AZN,neutral
128738.0,Amylin Shares Active on Monday; Stock Down 4%,2012-04-02 13:05:00-04:00,AZN,positive
128739.0,ImmunoCellular's Intellectual Property Steadily Increases,2012-03-28 22:43:00-04:00,AZN,positive
128740.0,"Trading Ideas: Stocks to Watch for Thursday (AMLN, SABA, ANGI, RHT, LGF, AE) ",2012-03-28 19:39:00-04:00,AZN,neutral
128741.0,Amylin Rejected $3.5 Billion Offer; Stock Soars,2012-03-28 13:07:00-04:00,AZN,negative
128742.0,UPDATE: Pareto Securities Upgrades AstraZeneca; Raises PT,2012-03-27 08:22:00-04:00,AZN,positive
128743.0,Benzinga's Top Upgrades,2012-03-27 07:37:00-04:00,AZN,positive
128744.0,"Pareto Securities Upgrades AstraZeneca from Sell to Hold, Raises PT from $46 to $47",2012-03-27 06:12:00-04:00,AZN,positive
128745.0,A Peek Into The Market Before The Trading Starts,2012-03-26 07:24:00-04:00,AZN,neutral
128746.0,"Financial Breakfast: Morning News Summary for March 26, 2012",2012-03-26 07:22:00-04:00,AZN,neutral
128747.0,US Court Denies Preliminary Injunction Application against the FDA and Dismisses AstraZeneca's Lawsuit without Prejudice  ,2012-03-26 07:21:00-04:00,AZN,negative
128748.0,US Court Denies Preliminary Injunction Application against the FDA and Dismisses AstraZeneca's Lawsuit without Prejudice,2012-03-26 06:44:00-04:00,AZN,negative
128749.0,AstraZeneca Announces Increased Coverage of BRILINTA Through Plan Preferred Formulary Status on Medco Health Solutions   ,2012-03-22 10:00:00-04:00,AZN,positive
128750.0,"St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now",2012-03-21 07:20:00-04:00,AZN,positive
128751.0,Morning Market Losers,2012-03-20 09:53:00-04:00,AZN,negative
128752.0,Targacept Down 14.3% Pre-Market on Disappointing Phase 3 Study Results  ,2012-03-20 08:38:00-04:00,AZN,negative
128753.0,Benzinga's Top Pre-Market Losers,2012-03-20 08:21:00-04:00,AZN,negative
128754.0,"From Earlier: AstraZeneca and Targacept Announce Remaining TC-5214 Phase 3 Efficacy Studies Do Not Meet Primary Endpoint, Regulatory Filing Will Not Be Pursued",2012-03-20 07:21:00-04:00,AZN,neutral
128755.0,From Earlier: AstraZeneca Files Lawsuit against the FDA for Decision Regarding Quetiapine Product Labeling and Exclusivity  ,2012-03-13 07:36:00-04:00,AZN,negative
128756.0,"Benzinga's M&A Chatter for Thursday March 8, 2012",2012-03-08 17:28:00-05:00,AZN,neutral
128757.0,Hearing Bernstein Saying Astra Zeneca Could Buy Amylin for $4.5B,2012-03-08 11:55:00-05:00,AZN,neutral
128758.0,FDA Approves Important Safety Label Changes For The Class Of Cholesterol-Lowering Drugs Known As Statins -Reuters,2012-02-28 13:20:00-05:00,AZN,positive
128759.0,AstraZeneca Announces First Direct-to-Patient Program Offering the Brand ARIMIDEX Tablets to Patients for Only $40 Per Month  ,2012-02-16 09:07:00-05:00,AZN,neutral
128760.0,Notable Call Options Activity in AstraZeneca,2012-02-14 11:09:00-05:00,AZN,neutral
128761.0,Three Conservative Stocks To Play The Stock Market Rally,2012-02-08 16:02:00-05:00,AZN,positive
128762.0,Notable Put Options Activity in AstraZeneca,2012-02-02 11:24:00-05:00,AZN,neutral
128763.0,"AstraZeneca Cuts 7,300 Jobs, Warns of Lower Profits",2012-02-02 06:45:00-05:00,AZN,negative
128764.0,AstraZeneca Reports Q4 EPS $1.61 vs $1.56 Est; Revenues $8.66B vs $8.59B Est				 ,2012-02-02 06:44:00-05:00,AZN,neutral
128765.0,"AstraZeneca To Cut 7,300 Jobs, Projects Drop In Profit",2012-02-02 04:52:00-05:00,AZN,negative
128766.0,From Earlier: Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin  ,2012-01-19 07:10:00-05:00,AZN,neutral
128767.0,Notable Call Options Activity in AstraZeneca,2012-01-18 10:47:00-05:00,AZN,neutral
128768.0,Market Roundup,2012-01-09 11:35:00-05:00,AZN,neutral
128769.0,AstraZeneca Reaffirms 2011 Earnings Forecast,2012-01-09 06:57:00-05:00,AZN,neutral
128770.0,AstraZeneca Reaffirms 2011 Earnings Forecast,2012-01-09 04:50:00-05:00,AZN,neutral
128771.0,ETF Showdown: Fun With Pharma,2011-12-30 16:10:00-05:00,AZN,positive
128772.0,Notable Put Options Activity on AstraZeneca,2011-12-28 14:57:00-05:00,AZN,neutral
128773.0,AstraZeneca and Targacept Announce Top-line Results from Second Phase 3 Study of TC-5214 as an Adjunct Treatment in Patients with Major Depressive Disorder  ,2011-12-20 07:38:00-05:00,AZN,negative
128774.0,Citi Reiterates Neutral On AstraZeneca ,2011-12-19 11:50:00-05:00,AZN,neutral
128775.0,AstraZeneca Announces Share Repurchase Programme,2011-12-15 11:31:00-05:00,AZN,positive
128776.0,Is Endo Pharmaceuticals Going to Seize Market Share? ,2011-12-12 15:41:00-05:00,AZN,positive
128777.0,A Peek Into The Market Before The Trading Start,2011-12-08 07:39:00-05:00,AZN,neutral
128778.0,"Astra, Bristol-Myers Report Phase 3 Dapagliflozin Results",2011-12-08 06:34:00-05:00,AZN,neutral
128779.0,"AstraZeneca to Reduce U.S. Sales Force by 1,150 Positions ",2011-12-07 13:01:00-05:00,AZN,neutral
128780.0,"AstraZeneca to Cut 1,150 Leadership Jobs -Bloomberg",2011-12-07 13:01:00-05:00,AZN,negative
128781.0,Teva Loses Bid Against Astrazeneca's Crestor; Had Claimed Drug Infringed on Patents,2011-12-01 11:15:00-05:00,AZN,negative
128782.0,Citigroup Initiates AstraZeneca at Neutral,2011-11-29 12:55:00-05:00,AZN,neutral
128783.0,ONGLYZA Approved for Use in Europe as Combination Therapy With Insulin in Adults,2011-11-28 08:00:00-05:00,AZN,positive
128784.0,"End-of-Day Market Summary for November 16, 2011",2011-11-16 16:15:00-05:00,AZN,neutral
128785.0, Bristol-Myers Squibb and AstraZeneca Announce Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients with Type 2 Diabetes  ,2011-11-16 16:06:00-05:00,AZN,positive
128786.0,Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients,2011-11-16 16:03:00-05:00,AZN,positive
128787.0,AstraZeneca Announces SATURN Demonstrated Effect of Intensive Statin Treatment on Reducing Atherosclerosis   ,2011-11-15 08:05:00-05:00,AZN,neutral
128788.0,"Financial Breakfast: Morning News Summary for November 8, 2011",2011-11-08 07:44:00-05:00,AZN,neutral
128789.0,AstraZeneca and Targacept Announce First Top-line Phase 3 Results for TC-5214 as an Adjunct Treatment in Patients with Major Depressive Disorder  ,2011-11-08 06:44:00-05:00,AZN,negative
128790.0,AstraZeneca Announces BRILINTA Receives Additional Class I Recommendation in New U.S. Guidelines from ACCF/AHA/SCAI for PCI  ,2011-11-07 16:01:00-05:00,AZN,neutral
128791.0,From Earlier: AstraZeneca Reports Q3 EPS $1.71 vs $1.68 Est; Revenues $8.21B vs $8.25B Est			,2011-10-27 08:39:00-04:00,AZN,neutral
128792.0,Bristol-Myers Squibb and AstraZeneca Announce U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months  ,2011-10-26 16:10:00-04:00,AZN,positive
128793.0,"Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS",2011-10-24 10:16:00-04:00,AZN,negative
128794.0,"Forest Laboratories Earnings Preview: Analysts Expect Rising Revenue, Falling EPS",2011-10-13 23:02:00-04:00,AZN,negative
128795.0,AstraZeneca to Cut 400 US Jobs,2011-10-06 15:54:00-04:00,AZN,negative
128796.0,AstraZeneca's MedImmune In-Licenses Cancer Immunotherapy Tremelimumab from Pfizer  ,2011-10-03 08:08:00-04:00,AZN,negative
128797.0,AstraZeneca Enters Into a Settlement Agreement with Handa Pharmaceuticals regarding U.S. SEROQUEL XR® Patent Litigation   ,2011-09-29 15:50:00-04:00,AZN,positive
128798.0,Notable Put Options Activity in AstraZeneca,2011-09-27 10:40:00-04:00,AZN,neutral
128799.0,Bristol-Myers Squibb and AstraZeneca Announce ONGLYZA When Added to Insulin in Adults with Type 2 Diabetes Maintained Reductions in Blood Sugar Levels Over 52 Weeks in Investigational Study Extension  ,2011-09-16 07:02:00-04:00,AZN,neutral
128800.0,Dentsply Sells $1B Debt Offer To Fund Astra Tech Deal,2011-08-16 16:51:00-04:00,AZN,negative
128801.0,Watson's Rosuvastatin Zinc Tablets Receive Tentative FDA Approval ,2011-08-10 08:03:00-04:00,AZN,positive
128803.0,Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca ,2011-08-04 07:58:00-04:00,AZN,neutral
128804.0,Jefferies Upgrades AstraZeneca To Hold,2011-08-04 06:07:00-04:00,AZN,neutral
128805.0,AstraZeneca Announces U.S. Enrollment Opportunities for KODIAC Study to Investigate an Experimental Drug for Constipation from Opioids   ,2011-08-01 10:01:00-04:00,AZN,positive
128806.0,AstraZeneca Reports Q1 EPS $1.73 vs $1.80 Est,2011-07-28 07:50:00-04:00,AZN,neutral
128807.0,Earnings Scheduled For July 28,2011-07-28 05:02:00-04:00,AZN,neutral
128808.0,"AstraZeneca Subpoenaed by DOJ Over Nexium, Prilosec, Plendil, Toprol; Can Not Predict If there Will be Any Liability",2011-07-26 09:24:00-04:00,AZN,negative
128809.0,"Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter",2011-07-25 12:45:00-04:00,AZN,negative
128810.0,UPDATE: FDA Approves New Medicine BRILINTA For Use in the US ,2011-07-20 17:27:00-04:00,AZN,positive
128811.0,"AstraZeneca Spikes on Brilinta Approval Rumor, Continues to Rise Following FDA Confirmation",2011-07-20 17:11:00-04:00,AZN,positive
128812.0,UPDATE: FDA Approves AstraZeneca Anticlotting Drug Brilinta,2011-07-20 16:58:00-04:00,AZN,positive
128813.0,AstraZeneca Says BRILINTA Not Yet Approved; Expecting Approval Decision Soon,2011-07-20 16:32:00-04:00,AZN,positive
128814.0,Hearing AstraZeneca Receives FDA Approval BRILINTA -Unconfirmed,2011-07-20 16:18:00-04:00,AZN,positive
128815.0,"News Summary for July 1, 2011",2011-07-01 07:53:00-04:00,AZN,neutral
128816.0,AstraZeneca Drug Nexium Gets Approved In Japan,2011-07-01 07:34:00-04:00,AZN,positive
128817.0,AstraZeneca and PTC Therapeutics Announce Strategic Oncology Drug Discovery Collaboration With Potential Extension to Other Therapeutic Areas,2011-06-29 08:03:00-04:00,AZN,neutral
128818.0,Goldman Sachs Reiterates Neutral on Bristol Myers Squibb and AstraZeneca,2011-06-27 08:12:00-04:00,AZN,neutral
128819.0,News Summary,2011-06-22 09:39:00-04:00,AZN,neutral
128820.0,"News Summary for June 22, 2011",2011-06-22 08:00:00-04:00,AZN,neutral
128821.0,"US Stock Futures Down, Fed In Focus ",2011-06-22 06:17:00-04:00,AZN,neutral
128822.0,AstraZeneca To Sell Astra Tech Unit To Dentsply For $1.8B,2011-06-22 02:45:00-04:00,AZN,neutral
128823.0,"News Summary for June 21, 2011",2011-06-21 08:06:00-04:00,AZN,neutral
128824.0,AstraZeneca Canada: Health Canada Approves BRILINTA Cardiovascular Treatment -Dow Jones,2011-06-01 08:14:00-04:00,AZN,positive
128825.0,Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest ROE,2011-06-01 01:12:00-04:00,AZN,positive
128826.0,Top Healthcare and Major Drugs stocks to watch- Sector Performance,2011-05-22 14:55:00-04:00,AZN,positive
128827.0,GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term,2011-05-18 06:29:00-04:00,AZN,neutral
128828.0,Long-Term Study Demonstrates Safety and Efficacy of SYMBICORT® in African American Patients with Asthma ,2011-05-16 08:02:00-04:00,AZN,positive
128829.0,FDA Approves NEXIUM I.V. for the Treatment of Gastroesophageal Reflux Disease with Erosive Esophagitis in Pediatric and Adolescent Patients   ,2011-05-02 10:03:00-04:00,AZN,positive
128830.0,"Earnings Roundup For April 28 (XOM, AZN, HST, PEP, POT, PG, IP, DOW, S, AET, BMY, VIA, CL, EQT, CCE, OXY)",2011-04-28 08:40:00-04:00,AZN,neutral
128831.0,AstraZeneca Reports Q1 Net Income of $2.91 Billion (AZN),2011-04-28 04:17:00-04:00,AZN,neutral
128832.0,"CEOWORLD Daily Business Roundup- China, GOOG, ZIP, BAC, MAT, HAS, GPC, KNL, SCHW, JPM, WFC…",2011-04-15 07:25:00-04:00,AZN,neutral
128833.0,AstraZeneca CEO On CNBC (AZN),2011-04-14 07:57:00-04:00,AZN,neutral
128834.0,"US Stock Futures Up As Investors Await Economic Data, Crude Oil Drops To $104.92 a barrel",2011-03-28 06:30:00-04:00,AZN,negative
128835.0,AstraZeneca to Pay $1 Billion+ to Resolve U.S. Tax Dispute (AZN),2011-03-28 06:28:00-04:00,AZN,negative
128836.0,Calls Purchased on AstraZeneca PLC (AZN),2011-03-23 11:06:00-04:00,AZN,neutral
128837.0,AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation,2011-03-15 12:07:00-04:00,AZN,neutral
128838.0,FDA Accepts New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes   ,2011-03-08 08:03:00-05:00,AZN,positive
128839.0,International News Trumps Domestic  02-11-2011,2011-02-11 17:45:00-05:00,AZN,neutral
128840.0,AstraZeneca and Targacept Initiate Phase 2b Clinical Trial of TC-5214 ,2011-02-07 08:58:00-05:00,AZN,neutral
128841.0,AstraZeneca and HealthCore Announce Real-World Evidence Data Collaboration ,2011-02-02 10:33:00-05:00,AZN,neutral
128842.0,AstraZeneca Revenues Disappoint - Analyst Blog,2011-01-28 13:39:00-05:00,AZN,negative
128843.0,AstraZeneca Revenues Disappoint - Analyst Blog,2011-01-28 13:12:00-05:00,AZN,negative
128844.0,BMY Misses by a Penny in Q4 - Analyst Blog,2011-01-27 13:31:00-05:00,AZN,negative
128845.0,BMY Misses by a Penny in Q4 - Analyst Blog,2011-01-27 13:00:00-05:00,AZN,negative
128846.0,"Earnings Scheduled For January 27 (CAT, MSFT, PG, T, BMY, LLY, AMZN, AZN, TWC, SNDK, NOK, CB, JBLU, VRSN, PMCS, CL, MSI, KLAC)",2011-01-27 03:44:00-05:00,AZN,neutral
128847.0,Decent Quarter for Dr. Reddy's - Analyst Blog,2011-01-26 09:08:00-05:00,AZN,neutral
128848.0,Decent Quarter for Dr. Reddy's - Analyst Blog,2011-01-26 08:30:00-05:00,AZN,neutral
128849.0,Earnings Preview: Abbott Labs - Analyst Blog,2011-01-25 09:01:00-05:00,AZN,neutral
128850.0,Earnings Preview: Abbott Labs - Analyst Blog,2011-01-25 08:30:00-05:00,AZN,neutral
128851.0,AstraZeneca Responds to FDA Letter - Analyst Blog,2011-01-24 16:01:00-05:00,AZN,neutral
128852.0,AstraZeneca Responds to FDA Letter - Analyst Blog,2011-01-24 15:40:00-05:00,AZN,neutral
128853.0,Financials & Tech See-Saw  01-21-2011,2011-01-21 18:44:00-05:00,AZN,neutral
128854.0,"CBST Beats on EPS, Misses on Sales - Analyst Blog",2011-01-21 12:31:00-05:00,AZN,negative
128855.0,"CBST Beats on EPS, Misses on Sales - Analyst Blog",2011-01-21 12:00:00-05:00,AZN,negative
128856.0,Bleeding Risk with MRK's Candidate  - Analyst Blog,2011-01-20 11:01:00-05:00,AZN,negative
128857.0,Bleeding Risk with MRK's Candidate  - Analyst Blog,2011-01-20 10:30:00-05:00,AZN,negative
128858.0,Earnings Preview: Cubist Pharma  - Analyst Blog,2011-01-17 11:01:00-05:00,AZN,neutral
128859.0,Earnings Preview: Cubist Pharma  - Analyst Blog,2011-01-17 10:15:00-05:00,AZN,neutral
128860.0,Merck's Blood Thinner in Trouble - Analyst Blog,2011-01-14 16:31:00-05:00,AZN,negative
128861.0,Merck's Blood Thinner in Trouble - Analyst Blog,2011-01-14 16:01:00-05:00,AZN,negative
128862.0,Cubist's Q4 Preliminary Sales Down - Analyst Blog,2011-01-13 11:01:00-05:00,AZN,neutral
128863.0,Cubist's Q4 Preliminary Sales Down - Analyst Blog,2011-01-13 10:45:00-05:00,AZN,neutral
128864.0,MedImmune and Micromet Announce Initiation of Phase 1 Trial of the CEA BiTE Antibody MEDI-565 ,2011-01-12 08:48:00-05:00,AZN,neutral
128865.0,Bristol-Myers Inks Deal - Analyst Blog,2011-01-11 14:31:00-05:00,AZN,neutral
128866.0,Bristol-Myers Inks Deal - Analyst Blog,2011-01-11 14:17:00-05:00,AZN,neutral
128867.0,PDLI's Synagis Lawsuit Invalidated - Analyst Blog,2011-01-11 11:31:00-05:00,AZN,negative
128868.0,PDLI's Synagis Lawsuit Invalidated - Analyst Blog,2011-01-11 10:45:00-05:00,AZN,negative
128869.0,AstraZeneca and Sarah Cannon Research Institute Join Forces,2011-01-11 09:06:00-05:00,AZN,positive
128870.0,FDA Delays AZN Drug Approval  - Analyst Blog,2011-01-10 13:01:00-05:00,AZN,positive
128871.0,FDA Delays AZN Drug Approval  - Analyst Blog,2011-01-10 12:32:00-05:00,AZN,positive
128872.0,Certriad Development Discontinued - Analyst Blog,2010-12-23 10:06:00-05:00,AZN,neutral
128873.0,Certriad Development Discontinued - Analyst Blog,2010-12-23 09:30:00-05:00,AZN,neutral
128874.0,"AstraZeneca, Abbott End Certriad Pact",2010-12-23 03:31:00-05:00,AZN,neutral
128875.0,"AstraZeneca, Abbott Kill Co-Development Deal Early",2010-12-23 03:29:00-05:00,AZN,negative
128876.0,"AstraZeneca, Abbott Kill Co-Development Deal Early",2010-12-23 03:29:00-05:00,AZN,negative
128877.0,AstraZeneca and Abbott End License Agreement for CERTRIAD Development,2010-12-22 17:03:00-05:00,AZN,positive
128878.0,Another Setback for AstraZeneca  - Analyst Blog,2010-12-22 09:03:00-05:00,AZN,neutral
128879.0,Another Setback for AstraZeneca  - Analyst Blog,2010-12-22 08:15:00-05:00,AZN,neutral
128880.0,Martek Biosciences: Premarket Trading,2010-12-21 07:27:00-05:00,AZN,neutral
128881.0,"AstraZeneca Halts Drug, Takes $445M Charge",2010-12-21 04:04:00-05:00,AZN,neutral
128882.0,Astrazeneca Off After Further Delay In Drug (AZN),2010-12-20 08:55:00-05:00,AZN,negative
128883.0,Regulatory Setback for AstraZeneca - Analyst Blog,2010-12-17 19:03:00-05:00,AZN,neutral
128884.0,Regulatory Setback for AstraZeneca - Analyst Blog,2010-12-17 18:21:00-05:00,AZN,neutral
128885.0,"Company News for December 17, 2010 - Corporate Summary",2010-12-17 10:33:00-05:00,AZN,neutral
128886.0,"Company News for December 17, 2010 - Corporate Summary",2010-12-17 09:55:00-05:00,AZN,neutral
128887.0,AstraZeneca Down On FDA Delay (AZN),2010-12-17 08:02:00-05:00,AZN,negative
128888.0,Market Stuck at Resistance  12-16-2010,2010-12-16 19:01:00-05:00,AZN,negative
128889.0,Puts Purchased on AstraZeneca PLC (AZN),2010-12-16 14:10:00-05:00,AZN,neutral
128890.0,MITI Presents Positive Data at ASH - Analyst Blog,2010-12-13 16:33:00-05:00,AZN,positive
128891.0,MITI Presents Positive Data at ASH - Analyst Blog,2010-12-13 16:00:00-05:00,AZN,positive
128892.0,Wells Fargo Initiating Coverage On RIGL With An Outperform Rating And A $10-12 Valuation Range,2010-12-10 10:41:00-05:00,AZN,positive
128893.0,Watch Relationships  12-09-2010,2010-12-09 18:23:00-05:00,AZN,neutral
128894.0,Forest Inks Deal for Pain Drugs - Analyst Blog,2010-12-08 11:33:00-05:00,AZN,negative
128895.0,Forest Inks Deal for Pain Drugs - Analyst Blog,2010-12-08 11:03:00-05:00,AZN,negative
128896.0,Credit Suisse Downgrades AZN To Underperform,2010-12-07 07:37:00-05:00,AZN,positive
128897.0,FDA Panel Reviews AstraZeneca Drug - Analyst Blog,2010-12-06 12:13:00-05:00,AZN,neutral
128898.0,FDA Panel Reviews AstraZeneca Drug - Analyst Blog,2010-12-06 10:33:00-05:00,AZN,neutral
128899.0,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,2010-12-03 16:01:00-05:00,AZN,neutral
128900.0,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,2010-12-03 15:32:00-05:00,AZN,neutral
128901.0,Enrollment for Medivation Study - Analyst Blog,2010-12-03 03:06:00-05:00,AZN,neutral
128902.0,Micromet Downgraded to Neutral - Analyst Blog,2010-12-03 02:21:00-05:00,AZN,neutral
128903.0,Enrollment for Medivation Study - Analyst Blog,2010-12-02 12:52:00-05:00,AZN,neutral
128904.0,Micromet Downgraded to Neutral - Analyst Blog,2010-12-02 11:27:00-05:00,AZN,neutral
128905.0,"Zacks Analyst Blog Highlights: California Pizza Kitchen, The Allstate, Prudential Financial, Micromet and AstraZeneca      - Press Releases",2010-11-11 10:33:00-05:00,AZN,neutral
128906.0,"Zacks Analyst Blog Highlights:  United States Steel, Bristol-Myers Squibb, AstraZeneca plc, BHP Billiton and Wyndham Worldwide   - Press Releases",2010-10-27 15:33:00-04:00,AZN,positive
128907.0,Calls Purchased on AstraZeneca PLC (AZN),2010-10-22 11:14:00-04:00,AZN,neutral
128908.0,Strong Cubicin Sales Drive Cubist - Analyst Blog,2010-10-18 11:03:00-04:00,AZN,positive
128909.0,Five ETFs With Stealth Yields,2010-10-05 04:11:00-04:00,AZN,negative
128910.0,Calls Sold on AstraZeneca (AZN),2010-09-29 10:29:00-04:00,AZN,neutral
128911.0,"Benzinga's Top Downgrades (AZN, SM, TKC, MFE)",2010-09-29 07:42:00-04:00,AZN,positive
128912.0,AstraZeneca Falls On Downgrade In Rating,2010-09-29 06:10:00-04:00,AZN,neutral
128913.0,Positive EU Opinion for AZN Drug - Analyst Blog,2010-09-28 00:03:00-04:00,AZN,positive
128914.0,"Top 4 Large-Cap Stocks In The Drug Manufacturers–Major Industry With The Highest EPS Estimates (AZN, NVS, ABT, GSK)",2010-09-22 05:24:00-04:00,AZN,positive
128915.0,BMY's Diabetes Candidate Encourages - Analyst Blog,2010-09-21 14:33:00-04:00,AZN,positive
128916.0,FDA Pushes Out Brilinta Action Date - Analyst Blog,2010-09-17 15:39:00-04:00,AZN,neutral
128917.0,Top Domain Names are Owned by Publicly Traded Companies,2010-09-13 15:50:00-04:00,AZN,positive
128918.0,Red Signal for AstraZeneca Drug - Analyst Blog,2010-09-07 11:42:00-04:00,AZN,neutral
128919.0,AstraZeneca Inks Agreement - Analyst Blog,2010-09-07 11:42:00-04:00,AZN,positive
128920.0,PDLI Gives Third-Quarter Outlook - Analyst Blog,2010-09-03 08:36:00-04:00,AZN,neutral
128921.0,Under The Hood: A Look At An Interesting Dividend ETF (CVY),2010-08-31 14:23:00-04:00,AZN,positive
128922.0,There is a rumor out on Wall Street today that AstraZeneca PLC (AZN) is looking to acquireDendreon Corp. (DNDN) At $55.00 to$60.00 a share.,2010-08-19 10:31:00-04:00,AZN,positive
128923.0,Medivation Narrows Loss - Analyst Blog,2010-08-11 07:05:00-04:00,AZN,negative
128924.0,"Which 52-Week-High Stock Will Outperform? (SI, MCD, AZN, MO, DE)",2010-08-10 12:32:00-04:00,AZN,neutral
128925.0,Watson Pharma Beats; Adjusts View - Analyst Blog,2010-08-05 15:41:00-04:00,AZN,neutral
128926.0,"Zacks Analyst Blog Highlights: The Clorox, AstraZeneca, Merck, Dean Foods and Coach - Press Releases",2010-08-04 10:26:00-04:00,AZN,neutral
128927.0,AstraZeneca EPS Beats & Ups - Analyst Blog,2010-08-03 14:45:00-04:00,AZN,neutral
128928.0,PDLI Matches Ests - Analyst Blog,2010-08-02 14:48:00-04:00,AZN,neutral
128929.0,REGN's Loss Narrower than Expected - Analyst Blog,2010-07-30 17:10:00-04:00,AZN,negative
128930.0,Standpoint Research Downgrades AstraZeneca (NYSE:AZN),2010-07-29 10:48:00-04:00,AZN,neutral
128931.0,A Peek Into The Market Before The Trading Starts,2010-07-29 09:24:00-04:00,AZN,neutral
128932.0,US Stock Futures Indicate Strong Opening Gains,2010-07-29 09:07:00-04:00,AZN,positive
128933.0,Standpoint Downgrades AstraZeneca (AZN) from Buy to Hold,2010-07-29 08:17:00-04:00,AZN,neutral
128934.0,10 Firms Expecting Clinical Trial Results,2010-07-14 07:14:00-04:00,AZN,neutral
128935.0,Q2 Wrap Up Holding Market Steady  06-30-2010,2010-06-30 15:04:00-04:00,AZN,neutral
128936.0,Pharmaceutical ETFs on the Rise ,2010-06-30 14:49:00-04:00,AZN,neutral
128937.0,Heavy Put Selling on Astrazeneca (AZN),2010-06-30 10:50:00-04:00,AZN,neutral
128938.0,"Benzinga’s Top Upgrades (BTU, AZN, NEE, DDMX)",2010-06-30 07:41:00-04:00,AZN,positive
128939.0,JP Morgan Upgrades AZN To Neutral,2010-06-30 06:12:00-04:00,AZN,positive
128940.0,"Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (AZN, LLY, GSK, BMY)",2010-06-30 05:58:00-04:00,AZN,positive
128941.0,"Top 5 Large-Cap NYSE Stocks In The Healthcare Sector With The Highest Return On Equity (GSK, LLY, AZN, ACL, NVO)",2010-06-07 06:26:00-04:00,AZN,positive
128942.0,"The Unusual Suspects (AIG, AZN, BRK-A, BRK-B, MCO, C, GNMK, IEP, LGF, SI, STP, PHYS, SNF, EWP, TEF)",2010-05-29 10:34:00-04:00,AZN,negative
128943.0,Look for Opportunity  05-25-2010,2010-05-25 17:55:00-04:00,AZN,positive
128944.0,Citi Raises Forecasts for AstraZeneca (AZN),2010-05-24 14:37:00-04:00,AZN,neutral
128945.0,FDA Approves AstraZeneca (AZN) And Pozen (POZN) Drug,2010-04-30 18:15:00-04:00,AZN,positive
128946.0,"Afternoon Market Update - Goldman Sachs (NYSE: GS), Merck (NYSE: MRK), AstraZeneca (NYSE: AZN)",2010-04-28 15:28:00-04:00,AZN,neutral
128947.0,"Whistleblower Gets Rewarded In AstraZeneca Case (AZN, LLY)",2010-04-28 07:28:00-04:00,AZN,positive
128948.0,AstraZeneca Settles Illegal Marketing Case (AZN),2010-04-27 19:19:00-04:00,AZN,negative
128949.0,US Stock Futures Slip; Focus Shifts To Pharmaceutical Stocks,2010-03-22 08:41:00-04:00,AZN,neutral
128950.0,AstraZenca Wins Seroquel Trial (AZN),2010-03-18 16:49:00-04:00,AZN,positive
128951.0,"Benzinga’s News Roundup (LXRX, MET, AZN, BA)",2010-03-08 07:59:00-05:00,AZN,neutral
128952.0,"Top 5 NYSE Stocks In the Healthcare Sector With The Highest ROA (NVO, ACL, HLF, AZN, VAR)",2010-03-03 07:58:00-05:00,AZN,positive
128953.0,"Top 5 NYSE Stocks In The Healthcare Sector With The Highest Dividend (ACL, AZN, GSK, NVS, JNJ)",2010-03-03 07:55:00-05:00,AZN,positive
128954.0,"AstraZeneca (AZN) Settles Tax Dispute, Raises Forecast",2010-02-23 06:38:00-05:00,AZN,negative
128955.0,"Movement Expected In The Shares Of These Companies Amid Significant Events (BRK.B, BX, JPM, ORCL,YHOO) ",2010-02-16 16:32:00-05:00,AZN,positive
128956.0,"Rigel Pharmaceuticals, Inc. (RIGL) Maintains An 1-Overweight Rating",2010-02-16 13:22:00-05:00,AZN,neutral
128957.0,"Pharmaceutical Giants AstraZeneca (AZN), Rigel (RIGL) Collaborate On Arthritis Drug ",2010-02-16 09:48:00-05:00,AZN,neutral
128958.0,"Company News for February 16, 2010 - Corporate Summary",2010-02-16 09:38:00-05:00,AZN,neutral
128959.0,"A Look At How Different Sectors Will Behave In 2010 (PG, KO, WMT, GSK, GILD, AZN, EXC, D, DUK)",2010-02-09 14:58:00-05:00,AZN,neutral
128960.0,"I Had A Dream... (TRV, IBM, CMG, APC, AZN)",2010-01-29 13:56:00-05:00,AZN,neutral
128961.0,AstraZeneca (AZN) To Cut 8000 Jobs By 2014,2010-01-29 08:26:00-05:00,AZN,negative
128962.0,"Market Round-up (BAC, JPM, NFLX, CSTR, FRE, AAPL)",2010-01-28 14:18:00-05:00,AZN,neutral
128963.0,"AZN Impresses With Q4 Results, Guidance And Dividend Hike",2010-01-28 13:39:00-05:00,AZN,positive
128964.0,"AstraZeneca (AZN) To Cut 10,400 Jobs",2010-01-28 12:20:00-05:00,AZN,negative
128965.0,"AZN Impresses With Q4 Results, 2010 Guidance; Announces Dividend Hike",2010-01-28 10:13:00-05:00,AZN,positive
128966.0,"Benzinga’s Top Pre-Market Losers (FLEX, AZN, POT, QCOM, ABFS, TTEK)",2010-01-28 08:54:00-05:00,AZN,negative
128967.0,"Earnings Round-up For Companies Reporting Before The Markets Open (MOT, T, AMZN, MMM, MSFT, MO, BDX, AEP, AZN, BMY, CAH, CEL, C, D, EL)   ",2010-01-28 06:43:00-05:00,AZN,neutral
128968.0,Great 2009 Prompts Astra Zeneca (AZN) to Eye Share BuyBack,2010-01-25 10:30:00-05:00,AZN,positive
128969.0,"AstraZeneca Upgraded, Sanofi-Aventis Downgraded",2010-01-21 06:52:00-05:00,AZN,neutral
128970.0,"Top 5 Large-Cap Stocks In The Healthcare Sector With The Highest ROE (GSK, GILD, AZN, ACL, MRK) ",2010-01-14 09:02:00-05:00,AZN,positive
128971.0,Teva Pharamaceuticals Surging On High Volume (TEVA),2010-01-08 12:17:00-05:00,AZN,neutral
128972.0,"Market Round-up (JNS, IIVI, ZIGO, KFT, CBY, BRK.A, BA, AZN, TEVA)",2010-01-07 13:20:00-05:00,AZN,neutral
128973.0,AstraZeneca (AZN) And Teva Pharmaceuticals (TEVA) Settle Patent Dispute Over Nexium,2010-01-07 10:56:00-05:00,AZN,negative
128974.0,"Benzinga’s News Roundup (BG, AZN, QCOR, BSX, CVX, MOS, PFE)",2009-12-24 09:03:00-05:00,AZN,neutral
128975.0,Strong Late-Stage Pipeline Products to Push AZN’s Growth,2009-12-04 14:46:00-05:00,AZN,positive
128976.0,"Benzinga’s News Roundup (CMCSA, BAC, DDS, TGT, AZN)",2009-12-03 08:37:00-05:00,AZN,neutral
128977.0,"Targacept (TRGT), Astra (AZN) in Blockbuster Deal",2009-12-03 08:02:00-05:00,AZN,positive
128978.0,"Cowen stays Neutral On Santarus (SNTS), Cites Litigation Concerns , PRX, MRK, AZN, NVS",2009-12-02 12:20:00-05:00,AZN,negative
128979.0,AstraZeneca  (AZN)  Submits US New Drug Application for Ticagrelor (BRILINTA(TM)),2009-11-19 06:05:00-05:00,AZN,neutral
128980.0,FTSE 100 Daily Analysis 30th October 2009,2009-10-30 02:50:00-04:00,AZN,neutral
128981.0,"AstraZeneca (AZN) Beats Q3 Earnings And Revenue Estimates, Guides Higher",2009-10-29 07:06:00-04:00,AZN,neutral
128982.0,AstraZeneca (AZN) Pulls Regulatory Submissions For A Lung Cancer Drug,2009-10-28 06:23:00-04:00,AZN,negative
128983.0,Is It Tea Time For This U.K. ETF (EWU)?,2009-10-23 16:07:00-04:00,AZN,neutral
128984.0,AstraZeneca (AZN) Gets Secretary Defense Award,2009-09-18 03:06:00-04:00,AZN,positive
128985.0,"Negative Implications for Eli Lilly's (LLY) Efficient, Says Leerink",2009-08-31 09:05:00-04:00,AZN,negative
128986.0,AstraZeneca (AZN) Says Blood Thinner Drug Brilinta Works Better Than Plavix,2009-08-30 12:24:00-04:00,AZN,positive
128987.0,"Trends in the U.K. and Irish Pharmaceutical and Biotechnology Industry, an Industrial Info News Alert",2009-08-17 05:01:00-04:00,AZN,positive
